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ABSTRACT   3 
ABSTRACT 
Exercise  training  is  well  recognised  as  an  effective  treatment  for  intermittent 
claudication.  The  mechanism  underlying  exercise  induced  improvements  is  multi-
factorial but remains poorly understood. Low angiotensin-converting enzyme (ACE) 
activity  has  been  associated  with  enhanced  responses  to  endurance  training. 
Specifically, low ACE activity has been associated with improved muscle metabolism, 
endothelial  function,  and  suppressed  inflammatory  responses;  processes  linked  with 
exercise  training  benefits  in  claudicants.  Furthermore,  pharmacological  inhibition  of 
ACE has been associated with enhanced angiogenesis in animal models of ischaemia, 
secondary to increases in vascular endothelial growth factor (VEGF). 
 
In this study, 11 claudicants were randomised to 8 weeks of supervised exercise training 
(n=6)  or  exercise  advice  (n=5).  Walking  ability  was  recorded  before  and  after  this 
period, and blood samples taken. Reverse transcription polymerase chain reaction (RT-
PCR) was used to determine the effects of exercise training on ACE, VEGF and VEGF 
receptor (VEGFR) gene expression, and enzyme-linked immunosorbant assays (ELISA) 
measured  changes  in  ACE  and  VEGF  protein  levels.  In  another  experiment,  a  cell 
culture model of hypoxia, utilising ECV 304 cells and diethylenetriamine-nitric oxide 
(DETA-NO), was used to study the effects of the ACE inhibitor ramiprilat on ACE and 
VEGF responses to hypoxia, using RT-PCR and ELISA.  
 
Supervised  exercise  improved  claudication  distance  by  105  metres  (p  <  0.05)  and 
maximum walking distance by 141 metres (p < 0.05). ACE mRNA expression increased 
30%, VEGF121 expression 43% and VEGF165 expression 70% (all p < 0.05). Soluble 
VEGFR-1 mRNA expression increased by 63% and VEGFR-2 72% (both p < 0.05).   4 
ACE  and  VEGF  protein  levels  remained  comparatively  stable.  In  the  cell  culture 
experiments, ramiprilat increased VEGF protein levels in hypoxia. Although a lack of 
experimental runs prevented statistical analysis, the results also suggest that ramiprilat 
has a stimulatory effect on ACE mRNA expression in hypoxia. 
  
Improvements in walking ability after exercise training are associated with increases in 
both  VEGF  and  VEGF  receptor  expression.  ACE  inhibitors  could  play  a  role  in 
improving claudication by potentiating increases in VEGF in addition to their known 
action of suppressing ACE activity.   5 
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CHAPTER 1 
INTRODUCTION   23 
CHAPTER 1 
1.1  INTERMITTENT CLAUDICATION 
Peripheral arterial disease is caused by atherosclerotic lesions in the arteries supplying 
the lower limbs, which result in a reduction of blood flow to the extremities. It is a 
significant  cause  of  functional  impairment,  mortality  and  morbidity  in  the  western 
world, and in the UK alone affects up to 20% of people over the age of 75.
49;243 With 
incidence increasing with age, and the continued growth of the elderly population, its 
prevalence is likely to rise considerably over the next 20 years.
43 
 
A wide spectrum of disease severity exists. Gangrene and limb loss occur in the most 
severe cases, whilst those with mild disease may be completely asymptomatic. Many 
individuals with mild disease experience pain on walking. This phenomenon has been 
termed  intermittent  claudication,  a  word  derived  from  the  Latin  word  „claudicatio‟ 
meaning „limping.‟ It was first coined by physiologists who, after ligating the femoral 
arteries of horses, noted that they limped before stopping intermittently as they ran in 
the field.
71 The term intermittent claudication is now used to describe muscular leg pain 
brought on by walking which, with continued walking causes the patient to stop, but is 
relieved within minutes by rest. The pain can be in one or both legs, and is typically felt 
in the calf muscle. Claudication affects 15 to 40% of patients with peripheral arterial 
disease. It is associated with decreased mobility, a reduced ability to perform normal 
daily activities, and can have a considerable negative impact on quality of life.
229;244 
 
1.1.1  Pathophysiology 
Although intermittent claudication may be caused by conditions such as popliteal artery 
entrapment, fibromuscular dysplasia and external compression syndromes, these causes   24 
are rare with the pathology underlying almost all cases being atherosclerosis.
43 Cigarette 
smoking is the greatest risk factor for developing atherosclerosis, with other risk factors 
including  old  age,  diabetes,  hypertension  and  hyperlipidaemia.  The  formation  of 
atherosclerotic plaques involves a complex interaction between lipids, the endothelium, 
inflammatory cells, platelets and vascular smooth muscle cells. In brief, injury to the 
endothelium, for example by cigarette smoking or low density lipoproteins, causes an 
inflammatory response characterised by the infiltration of inflammatory cells into the 
arterial wall, smooth muscle cell proliferation and lipid deposition.
211 The consequence 
of  this  process  are  occlusive  or  stenotic  atherosclerotic  lesions  which  may  occur 
anywhere in the arterial tree, but primarily in large and medium sized vessels. 
 
In healthy subjects, the onset of exercise produces a series of physiological responses to 
enable  the  metabolic  demands  of  exercise  to  be  met.  Almost  immediately,  cardiac 
output and respiratory rate increase, and peripherally vasodilatation occurs in active 
muscles.
125;132 The net result is a large increase in blood flow to the active muscles, 
resulting in increased oxygen delivery and carbon dioxide removal, thereby allowing 
exercise to be sustained.
125 However, in claudicants atherosclerotic lesions in the main 
arteries supplying the legs interfere with blood flow to the leg muscles sufficiently to 
limit  blood  flow  increases  after  the  onset  of  exercise.  Thus,  the  failure  to  increase 
oxygen delivery in response to exercise leads to an imbalance in the demand for and the 
supply  of  oxygen.  Subsequently,  the  supply  of  adenosine  triphosphate  (ATP) 
synthesised by aerobic metabolism becomes insufficient to sustain the level of exertion, 
causing  anaerobic  metabolism  to  predominate.  This  reliance  on  anaerobic  pathways 
during walking leads to an accumulation of lactic acid and phosphate ions in the leg 
muscles, causing muscular pain and fatigue.
255    25 
Although the pathogenesis of intermittent claudication is initiated by atherosclerosis, 
there is a poor correlation between the pressure drop across the limb and ischaemic 
symptoms and function.
113 This is principally due to the complex pathophysiology of 
intermittent claudication, with several other pathological processes contributing to the 
condition  causing  a  further  loss  of  walking  performance  (Figure  1.1).
86  Repeated 
episodes  of  ischaemia  and  reperfusion,  with  the  associated  generation  of  reactive 
oxygen species, damages skeletal muscle causing neurological, muscular and metabolic 
disturbances.
117;284 Distal axonal denervation of muscle fibres, muscle fibre atrophy and 
loss  of  muscle  strength  have  all  been  described.
56;199  Oxidative  metabolism  is  also 
considerably impaired, with studies showing a decrease in the level of aerobic enzymes, 
a reduction in capillary density with increasing severity of disease, and a reciprocal 
increase in anaerobic enzyme levels.
56 Furthermore, abnormal muscle metabolism leads 
to the accumulation of intermediates of oxidative metabolism such as the acylcarnitines 
in the muscle. These are formed from acetyl-CoA intermediates in the oxidation of fatty 
acids,  proteins,  and  carbohydrates,  and  are  detrimental  to  muscle  function.
115  In 
addition, abnormalities in endothelial function may lead to a misdistribution of blood 
flow in the microcirculation, with blood flow increased through arterio-venous shunts, 
and  decreased  through  nutritional  capillaries.
1  Changes  in  blood  viscosity, 
microthrombi,  white  blood  cell  and  platelet  activation  also  contribute  to  decreased 
regional blood flow and ischaemia.
83;86 Finally, another major issue is general physical 
deconditioning caused by the relative inactivity of these patients.
71 
 
1.1.2  Natural History 
In  addition  to  causing  severe  functional  disability  and  reducing  quality  of  life, 
intermittent claudication is also a significant marker for systemic atherosclerosis, with a   26 
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Figure 1.1  Summary  of  the  Pathophysiological  Processes  Involved  in 
Intermittent Claudication. 
 
   27 
large proportion of patients also having coronary artery and cerebrovascular disease. 
Overall, 50 percent of claudicants will die within 10 years, more than three times that of 
an age matched normal population. The commonest causes of death are myocardial 
infarction  and  stroke.  Indeed,  a  claudicant  is  more  likely  to  die  from  myocardial 
infarction than a comparable patient with angina.
229 In contrast, the natural history of 
arterial disease of the lower limbs is relatively benign. The majority of patients can be 
managed conservatively, and do not require interventional procedures. Up to 75 percent 
of patients with intermittent claudication will have limb symptoms that remain stable or 
improve. Only 25 percent deteriorate, and only 5 percent will ever need intervention in 
the  form  of  endovascular  procedures  or  surgery.  About  2  percent  of  patients  with 
intermittent claudication, usually diabetics and heavy smokers, will eventually need a 
major amputation.
71 
 
1.1.3  Management 
Given  the  significant  vascular  mortality  and  morbidity  in  patients  with  peripheral 
arterial disease, a key part of management involves secondary prevention in optimising 
cardiovascular risk factors to reduce the number of cardiac and cerebral events. This 
includes encouraging smoking cessation, and ensuring good control of blood pressure 
and diabetes. Patients should also be started on anti-platelet therapy, such as aspirin or 
clopidogrel, and unless any contra-indications are present be started on a statin to reduce 
cholesterol.
43 
 
Regarding the specific treatment of peripheral arterial disease, the severity of disease 
determines both symptoms and management. In the presence of critical ischaemia, in 
which the viability of a limb is threatened, surgery or endovascular procedures such as   28 
angioplasty are the widely accepted management modalities.
71 The treatment options for 
patients  with  less severe symptoms  such as  intermittent  claudication include bypass 
surgery, endovascular procedures, drug therapy and exercise.
229;255 At present, there is 
no consensus about management and intervention rates vary greatly between centres. 
Surgery  is  generally  reserved  for  those  with  debilitating  symptoms  not  suitable  for 
angioplasty and unresponsive to conservative measures, but is associated with increased 
morbidity and mortality.
43 Several drug therapies have been used to try to improve the 
symptoms  of  claudication  with  generally  limited  success.
111  The  main  exception  is 
cilostazol, a phosphodiesterase inhibitor, which has been shown to increase both pain-
free and maximal treadmill walking distance, and improve quality of life.  However, 
common  side-effects  include  headache,  diarrhoea  and  palpitations,  and  the  drug  is 
contra-indicated in the presence of heart failure.
13 There is also evidence that statins 
increase pain-free walking distance in addition to lowering cholesterol.
163  
 
The continual development of percutaneous transluminal angioplasty (PCTA) has led to 
its widespread use in the treatment of intermittent claudication. However, its role is still 
controversial.
43 The recent trend in the treatment of intermittent claudication has been 
towards a more conservative approach, and in those with relatively mild symptoms, 
exercise still remains the cornerstone of treatment.
49  
 
1.2  EXERCISE FOR INTERMITTENT CLAUDICATION 
The  benefits  of  exercise  for  claudicants  have  been  known  for  many  years. 
Improvements in walking after exercise training were first described by Erb in 1898. In 
1988, Housley described the treatment of intermittent claudication with the 5 words: 
„stop  smoking  and  keep  walking‟.
255  More  recently,  the  TransAtlantic  Inter-Society   29 
Consensus  (TASC)  working  group  publication  made  a  recommendation  that  „a 
programme of exercise therapy (preferably supervised) should always be considered as 
part of the initial treatment for patients with intermittent claudication‟.
71 To date, a large 
number  of  clinical  trials  have  demonstrated  the  efficacy  of  exercise  for  improving 
walking distance, functional capacity and quality of life. 
 
1.2.1  Supervised and Unsupervised Exercise Programmes 
In clinical practice, exercise training in claudicants ranges from simple advice, in which 
patients are encouraged to walk regularly and to persist through the claudication pain as 
much  as  possible,  to  more  formal  supervised  exercise  programmes.  In  the  UK,  the 
majority of patients are only given exercise advice and few supervised programmes are 
available, due to the fact that they are very labour intensive and expensive.
243  
 
The majority of trials  examining the effectiveness  of  exercise training have studied 
supervised  training  programmes.  A  meta-analysis  of  21  exercise  rehabilitation 
programmes demonstrated that the distance walked to the onset of claudication pain on 
a treadmill increased by 179 percent and the maximal walking distance by 122 percent 
following a period of exercise training. Furthermore, the components of an exercise 
programme that led to the greatest improvements in walking distances were: training 
session greater than 30 minutes duration, frequency of training sessions at least 3 times 
per  week,  walking  used  as  the  mode  of  training,  use  of  near  maximal  pain  during 
training as the end point, and programme length of greater than 6 months.
99 This meta-
analysis included non-controlled observational studies. A Cochrane review analysed 10 
randomised controlled trials involving nearly 250 patients enrolled mainly in supervised 
walking  programmes.  This  analysis  demonstrated  a  significantly  increased  maximal   30 
walking time of 6.5 minutes after exercise therapy, with an improvement in walking 
distance of about 150 percent.
148 
 
Some studies have made comparisons between the benefits of supervised exercise and 
unsupervised  exercise.  In one trial,  patients  were randomised to  either  a supervised 
weekly exercise class or exercise advice alone. After 6 months the supervised exercise 
group had improved their walking distance by 129 percent compared to only 69 percent 
for the exercise advice only group.
49 Several other studies also show limited benefits for 
unsupervised  exercise,  with  the  bulk  of  evidence  showing  that  supervised  exercise 
programmes provide the most symptomatic benefits.
197;243 A recent Cochrane review of 
8  randomised  controlled  trials  showed  a  significant  difference  in  improvement  with 
supervised  exercise  training,  with  an  approximately  150  metre  greater  increase  in 
walking distance compared to unsupervised training. This difference was maintained at 
6 months.
18 However, despite this evidence unsupervised training is likely to be more 
effective than no training at all.
71 There are several reasons why supervised training may 
be  more  beneficial  than  unsupervised  training.  Patients  enrolled  on  a  structured 
supervised  exercise  programme  are  much  more  likely  to  comply  with  treatment 
compared to those only given advice. In addition, supervised training regimes consist 
mainly of treadmill walking, which is able to produce higher workloads compared to 
walking on level ground at normal speed. These higher workloads potentially stimulate 
greater adaptations to training, including cardiovascular adaptations.
18  
 
Other trials have shown treadmill training to be more effective than strength training in 
improving  walking  performance  in  claudicants.
116  In  addition  to  walking  ability, 
exercise programmes have been shown to produce improvements in functional status,   31 
physical activity levels, and quality of life.
97;198 Moreover, the benefits and effectiveness 
of  exercise  are  similar  in  both  smokers  and  non-smokers.
98  Exercise  rehabilitation 
programmes have been shown to be safe, with no associated morbidity or mortality. 
Initial  studies  have  also  shown  improvements  in  glucose  metabolism,  reduction  in 
cholesterol levels, and enhanced smoking cessation. These benefits are not seen with 
other  interventions  and  could  potentially  decrease  cardiovascular  risk  and 
mortality.
71;148 
 
1.2.2  Exercise Compared to Angioplasty for Intermittent Claudication  
While  the  mainstay  of  treatment  for  intermittent  claudication  remains  conservative 
therapy, improvements in the safety and technique of PCTA have resulted in an increase 
in  the  number  of  these  procedures  to  treat  patients  with  relatively  mild  peripheral 
arterial disease. PCTA involves dilating a stenosed or occluded artery, most commonly 
using a balloon with or without leaving a stent in-situ. However, the role of PCTA in 
treating patients without critical ischaemia is still controversial. Guidelines published by 
the American Heart Association and American College of Cardiology in 2005 stated 
that  patients  with  claudication  should  only  be  considered  for  revascularisation  if 
conservative measures had failed or were predicted to fail, and only then in the presence 
of severe disability.
43  
 
Although  PCTA  has  been  shown  to  improve  walking  distance  and  quality  of  life 
compared to conservative treatment, more recent trials have compared the long-term 
efficacy of PCTA with exercise training.
43;44 A Cochrane review demonstrated PCTA to 
have  short  term  benefits  that  were  not  sustained  in  the  long-term.
96  Another 
randomised-controlled  trial  showed  patients  in  an  exercise  group  to  have  greater   32 
improvements at 15 months compared to a PCTA group. In addition, claudicants with 
superficial  femoral  artery  disease  seem  to  benefit  more  from  exercise,  compared  to 
those  with  aortoiliac  disease.
188  A  further  Cochrane  review  showed  no  significant 
benefits from the placing of a stent compared to angioplasty alone in claudicants.
12 
 
In summary, a large number of trials have shown exercise training to be a safe, non-
invasive and effective method to increase the walking ability, quality of life and general 
health of claudicants. It is beneficial to all patients who are able to exercise, is more 
effective than PCTA in the long-term and should remain as the principal treatment for 
intermittent claudication. 
 
1.2.3  Mechanisms for Improvement with Exercise 
Although the benefits of exercise are well recognised, the precise mechanisms that lead 
to an improvement in walking ability are not fully understood, and have recently been 
identified as an area requiring further research.
86 However, it appears that a combination 
of  adaptive  mechanisms,  some  not  observed  in  healthy  individuals,  account  for  the 
benefits  seen  after  training  (Figure  1.2)  These  act  by  reversing  some  of  the 
pathophysiological processes underlying the condition, and are described below: 
 
Increased Blood Flow  
Traditionally, improvements in walking ability following exercise have been attributed 
to an increase in blood flow secondary to the development of collateral vessels that 
„bypass‟ the arterial stenoses or occlusions. The development of these collateral vessels 
is a universal response to muscle ischaemia, but is inconsistent and the vessels produce 
variable amounts of flow.
209 However, in some cases these collaterals may compensate  33 
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Figure 1.2  Summary of Potential  Mechanisms Leading to Improved Walking 
Ability with Exercise Training. 
At present, data are insufficient to accurately quantify the relative importance of each 
mechanism. Adapted from Stewart et al.
244   34 
for the arterial stenoses enough to minimise or even eliminate ischaemic symptoms, 
with proximal collateral vessels appearing to be more effective than distal collaterals in 
reducing symptoms.
86 The development of collateral vessels involves the enlargement 
and  remodeling  of  pre-existing  arterioles  into  mature  vessels,  a  process  called 
arteriogenesis.
222 The mechanism underlying arteriogenesis is poorly understood, but 
may involve increased sheer stress in the arterioles, caused by the redistributed blood 
flow, activating the endothelium and stimulating the release of factors such as placental 
growth factor (PlGF).
157;222 Vascular endothelial growth factor (VEGF) is not thought to 
play a major role.
110 Other studies have shown that muscle capillaries may also become 
arteriolised- a process associated with increased fibroblast growth factor-2 expression.
15 
 
Despite  the  significant  evidence  for  collateral  vessel  formation,  the  development  of 
collateral vessels and an increase in gross blood flow appears to play a limited role in 
improving walking ability with exercise training in claudicants. The majority of studies 
in claudicants have shown little or no increase in blood flow following an  exercise 
programme,  even  when  significant  improvements  in  walking  ability  have  been 
recorded.
244;255  When  increases  in  blood  flow  have  been  detected,  they  are  poorly 
correlated  to  improvements  in  walking  distance.
71;114  Similarly,  studies  have 
consistently shown a poor correlation between leg blood flow and walking ability.
255 
PCTA, which results in a patent artery and increased blood flow, is associated with less 
marked increases in walking ability than exercise.
188 These findings might be explained 
by animal models of ischaemia, which show that arteriogenesis occurs 10 days after 
femoral  artery  ligation,  peaks  at  20-40  days,  and  is  not  temporally  associated  with 
ischaemia.
110  One  might  speculate  that  in  stable  claudicants  (the  subjects  of  most 
exercise  studies),  collateral  development  has  already  occurred  and  thus  would  be   35 
unlikely to contribute to improvements in walking ability. Furthermore, since ischaemia 
per se does not appear to be the stimulus for arteriogenesis, exercise programmes that 
involve  repeated  episodes  of  ischaemia  would  be  unlikely  to  activate  the  pathways 
linked to arteriogenesis. 
 
As there is currently little evidence to support an increase in blood flow as a major 
factor in the increase in walking ability after training, other mechanisms must account 
for the improvements seen. Some have proposed that while overall blood flow does not 
increase, training may result in a redistribution of blood from inactive to exercising 
muscles. Another finding is increased capillary density in the muscles.
261 The sprouting 
of new capillaries in the muscles is a separate phenomenon to arteriogenesis, and is 
termed angiogenesis.
253 Unlike arteriogenesis, angiogenesis is mediated by ischaemia 
and it has been suggested that repeated training, causing transient hypoxia, may increase 
the  expression  of  VEGF  resulting  in  endogenous  angiogenesis.
244  Several  animal 
models have shown upregulation of VEGF with ischaemia.
151 The effects of increased 
capillary density in active muscles may include a redistribution of blood flow, improved 
substrate  delivery  and  the  enhanced  removal  of  metabolites.  This  is  supported  by 
findings showing a reduction in femoral venous oxygen saturation in claudicants after 
training, indicating increased oxygen uptake in the muscles.
239 Therefore, while gross 
increases in blood flow do not appear to be important in the improvement in walking 
ability with exercise training, the improved local delivery and distribution of the limited 
blood  supply  due  to  angiogenesis  could  be  a  much  more  important  mechanism 
underlying  improvements.  Moreover,  the  mechanism  underlying  angiogenesis  is 
promoted by ischaemia, and will thus be stimulated by an exercise programme. VEGF 
and angiogenesis will be discussed in more detail in Section 1.4.   36 
Changes in Muscle Metabolism 
Several adaptations occur in skeletal muscle following exercise training that lead to an 
improvement  in  the  aerobic  capacity  of  the  muscles  and  hence  a  reversal  of  the 
metabolic dysfunction seen in claudicants prior to training. Animal models have shown 
that these adaptations only occur with a combination of training and hypoxia, and that 
hypoxia alone does not induce any change.
255 Studies of muscle biopsies before and 
after an exercise training programme have revealed significant increases in oxidative 
enzymes such as cytochrome oxidase and succinic oxidase, with smaller increases in 
citrate synthase after training.
121 Fatty acid oxidative metabolism is also enhanced, as 
shown  by  the  decrease  in  respiratory  exchange  ratio  for  a  given  workload  after 
training.
114 This increase in fatty acid metabolism reflects an increase in mitochondrial 
function and/or better oxygen delivery, but is generally indicative of increased oxidative 
capacity.  In  contrast,  no  changes  are  seen  in  anaerobic  capacity.
255  The  decreased 
reliance on anaerobic pathways has been observed in studies examining venous blood 
samples in claudicants, with decreased lactic acid levels at similar workloads noted after 
a period of training.
239;254 An increase in arteriovenous oxygen gradient is also noted, 
indicating  increased  muscle  oxygen  extraction,  possibly  related  to  increased  muscle 
myoglobin concentration.
122;144 Furthermore, exercise training has also been shown to 
reduce the level  of acylcarnitines  that accumulate  in  the leg muscles  of claudicants 
secondary to defective oxidative metabolism, with the extent of removal correlated to 
improvements in walking ability.
114;115 
 
Another  metabolic  effect  potentially  underlying  exercise  related  improvements  in 
claudicants  is  ischaemic  preconditioning,  a  phenomenon  whereby  short  periods  of 
ischaemia offer protection from a later episode of prolonged ischaemia. This was first   37 
described in the heart, but has now been demonstrated in many other tissues including 
skeletal muscle.
301 Several short periods of ischaemia have been shown to improve the 
subsequent  ischaemic  tolerance  of  skeletal  muscle,  with  preservation  of  force 
production, decrease in lactate accumulation, decreased ATP depletion and reduction of 
necrosis all observed.
2;32 The mechanism for this protection is thought to relate to the 
activation of Protein kinase C by triggers such as adenosine and bradykinin. This leads 
to  altered  nuclear  transcription  and  the  opening  of  mitochondrial  KATP  channels, 
resulting  in  preserved  ATP  generation  in  low  oxygen  conditions.
300  Whether  these 
effects are reflected in less severe models of ischemia such as intermittent claudication 
or produce long-term benefits remain to be seen. However, in one study claudicants 
„preconditioned‟ by performing several submaximal walking exercises performed better 
in a subsequent maximal walking test.
37 
 
Changes in Endothelial Function and the Microcirculation 
Endothelial  dysfunction  has  been  demonstrated  in  patients  with  peripheral  arterial 
disease,  secondary  to  a  decrease  in  nitric  oxide  (NO)  synthesis.
299  This  causes  a 
decrease in exercise induced hyperaemia, and hence impaired substrate delivery to the 
muscles.  Short-term  exercise  has  been  shown  to  stimulate  endothelium-dependent 
vasodilatation. In the long-term, the sheer stress caused by increased blood flow from 
repeated episodes of exercise increases the endothelial expression of NO synthase and 
prostacyclin,  improving  endothelial  function  and  vasodilatation  in  response  to 
exercise.
179  Although  few  studies  of  endothelial  function  in  claudicants  have  been 
performed, one study has shown an increase in endothelial dependent vasodilatation of 
61%  and  an  increase  in  post-occlusive  reactive  hyperaemic  blood  flow  of  15%, 
following a 6 month period of exercise rehabilitation.
27   38 
Reduction of Exercise-Induced Inflammation 
It has been suggested that exercise training could actually be harmful to patients, by 
promoting  a  systemic  inflammatory  response  that  decreases  muscle  function  and 
promotes  atherosclerosis.
268  Indeed,  in  claudicants  baseline  levels  of  inflammatory 
markers are raised, and exercise to the point of muscle pain generates free radicals, 
activates neutrophils and produces an inflammatory reaction.
267 However, in the long-
term  exercise  training  causes  an  attenuation  of  these  inflammatory  markers,  with 
training resulting in a decrease in C-reactive protein and serum amyloid levels.
266 This 
decrease in the inflammatory response may lead to improvements in muscle function 
and  walking  ability,  and  concerns  that  exercise  training  might  potentiate  vascular 
inflammation and atherosclerosis appear to be unjustified.
267 
 
Changes in Haemorheology 
Haemorheology describes the behaviour and fluidity of blood, which is abnormal in 
claudicants with many having elevated blood viscosity.
254 Exercise training has been 
shown to reverse these abnormalities, with a reduction of blood and plasma viscosity, an 
increase in red cell filterability, and a decrease in red cell aggregation noted.
83 These 
changes  increase  the  fluidity  of  blood  and  are  thought  to  allow  increased  oxygen 
delivery to exercising muscles, thus enhancing walking performance. However, other 
studies have revealed no benefits after an exercise programme.
52;254 
 
Changes in the Cardiorespiratory System and Biomechanics of Walking  
Some of the benefits of exercise training may be due to an improvement in systemic 
cardiovascular status. Exercise trained patients have lower resting and exercise heart 
rates compared to untrained patients. Peak oxygen consumption also increases.
114 One   39 
group has demonstrated that upper limb exercise training in claudicants, resulting in an 
increase in cardiovascular fitness, also produces significant improvements in walking 
distance similar to those observed after lower limb training.
282;312 Another observation 
noted after walking programmes is a decrease in steady-state oxygen consumption for 
equivalent workloads during treadmill testing.
115;254 This implies that the oxygen cost 
for  the  same  workload  has  decreased.
255  However,  although  central  cardiovascular 
adaptations may improve walking ability, significant improvements in walking distance 
may occur in the absence of any increase in cardiovascular fitness.
178 
 
Another potential factor leading to improvements after an exercise programme is an 
improvement  in  the  biomechanics  and  mechanical  efficiency  of  walking  after 
training.
244;255 Patients with claudication pain often adapt their gait to favour stability at 
the expense of velocity. This maladaptation increases the oxygen cost of walking, but 
may be reversed by exercise training.
244 This theory is supported by evidence which 
shows  that  after  4  months  training,  less  oxygen  is  used  at  a  given  workload  on  a 
treadmill.
290 Other studies have also reported that oxygen uptake, respiratory exchange 
ratio, lactate levels, and heart rate were all lower in exercise trained claudicants.
114;116 
Whilst this may reflect improved biomechanics and mechanical efficiency, an increase 
in muscular metabolic efficiency may also contribute to this effect, and may also help to 
explain increases in walking ability noted after upper limb training.
282 One factor that 
has  been  shown  to  enhance  muscular  efficiency  in  response  to  training  is  a 
polymorphism of the angiotensin converting enzyme (ACE) gene, which forms part of 
the renin-angiotensin system.
288 In addition, this polymorphism is allied to improved 
endurance, reduced inflammation and enhanced endothelial function, all factors known 
to be important for increasing walking ability in claudicants after training.   40 
1.3  ANGIOTENSIN-CONVERTING ENZYME 
ACE forms an integral part of the renin-angiotensin system (RAS). Its main role is in 
the production of angiotensin II (Ang-II) from angiotensin I, and the degradation of 
bradykinin (BK). Ang-II and BK are the key physiologically active components of the 
RAS, and thus their rate of production or degradation is one of the major determinants 
of the  activity  of the RAS.  A  functional polymorphism of the ACE  gene has been 
described  that  is  linked  to  variation  in  ACE  activity,  and  has  been  shown  to  have 
widespread physiological effects. The effects of ACE and the ACE I/D polymorphism 
will be discussed in this section. 
 
1.3.1  Renin-Angiotensin System: Overview 
The Circulating Renin-Angiotensin System 
The  discovery  of  a  metabolic  pathway  that  contributed  a  major  role  to  circulatory 
homeostasis was made in the 1950‟s.
54 This pathway, termed the circulating RAS, is 
important in regulating blood pressure, sodium homeostasis and fluid balance.
107 In the 
circulating RAS, a decrease in renal perfusion pressure stimulates the production and 
release of renin, a proteolytic enzyme, from the juxta-glomerular cells of the kidney into 
the circulation. Renin cleaves angiotensinogen, a circulating α2-globulin synthesised by 
the  liver,  to  form  the  decapeptide  angiotensin-I.  ACE,  which  is  found  both  as  a 
membrane bound protein at the cell surface and in circulating plasma (soluble ACE), 
subsequently  further cleaves  angiotensin-I to  form  the octapeptide  Ang-II.
145 Ang-II 
exerts several effects including salt and water retention via the release of aldosterone 
from the adrenal cortex, and vasoconstriction.
54 Moreover, another important role of 
ACE  is  in  the  degradation  and  inactivation  of  BK,  which  otherwise  has  potent 
vasodilatory effects and influences muscle metabolism. Finally, Ang-II can be further   41 
degraded  to  form  angiotensin  III,  angiotensin  IV  and  angiotensin-(1-7).  These 
biologically active peptides may contribute some of the effects of RAS, although their 
relative  contribution  is  unclear.
36  The  key  components  of  the  circulating  RAS  are 
summarised in Figure 1.3. 
 
Local Renin-Angiotensin Systems 
In addition to the circulating RAS, local RASs have also been described in various 
tissues including the heart, brain, lung, pancreas and adipose tissue.
131 A local RAS has 
now been discovered in skeletal muscle.
72;221 This local skeletal muscle RAS depends 
on a combination of in-situ synthesis of all the RAS components and the uptake of renin 
or prorenin from the circulation.
63 ACE has been identified on both skeletal muscle 
membranes and on endothelial cells of the capillary bed.
72;221 In animal models, local 
skeletal muscle ACE  accounts for up to  50% of  BK hydrolysis,  and  angiotensin  II 
generated locally has been shown to be of functional importance.
72;131 The role of this 
local RAS is still debated but may include growth stimulation, neovascularisation, and 
the  regulation  of  inflammation.
126  The  importance  of  tissue  RAS  as  a  potential 
therapeutic target comes from evidence that the anti-hypertensive properties of ACE 
inhibitors correlate better with the inhibition of tissue ACE, rather than plasma ACE. 
Furthermore, the additional benefits of ACE inhibitors such as improved endothelial 
function and reduction in inflammation, appear to be independent of changes in blood 
pressure, and are thought to relate to effects on local RAS systems.
75 
 
Angiotensin-II Receptors 
Ang-II produces its effects via two main receptors, type I (AT1) and type II (AT2), 
which  were  originally  classified  according  to  their  ability  to  bind  with  various  42 
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Figure 1.3  Summary of the Renin-Angiotensin System 
ACE catalyses the production of Ang-II and the degradation of BK. Thus, a decrease in 
ACE activity will lead to lower levels of Ang-II and increased levels of BK. 
   43 
antagonists.
264 More recently, two other angiotensin II receptors (AT3 and AT4) have 
been described, but their role has yet to be clearly defined.
150 AT1 and AT2 receptors are 
both seven transmembrane domain G-protein coupled receptors, although they appear to 
have  quite  different  pharmacology.  The  AT1  receptor  is  expressed  ubiquitously  and 
appears to mediate most of the well known biological effects of Ang-II.
150 In contrast, 
the role of the AT2 receptor is less well understood. Although it is highly expressed in 
foetal  tissues  during  development,  its  expression  decreases  markedly  after  birth. 
However, the AT2 receptor can be upregulated in pathological conditions, for example 
after  injury,  during  wound  healing  and  by  ischaemia.
150;236  It  appears  to  have  an 
opposing role to the AT1 receptor, antagonising its actions.
127  
 
1.3.2  The ACE I/D Polymorphism 
Since ACE acts as the primary catalyst for Ang-II production, any factor affecting ACE 
activity  will  have  substantial  effects  on  the  RAS.  The  ACE  gene  is  located  on 
chromosome 17q23, spanning 21 kilobases and containing 26 exons. Two isoforms of 
ACE are produced by this gene: gonadal ACE is expressed only in the testes and will 
not be considered further, while somatic ACE is expressed throughout the body.
124 ACE 
levels have been shown to vary considerably between individuals, but less so within 
families, indicating a genetic influence on ACE levels.
34  
 
Rigat et al. discovered a functional polymorphism of the ACE gene consisting of the 
presence (insertion, I-allele) or absence (deletion, d-allele) of a 287 base pair fragment 
at intron 16 on the ACE gene (Figure 1.4).
203 Presence of the I-allele is known to affect 
both serum and tissue ACE, and is associated with reduced ACE activity.
64;203 Thus, 
three genotypes are possible: II (with low ACE activity), ID (with intermediate ACE  44 
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Figure 1.4  Schematic  Diagram  of  the  ACE  Gene  Illustrating  the 
Insertion/Deletion Polymorphism 
The ACE gene is found on the long arm of chromosome 17. The I/D polymorphism 
consists of the presence (I-allele) or absence (D-allele) of a 287bp Alu repeat sequence 
at intron 16 of the ACE gene.   45 
activity)  and  DD  (with  high  ACE  activity).  In  Caucasians,  the  I-  and  D-alleles  are 
equally common. Thus, 25% of the population will have the II genotype, 50% ID, and 
25% the DD genotype.
131;167  
 
Although the polymorphism occurs within an intron, it is a very strong marker for ACE 
activity and accounts for up to  47% of the variance in  serum ACE activity.
203  The 
insertion  consists  of  a  repeat  alu  sequence.
204  These  alu  insertional  elements  are 
abundant and occur throughout the human genome, and can reduce the transcription of 
adjacent regions in the genome by a variety of mechanisms, for example by inducing 
methylation or by promoting local nucleosome assembly.
213 Indeed, in heterozygote ID 
individuals, more ACE mRNA has been shown to originate from the D-allele than the I-
allele.
246 However, it also remains possible that the I/D polymorphism is only a marker 
for  ACE  activity,  and  that  it  is  in  strong  linkage  disequilibrium  with  another 
polymorphism which may be directly responsible for the variations in ACE.
186 
 
The ACE I/D polymorphism has been associated with many pathological conditions, 
including diabetic renal disease, atherosclerosis and cardiac growth.
25;35;169 Low ACE 
activity has also been linked to many functional and physiological changes, which could 
be of significance in considering adaptations seen in claudicants in response to training. 
 
1.3.3  ACE Polymorphism: Effects on Endurance Training 
A number of recent studies have suggested that presence of the I-allele is associated 
with increased endurance performance, with an excess of I-alleles occurring in elite 
endurance athletes. These studies are summarised in Table 1.1. In addition, the benefits 
of  the  I-allele  relate  to  an  improved  training  response  rather  than  endowing  an  46 
 
Table 1.1  Studies  Showing  an  Association  Between  ACE  I/D  Genotype  and 
Physical Performance 
 
Reference  Subjects  End-point  Findings 
Montgomery et 
al.
170 (1998) 
British male 
Caucasian army 
recruits  (n=123) 
Repetitive elbow flexion 
with a 15kg barbell after a 
10 week general physical 
training program 
I-allele associated with 
improved response to 
endurance training 
Montgomery et 
al.
170 (1998) 
Elite Mountain 
Climbers  (n=25) 
Genotype distribution 
among elite climbers 
compared to controls 
An excess of II- and 
deficiency of DD-genotypes 
in the elite climbers 
Gayagay et al.
101  
(1998) 
Australian Caucasian 
Olympic trial male 
and female rowers 
(n=64) 
Allele and genotype 
distribution in elite rowers 
compared to matched 
controls 
I-allele and II genotype 
frequency significantly 
increased in elite rowers 
Myerson et al.
173  
(1999) 
British male and 
female Olympic 
standard runners of 
mixed distances 
(n=79) 
Allele frequency and 
genotype distribution 
compared to distance run 
and matched controls 
I-allele associated with 
endurance events and D-
allele associated with power 
events 
Woods et al.
293  
(2001) 
Caucasian elite male 
and female 
swimmers (n=56) 
Allele and genotype 
distribution in elite 
swimmers compared to 
non-elite swimmers 
DD genotype and D-allele 
associated with elite power-
orientated short distance 
swimmers 
Nazarov et al.
175  
(2001) 
Russian athletes of 
both sexes from 
various sports 
(n=217) 
Allele and genotype 
distribution of 
„outstanding‟ athletes 
stratified by event 
duration compared to 
matched controls 
An excess of the D-allele 
associated with outstanding 
short distance athletes, and 
an excess of the I-allele 
associated with outstanding 
middle distance athletes 
Tsianos et al.
272  
(2004) 
Elite male and 
female long distance 
swimmers (n=35) 
Comparison of ACE 
genotype frequency with 
swimming event 
longevity 
I allele associated with 
longer distance and D allele 
with shorter distance 
swimmers 
Hruskovicova et 
al.
123  (2006) 
Successful long 
distance runners and 
skaters (n=455) 
Genotype and allele 
frequency compared to 
sedentary controls 
An excess of the I-allele and 
II genotype in successful 
marathon runners and 
skaters 
           47 
individual  with  innate  endurance  capacity,  as  prior  to  training  performance  is 
independent  of  genotype.
170  In  contrast  to  the  I-allele,  the  D-allele  appears  to  be 
associated with increased power-orientated performance (Table 1.1). In addition, several 
studies, summarised in Table 1.2, have found no association between ACE genotype 
and athletic performance. However, a common attribute of these studies of elite athletes 
was that they were selected from a wide range of disciplines, and often from events in 
which  endurance  performance  alone  was  not  a  pre-requisite  for  success.  Such 
heterogeneous groups of athletes were unlikely to produce reliable information. The 
studies  of  response  to  training  in  army  recruits  also  used  subjects  from  broad 
backgrounds, and exposed them to diverse training regimes and were thus unlikely to 
find a significant correlation.
238 
 
ACE Polymorphism and Skeletal Muscle Efficiency 
In searching for a potential physiological interaction between the I-allele and enhanced 
endurance trainability, some investigators have measured maximal oxygen uptake (VO2 
max), a standard measure of cardiorespiratory fitness.
130 Several studies have shown no 
relationship  between ACE genotype or improved endurance with  VO2  max.
130;131;295 
Indeed, individuals with similar VO2 max can differ widely in endurance performance.
60 
It is thus unlikely that the enhanced endurance performance associated with the I-allele 
is related to changes in cardiovascular capacity. The lack of association between VO2 
max and endurance may also explain some of the negative studies reported in Table 1.2. 
 
Another theory proposes a local muscular effect as the underlying physiological link 
between the  I-allele  and endurance performance.
288  One study  revealed that oxygen 
consumption at a fixed workload in army recruits decreased significantly after general  48 
 
Table 1.2  Studies  Showing  No  Association  Between  ACE  I/D  Genotype  and 
Physical Performance 
 
Reference  Subjects  End-point  Findings 
Taylor et al.
260  
(1999) 
Australian Caucasian 
national standard 
aerobic athletes of 
both sexes and 
various sports 
(n=120) 
ACE I/D polymorphism 
genotype distribution 
among athletes compared 
to matched controls 
No difference in ACE 
genotype frequencies 
between athletes and 
controls 
Rankinen et al.
196  
(2000) 
Male endurance 
athletes from various 
sports (n=192) 
I/D allele and genotype 
distribution, and maximal 
oxygen uptake in athletes 
compared to sedentary 
controls 
I/D allele and genotype 
frequencies similar between 
athletes and controls. No 
association between I-allele 
and maximal oxygen uptake 
Rankinen et al.
195  
(2000) 
Healthy Caucasian 
and black sedentary 
subjects of both 
sexes (n=476) 
Changes in 
cardiorespiratory 
endurance parameters 
following a personalised 
20 week training program 
No association between 
ACE genotype and 
responses to endurance 
training, except in 
Caucasians where DD 
homozygotes had greatest 
improvements 
Sonna et al.
238 
(2001) 
Male and female 
ethnically diverse 
US Army recruits 
(n=147) 
Changes in peak oxygen 
uptake and performance 
in Army Physical Fitness 
Test (APFT) following an 
8 week physical training 
programme 
No significant association 
between ACE genotype and 
peak oxygen uptake or 
APFT score before and after 
training 
Scott et al.
224  
(2005) 
International Kenyan 
distance runners 
(n=70) 
Comparison of I/D allele 
frequency with national 
athletes and matched 
controls 
ACE I/D polymorphism not 
associated with elite 
endurance status in Kenyans 
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training. This reduction was more marked in subjects with II genotype compared with 
DD  subjects,  suggesting  an  ability  after  training  to  perform  „more  work  for  less 
oxygen‟.
295 Delta efficiency, which represents the efficiency of muscular contraction, 
was also examined in these recruits. Prior to training, delta efficiency was independent 
of  genotype,  but  after  training  delta  efficiency  increased  in  II  subjects,  whereas  no 
changes  were  seen  in  DD  recruits.
288  At  least  some  of  these  effects  on  muscular 
efficiency are thought to be mediated by elevation of BK activity.
287 Another study has 
shown that the II genotype leads to a relative sparing of energy reserves during a period 
of intense training, suggesting enhanced metabolic efficiency.
168 Thus, in summary the 
low ACE activity related I-allele is associated with improved responses to endurance 
training, a benefit which seems to be allied to an improvement in muscular efficiency. 
 
1.3.4  ACE Polymorphism: Effects on Inflammation 
Reduction of inflammation has previously been postulated as a cause for improvements 
in claudicants with exercise (Section 1.2.3). Moreover, increased inflammatory markers 
are associated with worse physical performance in elderly.
47 The RAS has an important 
function in regulating inflammatory responses and ACE has been shown to have a pro-
inflammatory role in almost every stage of acute inflammation.
166 An increase in local 
ACE expression is associated with macrophage activation, and may play a crucial role 
in conducting local tissue inflammatory responses.
146 ACE may also be important in 
regulating systemic inflammation via the Ang-II stimulation of interleukin-6.
31  
 
Reduction  in  ACE  activity  has  been  shown  to  attenuate  systemic  inflammatory 
responses.
166 Likewise, AT1 receptor antagonists have been shown to reduce levels of 
C-reactive protein and pro-inflammatory factors in normal individuals.
62 Conversely, in   50 
inflammatory diseases such as acute respiratory distress syndrome (ARDS), patients 
have both elevated ACE activity and Ang-II levels, and the D-allele is associated with 
increased incidence and poorer outcome.
160;285 Similarly, in meningococcal septicaemia 
the  ACE  DD  genotype  is  associated  with  increased  severity  of  sepsis  and  higher 
mortality.
108 
 
1.3.5  ACE Polymorphism: Other Associations 
In addition to muscular efficiency  and inflammation, the ACE genotype is allied to 
other associations that may augment the response to exercise training in claudicants. 
Low ACE activity associated with the I-allele has been suggested to mediate some of its 
effects by improving endothelial function through the increase in half-life of BK.
131 
Supporting  this  theory  is  evidence  which  shows  that  endothelial  dependent 
vasodilatation  is  significantly  higher  in  endurance  athletes  with  the  II  genotype, 
compared to those of DD genotype.
256 The DD genotype has also been associated with 
endothelial  dysfunction  and  reduced  vasodilatory  responses  in  the  coronary  and 
peripheral arteries of normal subjects.
33;172 However, one study has shown no effect of 
the  I/D  polymorphism  on  endothelial  function.
212  An  increase  in  vasodilatation  has 
already  been  proposed  as  a  mechanism  for  improvements  in  walking  ability  with 
training, and thus changes in ACE activity may modulate this effect.  
 
The I-allele is also associated with an increase in slow twitch, fatigue resistant type I 
muscle  fibres,  and  a  reciprocal  decrease  in  fast  twitch,  fatigable  type  IIb  muscle 
fibres.
310 Likewise, elite rowers shown to have an excess of the I-allele also have a 
tendency to possess a high proportion of type I muscle fibres.
131 Although low ACE 
activity related to the I-allele has been related to many benefits that could improve   51 
claudicants‟  responses  to  exercise  training,  as  yet  no  evidence  is  available  that 
associates the I/D polymorphism with angiogenesis. However, the RAS has been shown 
to be involved in the angiogenic process, with ACE inhibitors demonstrated to modulate 
the process in contrasting ways within different tissues and disease states. 
 
1.4  ACE AND ANGIOGENESIS 
The sprouting of new capillaries in muscle, termed angiogenesis, has been suggested as 
a  mechanism  for  improvement  in  claudicants  after  exercise  training.
253;261;292  The 
beneficial  effects  of  increased  capillary  density  in  active  muscles  could  include  a 
redistribution of blood flow with less shunting, improved substrate delivery and the 
enhanced removal of metabolites, enabling best use of the limited blood supply. 
 
1.4.1  Angiogenesis: Cellular Events 
Angiogenesis is characterised by the sprouting of new capillaries from the ends or sides 
of pre-existing vessels (Figure 1.5). Several distinct events have been established and 
are described below: 
 
Increased Vascular Permeability and Breakdown of Cell Contacts 
Angiogenesis is initiated by vasodilatation and an increase in vascular permeability. 
This allows the extravasation of plasma proteins, which provide a provisional scaffold 
for  migrating  endothelial  cells.
39;78  Inter-endothelial  cell  contacts  are  relaxed,  the 
underlying matrix loosens and smooth muscle cells detach, allowing the endothelial 
cells to migrate.
158 Proteinases such as the matrix metalloproteinases and plasminogen 
activators are also released, which degrade the extracellular matrix, causing the release 
of more growth factors and creating room for endothelial cells to migrate into.
176    52 
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Figure 1.5  Vascular Growth in the Adult 
Vascular growth may occur via Vasculogenesis (the mobilisation of angioblasts from 
the bone marrow), Angiogenesis (capillary sprouting) or by Arteriogenesis (collateral 
growth from existing vessels). Taken from Carmeliet.
39 
   53 
Migration and Lumen Development  
With the physical barriers to angiogenesis degraded, endothelial cells proliferate and 
migrate  into  the  cleared  path.  As  they  migrate  into  the  extracellular  matrix,  the 
endothelial  cells  initially  assemble  into  solid  cords,  which  subsequently  develop  a 
lumen. This is achieved by intercalation and thinning of the cells, and is accompanied 
by fusion with pre-existing vessels to increase their diameter and length.
39;57 
 
Survival and Remodelling 
Once the new vessels are assembled, the endothelial cells become quiescent and can 
survive for years. With time remodelling occurs and the vessels mature into a structured 
network of branching vessels.
38  
 
The  angiogenic  process  is  mediated  by  many  different  angiogenic  factors  including 
placental  growth  factor  (PlGF),  platelet  derived  growth  factor  (PDGF),    fibroblast 
growth factors (FGF) and Angiopoietin-2.
38;153;158;189 Another crucial factor regulating 
angiogenesis, which is involved in many stages of the process, is VEGF. 
 
1.4.2  Vascular Endothelial Growth Factor  
Vascular  endothelial  growth  factor-A  (VEGF)  is  the  most  important  mediator  of 
neovascularisation  associated  with  human  diseases.
89  It  is  a  multi-tasking  cytokine, 
affecting  diverse  tissues  and  stimulating  a  variety  of  events.
308  VEGF  belongs  to  a 
family of related growth factors, which also includes VEGF-B, VEGF-C, VEGF-D and 
PlGF. VEGF-C and VEGF-D are primarily lymphangiogenic factors, while PlGF has a 
primary role in arteriogenesis.
253 The role of VEGF-B in vivo is not known, but it may 
act a weak angiogenic factor.
235   54 
VEGF Isoforms 
The  VEGF  gene  is  located  on  chromosome  6p23.1  and  spans  approximately  14 
kilobases, containing 8 exons and 7 introns.
208;265 As a result of differential splicing and 
proteolytic processing,  at  least  six isoforms  are produced from the  gene, which are 
named according to the number of amino acid residues: 121, 145, 165, 183, 189 and 
206. Of these VEGF121, VEGF165 and VEGF189 are the major forms secreted by most 
cells types.
208 VEGF121 lacks the amino acid residues encoded by exons 6 and 7, and 
exists as a freely diffusible protein as it does not bind to cell surface heparins. Although 
VEGF121 mRNA transcripts are the most abundant, VEGF165 is the most common and 
biologically active protein.
201;309 VEGF165 lacks the residues encoded by exon 6, and has 
intermediate properties with approximately half binding to the extracellular matrix and 
half freely diffusible. The importance of the VEGF165 isoform as the principle effector 
of VEGF is underlined by studies showing that mice lacking the equivalent of VEGF165 
tend to die soon after birth, whilst those only expressing VEGF165 and no other isoforms 
are  healthy.
42;240  Finally,  VEGF189  is  almost  completely  bound  to  the  extracellular 
matrix, making it a reservoir for VEGF that can be mobilised by proteolysis.
90 
 
VEGF Receptors 
The biological effects of VEGF are mediated via two related receptor tyrosine kinases, 
VEGFR-1  (fms-like  tyrosine  kinase,  Flt-1)  and  VEGFR-2  (kinase-insert  domain 
receptor,  KDR)  found  on  the  vascular  endothelium.
231;262  The  precise  function  of 
VEGFR-1 is still a matter for debate. However, the evidence suggests that the properties 
of VEGFR-1 vary depending on the developmental stage, pathology and tissue type.
90 
In some circumstances, VEGFR-1 is thought to act as a „decoy‟ receptor, negatively 
regulating the actions of VEGF by binding it but not transmitting an intracellular signal.   55 
In other situations, VEGFR-1 is capable of VEGF signalling, but only weakly.
308 In 
addition,  a  soluble  form  of  VEGFR-1  exists  (sVEGFR-1),  created  by  alternative 
splicing of VEGFR-1 mRNA and consisting of the extracellular domain of the VEGFR-
1.
135 sVEGFR-1 acts purely as a decoy, binding free VEGF to form an inactive complex 
and  thereby  inhibiting  its  actions.
89  Conversely,  VEGFR-2  is  the  most  biologically 
important of the VEGF receptors, and is the primary receptor mediating the mitogenic, 
angiogenic  and  permeability  enhancing  effects  of  VEGF  in  the  endothelium.
90;253 
Indeed,  mice  lacking  the  equivalent  of  VEGFR-2  completely  fail  to  develop  a 
vasculature and die in utero.
228 Lastly, VEGF may also bind to neuropilin receptors.
137 
These are non-tyrosine kinase receptors, and due to the lack of any associated signalling 
function are not thought to be functional per se.
308 The relationship between the major 
VEGF isoforms and receptors are summarised in Figure 1.6. 
 
1.4.3  VEGF and Angiogenesis 
The link between VEGF and angiogenesis has been demonstrated in many studies, with 
VEGF playing a major role in several stages of the process. As well as its importance as 
a factor in angiogenesis in the developing embryo, VEGF also mediates pathological 
angiogenesis in the adult. The effects of VEGF in angiogenesis are regulated almost 
entirely by VEGFR-2.
46 However, more recent data have also indicated an essential role 
for  VEGFR-1  in  pathological  angiogenesis,  which  acts  by  potentiating  VEGFR-2 
signalling.
46;185 
 
In  the  initial  stages  of  angiogenesis,  VEGF  mediates  an  increase  in  vascular 
permeability  by  redistributing  intercellular  adhesion  molecules  and  altering  cell 
membrane  structure.
78  In  fact,  VEGF  was  originally  termed  vascular  permeability  56 
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Figure 1.6  Overview of the Interactions Between the Major VEGF Isoforms and 
Receptors Involved in Angiogenesis 
The majority of the biological effects of VEGF are mediated by the binding of VEGF165 
to VEGFR-2 receptors. VEGFR-1 receptors can sometimes produce a weak intracellular 
signal, whilst sVEGFR-1 receptors are inhibitory and act by binding free VEGF. 
   57 
factor.
227  VEGF  also  subsequently  stimulates  the  proliferation  and  migration  of 
endothelial cells from existing vessels to new sites.
88 Moreover, VEGF121 and VEGF165 
in  combination  with  Angiopoietin-1  are  critical  in  lumen  formation  and  increasing 
vessel diameter.
247 In the longer term, VEGF acts as a survival factor for endothelial 
cells, with a reduction in VEGF level associated with vessel regression.
8;41 In concert 
with  the  local  environment,  VEGF  is  also  important  in  the  differentiation  of  the 
endothelium  according  to  local  needs,  and  the  remodelling  of  new  vessels  into 
functional networks.
40;205 
 
The strong link between VEGF and angiogenesis has led to  attempts  to manipulate 
VEGF in an attempt to enhance angiogenesis and produce clinical improvements in 
ischaemia.  Activation  of  VEGF  in  rabbits  with  ischaemic  legs  has  been  shown  to 
increase  capillary  density  and  improve  blood  flow.
61  Recent  trials  using  adenoviral 
VEGF gene transfer techniques to upregulate VEGF and stimulate angiogenesis have 
also  been  successful  in  animal  models.  However,  human  trials  including  the  recent 
Regional Angiogenesis with Vascular Endothelial growth factor (RAVE) trial, using 
similar adenoviral gene transfer techniques to upregulate VEGF, have not been related 
to  any  clinical  improvements  in  humans.
194  The  results  of  this  trial  illustrate  the 
complex processes underlying VEGF regulation.  
 
1.4.4  VEGF Regulation   
Hypoxia-Inducible Factor (HIF)-1  
The  major  stimulus  underlying  VEGF  transcription  is  hypoxia.  VEGF  and  VEGFR 
regulation  in  hypoxia  is  summarised  in  Figure  1.7.  Hypoxia  triggers  numerous 
responses  in  a  cell  including  an  increase  in  VEGF  mRNA,  and  it  has  now  been   58 
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Figure 1.7  VEGF and VEGF Receptor Regulation in Hypoxia 
Hypoxia leads to stabilisation of HIF-1α and increased HIF-1 levels. HIF-1 directly 
upregulates VEGF and VEGFR-1 expression. Growth factors and cytokines induced by 
HIF-1 may in turn upregulate VEGF and VEGFR-2. VEGFR-2 is also upregulated by 
VEGF itself.   
   59 
established that hypoxia-inducible factor (HIF)-1 is the key mediator of these hypoxic 
responses.
226  HIF-1  is  a  transcriptional  factor  which  acts  as  the  master  regulator  of 
oxygen homeostasis and has been linked to over a hundred target genes.
192;225 It consists 
of  a  heterodimer  composed  of  a  constitutively  expressed  HIF-1β  subunit  and  an 
inducibly  expressed HIF-1α subunit,  and is  regulated by  cellular oxygen levels and 
growth factors.
283 The HIF-1α subunit is usually subject to rapid degradation in non-
hypoxic  conditions.  However,  this  process  is  inhibited  by  hypoxia  resulting  in  an 
exponential  increase  in  HIF-1α  levels  as  oxygen  concentrations  decrease.
305  This 
stabilization of HIF-1α increases the formation of HIF-1 heterodimers, which in turn 
bind  to  hypoxia-responsive  elements  (HRE)  in  the  promoters  of  hypoxia  inducible 
genes,  including  VEGF  and  VEGFR-1,  initiating  transcription.
95;102  However,  the 
VEGFR-2 promoter lacks this site, although its expression is also increased in hypoxia. 
VEGFR-2 expression is autoregulated, with levels increased by VEGF and bFGF.
187;230 
 
VEGF Expression in Ischaemic Skeletal Muscle 
Although ischaemia has been demonstrated to increase VEGF expression via HIF-1, 
studies of human skeletal muscle from patients with leg ischaemia have revealed a more 
complex picture. VEGF and VEGFR-2 have both been shown to be downregulated in 
subjects with chronic ischaemia.
274;278 However, in cases of acute-on-chronic ischaemia 
HIF1-α, VEGF and VEGFR-2 gene expression are all significantly upregulated by 3-, 7- 
and 2-fold respectively.
274;278 In other words, different gene expression patterns occur in 
different states, with increases in HIF-1α, VEGF and VEGFR-2 associated only with 
acute  ischaemia.  Indeed,  one  might  speculate  that  the  repeated  episodes  of  acute 
ischaemia  produced  by  an  exercise  training  programme  could  over  time  stimulate 
increases in the VEGF/VEGFR-2 axis and produce angiogenesis. However, one study   60 
of  claudicants  showed  no  acute  rise  in  VEGF  protein  levels  in  response  to  acute 
exercise, or any increase in VEGF levels after 6 weeks training.
292 As yet, no study in 
humans has examined the effects of exercise training in claudicants on VEGF/VEGFR 
gene expression. 
 
Growth Factor and Cytokine Regulation 
In addition to hypoxia and HIF-1, VEGF production is also regulated by the paracrine 
or autocrine release of growth factors including epidermal growth factor, transforming 
growth factor (TGF)-α, TGF-β, keratinocyte growth factor, insulin-like growth factor-1, 
FGF and PDGF.
91;177 Inflammatory cytokines such as Il-1α and Il-6 also induce VEGF 
expression  in  some  cell  types.
177  Finally,  Ang-II  and  BK,  which  are  both  closely 
modulated by ACE and whose activity is altered by ACE inhibition, have also been 
demonstrated to regulate VEGF release.
233;289 
 
1.4.5  Effects of ACE Inhibition on VEGF and Angiogenesis  
The role of the RAS and of ACE in angiogenesis has recently been the subject of many 
studies, and is not yet fully understood. The evidence accumulated to date has often 
been conflicting, frequently with opposite effects observed depending on the tissues 
examined and experimental protocols used. Many of these studies have examined the 
effects of ACE inhibitors on angiogenesis. These are outlined below: 
 
Effects of ACE Inhibitors in Cancer 
The suggestion that ACE inhibitors could decrease the incidence of cancer led to the 
instigation  of  many  studies  examining  their  effects  on  tumour  growth  and 
angiogenesis.
149 One of the initial studies revealed that captopril inhibited angiogenesis   61 
and tumour growth in rats.
281 Further studies have shown that perindopril significantly 
inhibits angiogenesis in vivo in mouse models of hepatocellular carcinoma and in head 
and  neck  squamous  cell  carcinoma.
180;298  Perindopril  also  inhibits  angiogenesis  in 
hepatocellular  carcinoma  in  association  with  a  concomitant  suppression  of  VEGF 
expression.
302 Decreased angiogenesis mediated by perindopril has been associated with 
a  reduction  in  Ang-II  production,  reduced  VEGF  promoter  activity  and  decreased 
VEGF  transcription.
298  Moreover,  decreases  in  both  Ang-II  and  VEGF  have  been 
suggested  as  key  mechanisms  underlying  reduced  angiogenesis  following  ACE 
inhibition.
303  
 
The relationship between Ang-II and VEGF has been investigated extensively. Ang-II 
has been found to stimulate angiogenesis in animal models.
87;193 Ang-II can also induce 
the  secretion  of  VEGF  in  several  human  cell  types  including  tumour  cells  by 
upregulating  HIF-1α  expression.
184;193;289  VEGF  is  similarly  able  to  induce  ACE 
transcription and protein levels, indicating a synergistic relationship between the RAS 
and VEGF.
219 The induction of VEGF by Ang-II is mediated primarily via the AT1 
receptor,  although  blockade  of  the  AT1  receptor  does  not  inhibit  angiogenesis, 
illustrating the complexity of the process.
51;302  
 
Thus, the effects of ACE inhibitors in tumour angiogenesis are likely to be result of 
multiple pathways, and not just VEGF transcription.
298 It is also important to consider 
that tumour cells are quite different to normal cells, representing a unique environment 
with an often chaotic and unbalanced expression of angiogenic factors and molecular 
signals.
57 Tumour vessels are also structurally and functionally disorganised compared 
to vessels in normal tissues.
57   62 
Effects of ACE Inhibitors in Proliferative Diabetic Retinopathy 
The discovery that lisinopril could decrease the progression of  diabetic proliferative 
retinopathy led to many studies examining the role of the RAS in retinal angiogenesis.
48 
In diabetes the retinal RAS is over-activated, with the severity of retinopathy correlating 
with the activity of the RAS.
65 VEGF is also significantly overexpressed.
4 Moreover, 
Ang-II is a stimulus for VEGF responses in the retina, as Ang-II increases VEGFR-2 
expression.
182  In  vivo  studies  have  also  shown  that  ACE  inhibition  reduces  VEGF 
expression in the retina, which is otherwise upregulated up to four fold.
103 Thus, it has 
been suggested that the overactive RAS  in diabetic retinas upregulates VEGF  most 
likely via Ang-II acting on AT1 receptors, and that ACE inhibition reduces angiogenesis 
by decreasing Ang-II signalling.
77;103 However, retinal VEGF expression is also closely 
linked to blood pressure, and it may be a reduction in blood pressure that underlies these 
effects rather than a direct effect of the RAS.
103;286 Evidence showing that β-blockers 
are equally efficacious in reducing diabetic retinopathy support this theory.
275 
 
Effects of ACE Inhibitors in Ischaemic tissues 
In  contrast  to  the  studies  of  tumour  and  retinal  angiogenesis,  studies  of  ischaemic 
tissues have demonstrated a completely opposite picture, with ACE inhibition related to 
increased  angiogenesis  in  both  ischaemic  limbs  and  cardiac  tissue.  This  differential 
effect was clearly illustrated in a study of diabetic mice, where perindopril was observed 
to increase angiogenesis in ischaemic hindlimbs but reduce vessel growth in the diabetic 
retina.
77 In separate studies, quinaprilat has been shown to potentiate angiogenesis in a 
rabbit model of hindlimb ischaemia, perindopril to  improve angiogenesis  and blood 
flow hypertensive rats (independent of changes in blood pressure), and perindopril to 
have  a  pro-angiogenic  effect  in  ischaemic  mice  hindlimbs.
85;233;250  Furthermore,   63 
lisinopril has also been demonstrated to increase capillarisation in the hypertensive rat 
myocardium,  an  increase  potentiated further in  response to  exercise training.
311 The 
timing  of  ACE  inhibition  is  also  crucial,  with  ACE  inhibition  prior  to  an  acute 
ischaemic insult impairing reparative angiogenesis compared to the positive effects of 
inhibition in established chronic ischaemia.
81 
 
The  mechanism  by  which  ACE  inhibition  increases  angiogenesis  in  ischaemia  is 
complex, and has not been fully elucidated. However, the evidence indicates that VEGF 
up-regulation plays an important role. In a rat ischaemic model, low dose perindopril 
was shown to induce angiogenesis in association with a rise in VEGF, but addition of a 
VEGF-neutralising antibody abolished this effect.
234 Other studies have also shown a 
rise in VEGF associated with ACE inhibitor induced angiogenesis.
77;233 
 
1.4.6  Role of Ang-II and BK in Ischaemia Induced Angiogenesis 
ACE  activity  plays an  important  role in  regulating skeletal  muscle angiogenesis.  In 
chronic  heart  failure,  a  condition  characterised  by  poor  muscle  perfusion,  ACE 
expression is inversely related to skeletal muscle capillary density.
221 The actions of 
ACE  are  to  produce  Ang-II  and  degrade  BK.  The  actions  of  these  molecules  in 
angiogenesis are described below: 
 
Angiotensin II 
Ang-II has a predominantly pro-angiogenic role in ischaemia, similar to that described 
previously in tumours. Rats with ischaemic limbs treated with Ang-II have increased 
angiogenesis allied to increases in VEGF. Furthermore, Ang-II mediated angiogenesis 
is prevented by VEGF neutralising antibodies.
252 Ang-II mediates angiogenesis via its   64 
AT1 receptor, as blockade of AT1 inhibits Ang-II related angiogenesis.
220;251;252 AT1 
receptor knockout mice also have impaired angiogenic responses to ischaemia, an effect 
independent of reduced blood pressure, but related to a decrease in VEGF expression.
220 
In contrast, the AT2 receptor has anti-angiogenic effects in ischaemia.  AT2 receptor 
knockout  mice  have  greater  angiogenesis  in  response  to  ischaemia  than  wild-type 
mice.
236 These anti-angiogenic properties of the AT2 receptor are partly mediated by its 
pro-apoptotic effects.
236 In addition, although the AT2 receptor does not alter VEGF 
levels, it has been shown to inhibit VEGF-mediated endothelial cell migration and tube 
formation by stopping VEGF signalling at the level of akt phosphorylation.
19;236   
 
Ischaemia  also  modulates  Ang-II  receptor  expression,  causing  marked  rises  in  AT2 
levels but no change in AT1 expression. This change in relative receptor level creates a 
potential increase in anti-angiogenic signalling by Ang-II, and could partly explain the 
pro-angiogenic role of ACE inhibition in ischaemia compared to tumour and diabetic 
retinal  angiogenesis.
19;236  However,  the  role  of  Ang-II  in  angiogenesis  is  further 
complicated by reports which illustrate that Ang-II levels during chronic ACE inhibition 
can be normal or even raised, due to increased feedback to raise renin levels and to 
Ang-II  generation  by  alternative  pathways.
277  Overall,  this  evidence  suggests  that 
although Ang-II can modulate angiogenesis in opposing ways via its 2 main receptors, it 
is unlikely to be a key factor in ACE inhibitor induced angiogenesis in ischaemia.  
 
Bradykinin 
A secondary effect of ACE inhibition is decreased BK degradation, leading to raised 
BK  levels.  Interestingly,  BK  has  been  shown  to  be  a  potent  activator  of  ischaemia 
induced  angiogenesis.  Upregulation  of  BK  by  kallikrein  gene  transfer  enhances   65 
angiogenesis in ischaemic limbs.
79;80 Furthermore, ischaemia induces the expression of 
BK1 receptors and blockade of BK1 or BK2 receptors blunts angiogenesis in ischaemia.
79 
As a result, it has been suggested that ACE inhibitors may stimulate angiogenesis via a 
BK-mediated  pathway.
85;250  In  support  of  this,  it  has  been  demonstrated  that  ACE 
inhibitor  induced  angiogenesis  is  completely  blunted  in  BK2  receptor  deficient 
mice.
77;233 In addition, BK2 receptor deficient mice also lack the rises in VEGF observed 
with  ACE  inhibition.
77  Stimulation  of  the  BK  pathway  is  thought  to  mediate 
angiogenesis  by  inducing  endothelial  NO  synthase  expression  and  stimulating  NO 
signalling  pathways.  BK  is  also  a  pro-inflammatory  cytokine,  and  can  upregulate 
inflammatory  factors  such  as  cyclo-oxygenase  2  (COX-2).  This  induction  of 
inflammation by BK could be another pathway to increase angiogenesis.
77;233 
 
In summary, the role of the RAS in angiogenesis is unclear with ACE inhibitors having 
opposite effects on angiogenesis depending on the tissues involved. These differences 
may be a product of the various pathways that ACE effects, and the relative importance 
and activation of each pathway in each tissue and disease state. For example, in the 
same animal model ACE inhibition has been shown to decrease the otherwise over-
expressed VEGF in the retina whilst increasing the relatively weakly expressed VEGF 
in ischaemic muscle.
77 In ischaemic muscle, the BK pathway appears to be the key 
factor in stimulating angiogenesis in response to ACE inhibition, whereas in cancer and 
diabetes, inhibition of the Ang-II pathway appears to be more important. The effects of 
ACE inhibition on VEGF and angiogenesis in ischaemic muscle  are summarised in 
Figure  1.8.  Although  the  crucial  role  of  VEGF  in  angiogenesis  has  now  been 
established, to date there have been no reports on how VEGF or its receptors change in 
response to an exercise program in claudicants. In addition, although ACE inhibitors   66 
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Figure 1.8  Effects  of  ACE  Inhibition  on  Angiotensin  II  and  Bradykinin  in 
VEGF-mediated Angiogenesis in Ischaemia  
In  ischaemia,  Ang-II  produces  pro-angiogenic  effects  via  AT1  and  anti-angiogenic 
effects via AT2, whilst BK is pro-angiogenic. ACE inhibition decreases the conversion 
of  Ang-I  to  Ang-II  and  increases  BK  levels.  In  ischaemia,  potentiation  of  the  BK 
signalling pathway is thought to be the most important factor in ACE inhibitor induced 
angiogenesis.   67 
have been shown in animal models of ischaemia to increase angiogenesis via VEGF, 
there are no studies illustrating the effects of ACE inhibition on VEGF in a human 
model of ischaemia. Finally, although the benefits of ACE inhibitors have traditionally 
been attributed to a decrease in Ang-II and increase in BK, recent evidence suggests that 
a novel ACE signalling pathway that could also explain some of the events. 
 
1.5  ACE REGULATION AND SIGNALLING 
1.5.1  ACE Regulation 
Although ACE is a critical component of the RAS, there are limited data available on its 
regulation at a cellular or tissue level. Drugs such as dexamethasone, bleomycin and 
aldosterone  have  been  reported  to  induce  ACE  expression.
66;68  In  addition,  several 
growth factors and cytokines, including endothelin-1, FGF, hepatocyte growth factor 
(HGF), oncostatin M and atrial natriuretic peptide (ANP) have all been demonstrated to 
induce ACE expression.
14;67;92;216;218 Conversely, tumour necrosis factor-α, interleukin-
1β and Ang-II are reported to downregulate ACE expression.
217;223 
 
The intra-cellular signalling pathways regulating ACE are poorly understood. However, 
the evidence suggests that increases in ACE mRNA are mediated by mitogen-activated 
protein  kinase  (MAPK)  and  protein  kinase  C  (PKC),  which  activate  various 
transcription factors.
68;279 Both bleomycin and HGF have been shown to activate ACE 
gene  transcription  via  activation  of  the  transcription  factor  early  growth  response-1 
(Egr-1), for which a binding site exists in the ACE gene promoter.
67;68 In addition, the 
transcription factor activating protein 1 (AP-1) is also activated by PKC and binds in the 
ACE promoter upregulating ACE expression.
84 Both Egr-1 and AP-1 are activated by 
PKC acting on the extracellular signal-regulated kinase 1/2 signalling pathway.
84    68 
ACE and Hypoxia 
ACE is known to be up-regulated by hypoxia, with studies showing an increase in ACE 
synthesis in endothelial cells, and increased activity and expression in pulmonary artery 
smooth muscle cells.
136;171;306 Hypoxia has also been shown to increase ACE, Ang-II 
and  AT1  in  pulmonary  artery  fibroblasts  via  HIF-1,  with  Ang-II  subsequently 
potentiating HIF-1 and cellular hypoxic responses in a positive feedback loop.
141 The 
effects  of  repeated  episodes  of  acute-on-chronic  hypoxia,  as  observed  in  exercising 
claudicants on ACE expression has not yet been studied. 
 
1.5.2  ACE Inhibitors and Cell Signalling 
Another well described  finding  associated with  chronic ACE inhibition  is  increased 
ACE gene expression and protein secretion, an effect which is independent of changes 
in Ang-II or BK levels.
58 In addition, some of the beneficial effects of ACE inhibition 
cannot be attributed to a decrease in Ang-II generation or an accumulation of BK.
94 
Subsequent investigation has led to the elucidation of a novel signalling pathway with 
membrane bound ACE acting as a key signalling molecule. 
 
The  short  cytoplasmic  tail  of  membrane  bound  ACE  contains  several  amino  acid 
sequences that can interact with cellular proteins. For example, casein kinase 2 (CK2) 
physically  interacts  with  the  cytoplasmic  tail  and  phosphorylates  a  serine  residue 
(Ser
1270)  on  the  amino  acid  chain,  stabilising  ACE  within  the  cell  membrane.
140 
Mitogen-activated protein kinase kinase 7 (MKK-7) and c-Jun N-terminal kinase (JNK) 
also associate with the ACE cytoplasmic tail. Interestingly, binding of an ACE inhibitor 
(ramiprilat or perindoprilat), or to a lesser degree BK to the extracellular domain of 
ACE increases CK-2 phosphorylation of Ser
1270, activating ACE-associated JNK. This   69 
subsequently leads to the translocation and accumulation of phosphorylated c-Jun in the 
nucleus, which alters gene expression.
138 This „outside-in‟ ACE signalling pathway has 
been  demonstrated  to  be  responsible  for  increasing  ACE  expression  and  COX-2 
expression via AP-1, and is summarised in Figure 1.9.
138;139 
 
Thus, in addition to its traditional roles, ACE acts as a signal transduction molecule 
activated by binding of an ACE inhibitor. The importance of this pathway has not yet 
been elucidated, but one could speculate that it could account for some of the benefits of 
ACE inhibition. COX-2, which is upregulated by this pathway, has been demonstrated 
to be an important mediator of angiogenesis. COX-2 has been demonstrated to increase 
VEGF expression, and COX-2 null cells do not produce VEGF.
10;214 Inhibition of COX-
2  has  also  been  shown  to  decrease  VEGF  expression.
162;304  Reciprocally,  VEGF 
upregulates COX-2 expression.
296 Thus, upregulation of COX-2 expression by the ACE 
„outside-in‟  signalling  pathway  could  potentially  enhance  VEGF-mediated 
angiogenesis.  Furthermore, upregulation  of ACE expression by this  pathway, in  the 
continued  presence  of  an  ACE  inhibitor,  could  lead  to  further  increases  in  ACE 
„outside-in‟ signalling.
94 
 
The discovery of an ACE signalling pathway also leads to the notion that genetically 
predisposed low ACE activity, linked to the I/D polymorphism as described by Rigat et 
al., could be a different entity to pharmacologically lowered ACE activity, which in 
addition  to  decreasing  ACE  activity  generates  other  cell  signalling  properties.  ACE 
inhibitors  may  thus  have  dual  benefits  in  ischaemia,  by  increasing  COX-2  (and 
potentially VEGF) gene expression via „outside-in‟ signalling, while maintaining ACE 
activity (but not ACE level) at a low level.   70 
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Figure 1.9  The  ACE  Inhibitor  and  BK-induced  ‘Outside-in’  ACE  Signalling 
Pathway 
ACE  inhibitor  or  BK  binding  to  ACE  leads  to  phosphorylation  of  ACE  Ser
1270. 
Depending on initial phosphorylation, ACE-associated JNK becomes activated, most 
likely via ACE-associated MKK-7, leading to an accumulation of phosphorylated c-Jun 
in the nucleus and enhancement of the DNA-binding activity of AP-1. AP-1 activation 
increases ACE and COX-2 gene expression. Adapted from Ryan et al.
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1.6  ACE AND INTERMITTENT CLAUDICATION  
In summary, besides its traditional role as a mediator of circulatory blood pressure and 
salt and water homeostasis, the RAS is found locally in many tissues where it regulates 
many processes including cell metabolism, inflammation and endothelial function. A 
functional polymorphism of the ACE gene exists, whereby the I-allele is associated with 
decreased ACE transcription and levels, and hence reduced ACE activity. Physiological 
links  exist  whereby variation in  ACE activity  could  modulate responses  to  exercise 
training  in  claudicants:  the  I-allele  and  associated  low  ACE  activity  is  related  to 
improved  metabolic  efficiency,  enhanced  response  to  endurance  training,  reduced 
inflammation  and  improved  vasodilatation,  all  areas  that  may  positively  affect  the 
response to training in claudicants. The RAS and ACE have also been implicated in 
ischaemic angiogenesis, where the RAS contributes a major role in regulating VEGF 
production,  and  ACE  inhibitors  have  been  revealed  to  potentiate  angiogenesis  in 
ischaemia.  
 
Despite this evidence, the effects of the ACE polymorphism and of ACE inhibition on 
walking ability in claudicants have not been extensively studied. The studies that have 
investigated the effects of the ACE polymorphism and ACE inhibitors in intermittent 
claudication will be discussed below: 
 
1.6.1  ACE I/D Polymorphism and Intermittent Claudication  
Very few studies have scrutinized possible links between the ACE I/D polymorphism 
and  peripheral  arterial  disease.  Conflicting  reports  have  been  presented  regarding  a 
potential association between the ACE polymorphism and the prevalence of peripheral 
arterial  disease,  with  the  majority  of  studies  finding  no  significant   72 
association.
133;202;258;271 However, given the heterogeneous populations analysed, these 
studies were unlikely to find a significant link. Only one study of Chinese diabetics 
associated  the  D-allele  with  a  significantly  increased  risk  of  peripheral  arterial 
disease.
263 Nevertheless, it remains doubtful that the ACE polymorphism is a major risk 
factor  for  the  development  of  peripheral  arterial  disease.  In  another  study,  the  II 
genotype was shown to be associated with a significantly reduced risk of atherosclerotic 
disease  progression  compared  to  subjects  with  the  DD  genotype.
259  However,  a 
subsequent investigation by the same group showed no relationship between the D-
allele and progression of atherosclerosis in patients with peripheral arterial disease.
257 
Finally,  a study of 65 subjects  with  hypertension secondary to  renal  artery stenosis 
reported an association between the DD genotype and increased severity of peripheral 
arterial disease. This association was not seen in subjects with essential hypertension 
and may be related to enhanced activation of the RAS in renovascular hypertension.
156  
 
As yet no published study has examined the effects of the ACE genotype on responses 
to  exercise  training  in  peripheral  arterial  disease.  However,  previous  work  in  our 
laboratory  studied  the  association  of  the  ACE  polymorphism  with  responses  to 
supervised exercise training in a group of stable claudicants. Pre-training assessments 
were independent of genotype. However, after training, subjects possessing an I-allele 
(n=12) improved claudication distance (CD) by 151% and maximum walking distance 
(MWD) by 251%, compared to only 46% and 29% respectively for subjects without an 
I-allele  (n=3).  Thus,  the  I-allele  appeared  to  be  related  to  improved  responses  to 
exercise training. No change in cardiovascular fitness or ankle brachial pressure index 
(ABPI) was found in the subjects, suggesting a local muscular effect as the mechanism 
for the improvement (see List of Presentations).   73 
1.6.2  ACE Inhibitors and Intermittent Claudication 
The  benefits  attributed  to  the  I-allele  of  the  ACE  polymorphism  are  thought  to  be 
mediated  by  its  associated  low ACE activity.  In contrast, ACE is  known to be up-
regulated by hypoxia (see Section 1.5). This activation of the RAS could be detrimental 
to training responses in claudicants, but a potential means of correcting this would be to 
suppress ACE activity pharmacologically using ACE inhibitors. These drugs are widely 
prescribed, and have been used for some time in the treatment of hypertension. Several 
different ACE inhibitors exist, which have slightly different effects according to their 
structure, lipid solubility and pharmacokinetics.  The majority in use today are pro-
drugs which are metabolised by the liver into an active form.
237 They are also effective 
in decreasing both serum and tissue ACE activity.
82 However, the potential for tissue 
inhibition for each drug is related to each drug‟s lipid solubility. For example ramiprilat, 
the active form of ramipril, is 23 times more lipophilic than enalaprilat and is associated 
with much more pronounced tissue ACE inhibition.
17 
 
Interestingly, ACE inhibitors have been discovered to have a variety of clinical benefits 
unrelated to changes in blood pressure, which may all be related to the effects of tissue 
inhibition and could have positive implications for claudicants. In the management of 
heart failure, the benefits gained from ACE inhibitors exceed what can be explained by 
improvements  in  cardiovascular  status,  and  it  has  been  suggested  that  some  of  the 
benefits in these patients may be the result of increased muscular efficiency.
167 ACE 
inhibitors  could  also  potentiate  ischaemic  pre-conditioning,  by  increasing  the 
availability  of  BK,  a  known  key  trigger  leading  to  preserved  ATP  generation  in 
ischaemic  conditions.
76;300  In  addition,  ACE  inhibition  helps  peripherally  in  chronic 
heart  failure,  improving  local  vasodilatation,  oxygen  extraction  and  exercise   74 
performance more than improvements in cardiac output.
74 ACE inhibitors have also 
been shown to decrease inflammation by preventing Ang-II mediated Il-6 production, 
an effect that has been linked to improved atherosclerotic plaque stability and a decrease 
in acute coronary syndromes.
20;105;166 Indeed, the HOPE study has shown that ramipril 
reduces deaths and cardiac events in a broad range of high risk patients, leading to the 
widespread prescribing of ACE inhibitors in vascular patients.
307 
 
Studies of ACE inhibitors in Intermittent Claudication 
The majority of reports on the effects of ACE inhibitors in ischaemic muscle have come 
from animal studies. One study reported that ACE inhibition enhanced blood flow to 
ischaemic muscles and increased exercise tolerance after training, a benefit potentially 
relevant to claudicants.
297 Moreover, the effects of ACE inhibitors on angiogenesis has 
already been discussed in detail in Section 1.4.5.  
 
Only  a  limited  number  of  studies  have  examined  the  effects  of  ACE  inhibitors  in 
claudicants. Several reports demonstrate that captopril preserves or even increases blood 
flow,  and  increases  walking  ability  in  hypertensive  claudicants.
45;152;181;207  These 
benefits seem to be independent of its blood pressure lowering effects.
118;250 However, 
other  trials  have  demonstrated  captopril  to  have  no  benefits  in  claudicants.
21;206 
Furthermore, captopril is one of the first generation of ACE inhibitors, possessing a 
sulphydryl  group  which  has  its  own  pharmacological  properties  completely  distinct 
from ACE inhibition.
11;191 Thus, any effect of captopril on claudicants in these studies 
cannot definitely be attributed purely to ACE inhibition. The sulphydryl group is also 
associated  with  several  side-effects,  and  captopril  has  markedly  less  tissue  activity 
compared to newer ACE inhibitors, and is thus now rarely prescribed.
17;128 Amongst   75 
other  ACE  inhibitors,  one  trial  demonstrated  an  association  between  lisinopril  and 
improved walking ability, although this was a similar effect to that of bisoprolol, and no 
placebo or control group was used.
276 Another study of perindopril showed no change in 
ABPI, a marginal increase in claudication distance and a slight reduction in walking 
distance compared to placebo.
183 
 
Many of the trials described above were poor quality studies, often with no placebo 
control and with low subject numbers. Indeed, a recent Cochrane review on the impact 
of drug treatment for hypertension on peripheral arterial disease included only 2 out of a 
possible 46 studies in the final review, with the others excluded due to poor quality.
155 
However, a more recent randomised double-blind controlled trial comparing ramipril to 
placebo in non-diabetic, normotensive claudicants provides more compelling evidence 
for the benefits of ACE inhibitors in claudication, with a significant increase in both 
pain free and maximum walking time recorded with ramipril compared to placebo.
3 As 
has  been  previously  stated,  ramipril  is  noted  for  its  lipid  solubility  and  hence  its 
enhanced tissue activity.
17 One could speculate that it is this tissue ACE inhibition in 
ischaemic limbs that would provide maximal benefit to claudicants. A summary of the 
studies performed to date on ACE inhibition and claudication is shown in Table 1.3. 
 
Thus far, no randomised control trial of supervised exercise training and ACE inhibitors 
in claudicants has been published. However, previous work in this laboratory examined 
the  effects  of  the  low  dose  ramipril  on  responses  to  a  supervised  exercise  training 
program using a randomised double-blind placebo controlled crossover study (See List 
of Presentations). In contrast to the study by Ahimastos et al., this trial showed ramipril 
to be significantly detrimental to training responses. Training on placebo increased CD  76 
Table 1.3  Summary  of  Studies  Performed  to  Date  of  ACE  Inhibitors  in 
Intermittent Claudication 
Reference  Subjects/Drugs  End-point  Findings 
Catalano et al.
45 
(1985) 
 
Captopril and 
hypertensive claudicants 
Pain free walking 
interval and ABPI 
Captopril improved both 
pain free walking interval 
and ABPI 
Libretti et al.
152 
(1986) 
8 weeks of captopril or 
chlorthalidone in 
hypertensive claudicants 
(n=40) 
ABPI, pain free and 
absolute walking 
intervals 
Captopril improves ABPI, 
pain free and absolute 
walking intervals compared 
to chlorthalidone 
Roberts et al.
207 
(1987) 
1 month each of 
captopril, atenolol, 
labetolol and pindolol in 
hypertensive claudicants 
(n=20) 
CD, MWD and blood 
flow 
Captopril preserved (but did 
not improve) blood flow, 
CD and MWD compared to 
placebo. Beta- blockers 
reduced BF, CD and MWD 
Bernardi et al.
21 
(1988)   
2 weeks each of 
captopril, nicardipine and 
placebo in normotensive 
claudicants (n=10) 
Pain free walking 
interval, duration of 
exercise and ABPI 
Captopril improved ABPI 
but had no effect on walking 
ability 
Roberts et al.
206 
(1992)   
3 months each of 
captopril and nifedipine 
in hypertensive 
claudicants (n=12) 
Calf blood flow and 
treadmill walking 
ability 
No difference in walking 
ability. Improved blood flow 
compared to nifedipine 
Van der Ven et 
al.
276 (1994) 
Effects of lisinopril and 
bisoprolol on exercise 
trained hypertensive 
claudicants  (n=11) 
Walking ability, 
blood flow and 
vascular resistance 
Walking ability improved on 
both lisinopril and 
bisoprolol. No change in 
vascular resistance or blood 
flow 
Overlack et al.
183 
(1994) 
6 weeks of perindopril or 
placebo in hypertensive 
claudicants (n=54) 
ABPI, CD and MWD  No change in ABPI. 
Marginal increase in CD and 
reduction in MWD with 
perindopril 
Novo et al.
181 
(1996) 
12 weeks each of 
captopril, ticlopidine and 
placebo in hypertensive 
male claudicants (n=24) 
CD and MWD  Captopril increased CD and 
MWD compared to placebo 
and ticlopidine 
Ahimastos et al.
3 
(2006) 
24 weeks of ramipril or 
placebo in normotensive 
claudicants (n=40) 
Pain free and 
maximum walking 
time 
Ramipril improved pain free 
and maximal walking time 
compared to placebo 
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by 90 metres and MWD by 754 metres, whilst after ramipril the improvement in CD 
was  only  35  metres  and  MWD  225  metres.  ABPI  was  unaffected  by  either  drug 
treatment. However, this was a pilot study involving only 8 subjects, and the data are 
not conclusive. 
 
Thus, the question still remains as to whether ACE and VEGF have a significant role in 
improving walking ability in claudicants after exercise training, and whether reduction 
of ACE activity with ACE inhibitors could play a role in improving exercise training 
responses and increasing walking ability. 
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CHAPTER 2 
HYPOTHESIS AND AIMS   79 
CHAPTER 2 
2.1  BACKGROUND 
Intermittent claudication remains a major and widespread health problem in the western 
world,  and  can  be  associated  with  a  significant  impairment  of  walking  ability  and 
quality of life.
243 The role of surgery and angioplasty for intermittent claudication is 
limited, and until now pharmacological treatments of the condition have provided little 
or no reduction in symptoms.
229 However, exercise training and supervised programmes 
in particular, have been associated with significant improvements in symptoms, and 
exercise therapy continues to be the mainstay for treatment.
244 The mechanism by which 
exercise  improves  intermittent  claudication  is  not  fully  understood  and  has  recently 
been identified as an area for potential research.
86 It is thought that the mechanism is 
multi-factorial,  and includes  angiogenesis,  changes in  muscle metabolism,  improved 
endothelial function, and a reduction in inflammation.
244;255 
 
One metabolic pathway that could influence responses to exercise training is the RAS. 
More specifically low ACE activity, associated either with the I-allele of the ACE I/D 
polymorphism or pharmacological reduction by ACE inhibitors, has been associated 
with increased muscular efficiency and endurance, reduced inflammation and enhanced 
endothelial function.
74;166;256;288 Thus, potential physiological associations exist whereby 
variation in ACE activity may modulate responses to exercise training in claudicants. 
Furthermore, previous unpublished work in this laboratory has associated the I-allele 
with enhanced response to training in claudicants. However, while many studies have 
examined the link between the ACE polymorphism and exercise training responses or 
endurance  performance,  as  yet  no  studies  have  examined  the  effects  of  an  exercise 
training programme on ACE expression and protein levels. These phenotypic responses   80 
(gene  expression  and  protein  levels)  potentially  provide  greater  information  than 
genotype studies, as ACE activity  per se can be linked directly to exercise training 
responses. It is possible that the ACE genotype is in linkage disequilibrium with another 
as  yet  undiscovered  factor,  rather  than  being  the  actual  factor  underlying  enhanced 
training responses. By quantifying the responses of the ACE gene to this environmental 
stimulus,  a  clearer  picture  on  whether  the  gene  is  of  influence  can  be  established. 
Furthermore,  ACE  activity  can  easily  be  modified  pharmacologically  using  existing 
widely used drugs, making it an amenable target for potential treatment of claudicants. 
 
The RAS is also involved in regulating angiogenesis via its interaction with VEGF. 
Angiogenesis  provides  many  potential  advantages  in  claudicants,  including  a 
redistribution  of  blood  flow,  reduced  shunting,  improved  substrate  delivery  and  the 
enhanced removal of metabolites. VEGF and its receptors, in particular the VEGF165 
isoform and VEGFR-2, play a vital role in almost all the stages of angiogenesis, and in 
ischaemia low ACE activity is related to increased VEGF and angiogenesis.
90 However, 
attempts  to  manipulate  VEGF  so  far  in  humans  have  produced  limited  clinical 
benefits.
194 Nevertheless, the link between the RAS and VEGF in ischaemia provides a 
possible  basis  for  augmenting  angiogenesis  in  claudicants.  In  animal  models  of 
ischaemia,  VEGF  is  upregulated  by  ACE  inhibitors,  most  likely  via  a  mechanism 
primarily  involving  BK  rather  than  Ang-II,  leading  to  improved  blood  flow  and 
endurance  performance.
233;297  Furthermore,  other  studies  have  shown  that  ACE 
inhibitors and BK (itself raised in association with low ACE activity) possess signalling 
properties via membrane bound ACE, and can cause increases in ACE and COX-2 (and 
potentially  VEGF)  expression.
93  Thus,  ACE  inhibitors  may  have  dual  benefits  in 
ischaemia,  by  increasing  gene  expression  via  „outside-in‟  signalling,  while  also   81 
maintaining low ACE activity. It is possible that some of the beneficial effects of ACE 
inhibition could be accounted for by this mechanism. The effects of exercise training in 
claudicants, or of ACE inhibition in a human model of ischaemia, on differential VEGF 
isoform and receptor gene expression and protein levels has not yet been studied. 
 
Thus, the evidence points towards low ACE activity, whether genetically inherited or 
pharmacologically manipulated, to be potentially of benefit to claudicants and walking 
ability, with  an increase in  VEGF-mediated  angiogenesis one of the  major  possible 
improvements. However, clinical trials of ACE inhibitors in claudicants have shown 
mixed results, and the possible benefit from using ACE inhibitors to treat intermittent 
claudication  remains  unclear.  Previous  work  in  this  laboratory  indicated  that  ACE 
inhibitors were detrimental to training responses in claudicants, whilst another recently 
published trial showed ramipril to be related to a significant improvement in walking 
ability.
3 One means to better understand the potential role of ACE, VEGF and ACE 
inhibition in claudicants would be to assess how exercise training in claudicants affects 
ACE and VEGF biology, as determined by mRNA expression and protein levels, and 
relate  these  molecular  changes  to  improvements  in  walking  ability.  In  addition,  the 
effects of ACE inhibition in hypoxia on ACE and VEGF could also be studied. Thus, 
the following questions will be addressed by this thesis: 
 
1.  How does repetitive exercise training in claudicants affect ACE and VEGF gene 
expression and protein levels? Are these changes related to improvements in 
walking ability? 
2.  Is VEGF receptor expression affected in the same way as VEGF? 
3.  How do ACE inhibitors affect ACE and VEGF in a human model of ischaemia?   82 
In considering the first question, whilst it is known that acute exercise or hypoxia leads 
to an increase in ACE activity and Ang-II, the effects of repetitive exercise training and 
hypoxia  on  ACE  expression  are  unknown.
171;294  Interestingly,  when  examining 
inflammatory  responses  in  claudicants,  acute  training  is  known  to  promote 
inflammation, but after a prolonged period of repetitive training inflammation becomes 
attenuated.
267  As  ACE  acts  as  a  pro-inflammatory  cytokine,  it  is  possible  that  this 
reduction in inflammation could be related to a concurrent decrease in ACE expression. 
 
Secondly, VEGF is known to be increased in acute hypoxia. However, when examining 
the effects of exercise training on VEGF, it is important to study all the various VEGF 
isoforms and receptor types, as these all have varying and often opposing roles in VEGF 
biology, and could respond differently to training. Furthermore, the reported association 
between ACE and VEGF suggests a potential synergistic effect, with a decrease in ACE 
activity likely to amplify any increase in VEGF. 
 
Finally, in considering the effects of ACE inhibition on ACE and VEGF in a human 
model  of  ischaemia,  results  of  studies  to  date  in  animal  models  suggest  that  ACE 
inhibitors  will  increase  both  ACE  protein  expression  and  VEGF  activity  (while 
maintaining low ACE activity by its effects on binding to ACE). 
 
2.2  HYPOTHESIS AND AIMS 
The central hypothesis of this thesis is that low ACE activity is related to improved 
responses to exercise training in claudicants, by a mechanism involving its interaction 
with VEGF (in addition to its general effects on endurance performance). This thesis 
will concentrate specifically on the effects of exercise training in claudicants on ACE   83 
and  VEGF,  the  interaction  between  ACE  and  VEGF,  and  on  the  effects  of  ACE 
inhibition on ACE and VEGF responses to hypoxia. A summary of the experimental 
hypothesis is illustrated in Figure 2.1. In more specific detail, the aims of this thesis are 
to: 
1.  Examine the effects of a supervised exercise training programme on walking 
ability in a group of claudicants. 
2.  Examine  the  effects  of  the  exercise  training  programme  on  ACE  gene  and 
protein expression, together with VEGF isoform/VEGF-R gene expression and 
VEGF  protein  levels.  In  addition,  examine  the  influence  of  these  molecular 
changes  on  the  physiological  responses  to  the  training  programme,  and 
investigate the link between changes in ACE and VEGF expression. 
3.  Examine in ACE I/D heterozygotes, the differential baseline allele expression 
and the individual responses of the I- and D-alleles to training. 
4.  Develop a stable human endothelial cell culture model of hypoxia in which ACE 
and VEGF are reliably expressed. 
5.  Assess how ACE inhibitors modulate ACE/VEGF expression and protein levels 
in a model of human tissue hypoxia. 
 
To address these aims, the following experiments were performed.  
 
2.3  EXPERIMENTAL DESIGN 
To address the first 3 aims, a randomised controlled clinical trial was developed to 
examine the effects of an exercise training programme on walking ability and ACE, 
VEGF and VEGF-R gene activity in patients with intermittent claudication. Patients 
were recruited to the trial and randomised to a treatment group (8 weeks supervised   84 
training) or a control group (exercise advice only). Prior to training, a set of baseline 
measurements was recorded. Walking ability was assessed by an incremental treadmill 
walking test and by a repetitive heel raise test. ACE, VEGF121, VEGF165, VEGF-R1, 
sVEGFR-1  and  VEGFR-2  mRNA  expression  were  all  determined  by  reverse 
transcriptase polymerase chain reaction (RT-PCR) of mRNA obtained from peripheral 
blood  mononuclear  cells  (PBMNs)  isolated  from  whole  blood.  ACE  genotype  was 
confirmed by PCR of genomic DNA isolated from PBMNs. Plasma levels of ACE and 
VEGF were measured using a sandwich enzyme-linked immunosorbant assay (ELISA). 
Differential expression of the D- and I- alleles in ACE I/D heterozygote subjects was 
assessed by RT-PCR as described above, using a specific primer set and  restriction 
enzyme  protocol.  This  protocol  exploited  a  known  linkage  between  the  ACE  I/D 
polymorphism and a single nucleotide polymorphism involving a G/A substitution that 
creates a restriction enzyme site. In the treatment group, the 8 week training period 
consisted  of  three  30  minute  sessions  of  supervised  treadmill  walking  exercise  per 
week. The control group was given standard verbal advice to do as much walking as 
possible,  and  to  try  to  walk  through  the  claudication  pain.  Following  the  8  week 
treatment period, all the initial assessments were repeated. 
 
To address the final 2 aims, a laboratory cell culture model of hypoxia was developed 
using  a  human  umbilical  vein  endothelial  cell  line  (ECV  304)  treated  with 
Diethylenetriamine-nitric oxide (DETA-NO). DETA-NO is a nitric oxide donor which 
has been shown previously to create a „metabolic hypoxia‟ by inhibiting the electron 
transport chain and cellular respiration, thus driving cells into anaerobic metabolism.
6 
Once a stable and viable model had been established the effects of hypoxia alone, ACE 
inhibition alone, and of ACE inhibition combined with hypoxia on ACE and VEGF   85 
gene  activity  was  measured.  ACE,  VEGF121  and  VEGF165  mRNA  expression  was 
determined by RT-PCR of mRNA extracted from cell lysates. ACE and VEGF protein 
levels were measured by ELISA of cellular protein extracted from the same cell lysates. 
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Figure 2.1  Summary of Hypothesis 
Both ACE and VEGF potentially play a role in the improvements in walking ability 
noted after exercise training. However, the effects of exercise training in claudicants on 
ACE and VEGF are unknown. Furthermore, evidence suggests that inhibition of ACE 
could potentiate VEGF responses in addition to decreasing ACE activity, both effects 
that could increase the benefits of training in claudicants. Thus, the central aim of this 
thesis was to examine the effects of exercise training on ACE and VEGF, and to assess 
the effects of ACE inhibition on ACE and VEGF responses in ischaemia. 
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CHAPTER 3 
MATERIALS AND METHODS   88 
CHAPTER 3 
3.1  CLINICAL TRIAL: TRAINING RESPONSES IN CLAUDICANTS 
The aim of this  trial was  to  examine the  responses of a  cohort of  claudicants  to  a 
supervised  exercise  training  programme,  specifically  looking  at  measurements  of 
walking ability in relation to changes in ACE, VEGF and VEGF receptor expression 
and protein levels. A separate group of claudicants who were given exercise advice 
alone were used as a control. 
 
3.1.1  Ethical Approval and Study Outline 
Ethical approval for the study was granted by the Joint UCL/UCLH Ethics Committee 
in  Ethics  of  Human  Research:  Committee  A.  An  overall  outline  of  the  study  is 
illustrated in Figure 3.1. In summary, patients fulfilling the study inclusion criteria were 
recruited. A series of baseline measurements were initially made. Demographic data and 
general  measurements  including  height,  weight,  blood  pressure  and  ABPI  were 
recorded. Walking ability was assessed on a treadmill using an incremental treadmill 
test and calf endurance by repetitive calf raises. A blood sample was taken for DNA, 
RNA  and  protein  analysis.  ACE,  VEGF121,  VEGF165,  VEGF-R1,  sVEGFR-1  and 
VEGFR-2 mRNA expression were all determined by RT-PCR of mRNA obtained from 
PBMNs isolated from blood. ACE genotype was confirmed by PCR of genomic DNA 
also isolated from PBMNs. Plasma levels of ACE and VEGF protein were measured 
using  an  ELISA.  Differential  expression  of  the  D-  and  I-  alleles  in  ACE  I/D 
heterozygote  subjects  was  assessed  by  RT-PCR  and  a  restriction  enzyme  protocol. 
Subjects were then randomised to receive either supervised treadmill exercise training 
three  times  a  week  or  exercise  advice  alone  for  8  weeks,  following  which  all  the 
baseline assessments were repeated.   89 
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Endurance, Ankle Brachial Pressure Index, DNA/RNA analysis, Protein Levels.
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Endurance, Ankle Brachial Pressure Index, RNA analysis, Protein Levels.
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Figure 3.1  Study Outline 
* Patients Randomized to Treadmill Training or Exercise Advice Only For 8 Weeks. 
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3.1.2  Patient Recruitment and Randomisation 
Patients were identified and recruited from vascular surgery clinics at the Middlesex and 
University College Hospitals,  London. Some subjects were also referred directly by 
their  GPs  for  assessment.  Subjects  with  stable but  limiting  intermittent  claudication 
were evaluated to take part in the trial. Eligibility was assessed by taking a full medical 
history, clinical examination and arterial duplex scanning. Only patients with a good 
history for intermittent claudication, signs of arterial disease on examination, an ankle-
brachial pressure index (ABPI) of ≤0.9, and an arterial duplex scan confirming arterial 
stenoses were included. Intermittent claudication was defined by a history of muscular 
leg  pain  associated  with  walking,  which  increased  on  further  walking  and  subsided 
within a few minutes on resting. Subjects with evidence of other significant disease 
processes that could limit walking distance or the subsequent response to an exercise 
programme  were  excluded.  Patients  prescribed  ACE  inhibitors  or  angiotensin  II 
receptor  antagonists,  which  potentially  alter  ACE  and  VEGF  expression,  were  also 
excluded. Full inclusion and exclusion criteria are shown in Table 3.1. Once the patient 
had  been  identified  as  suitable  for  the  trial,  they  were  informed  and  given  an 
information leaflet about the trial, and offered an appointment to attend the exercise 
laboratory at the Middlesex Hospital. At this appointment, they were briefed in detail 
about the trial, assessed for their ability to walk on a treadmill and if in agreement full 
written informed consent was obtained. 
 
On  entry,  demographic  data  such  as  age,  sex,  and  cardiovascular  risk  factors  were 
recorded.  A  detailed  vascular  history  including  estimated  walking  distance,  affected 
leg(s) and previous vascular interventions was taken. The disease distribution on arterial 
duplex scan was noted. Each subject then completed a 1 week run-in period, consisting  91 
 
Table 3.1  Study Inclusion and Exclusion Criteria 
 
INCLUSION CRITERIA 
History and examination findings consistent with intermittent claudication 
Arterial duplex scan confirming arterial stenoses and resting ABPI ≤0.9 
Claudication symptoms stable for > 3 months 
 
 
EXCLUSION CRITERIA 
Unlimited walking distance 
Unable to walk on a treadmill 
Evidence of critical ischaemia (rest pain or ulceration) 
Severe cardiac or respiratory disease 
Walking distance limited by other factors such as osteoarthritis or back pain 
Patient prescribed ACE inhibitors or angiotensin II receptor antagonists 
Angioplasty or surgical intervention within the last 6 months 
Diabetic neuropathy 
Claudication symptoms not stable 
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of 3 half hour sessions walking on a treadmill (Cardiokinetics Meditrack), allowing 
them to familiarise themselves with the treadmill prior to taking the initial walking test. 
This important adaptation period reduced the potential error in measuring a subject‟s 
initial walking distance, which could have been underestimated due to the subject‟s 
unfamiliarity with walking on a treadmill. These sessions took the format of a training 
session, as described in Section 3.1.5. Subjects were subsequently randomly assigned to 
either  the  treatment  group  (supervised  training)  or  control  group  (exercise  advice). 
Randomisation was achieved using identical sealed envelopes containing a card marked 
either  „Training  Group‟  or  „Control  Group‟.  Twenty  five  of  each  card  was  initially 
produced and placed in an envelope. Once sealed, the envelopes were randomly marked 
from 1 to 50, and the envelopes allocated in numerical order to each recruited patient. 
Although a large number of patients were screened for inclusion in the study, only 11 
subjects were recruited, 6 of whom were randomised to the training group and 5 to the 
control group. Although chronic obstructive airways disease (and hypoxia) is known to 
have  adverse  effects  on  skeletal  muscle  performance  and  metabolism,  it  was  not 
excluded as this would have severely limited available recruits.
159 Nevertheless, none of 
the recruited subjects had significant symptomatic pulmonary disease.  
 
3.1.3  Patient Assessments 
At initial and final assessments, a blood sample was taken and general measurements 
recorded first. This was followed by measurement of walking ability on a treadmill and 
after a 5-10 minute break, calf muscle endurance. The protocols are described below: 
 
General Measurements 
Height, weight, resting heart rate and blood pressure were recorded in each subject.   93 
Walking Distance  
A graded treadmill protocol was chosen to assess patient walking ability, using testing 
protocols  based  on  those  recommended  by  the  TASC  working  group.
142  Graded 
treadmill protocols have advantages compared to constant protocols. The results of a 
graded test are more reproducible and the same test can also be applied to claudicants 
with  a  broad  range  of  walking  ability.
112;143  Both  the  distance  to  the  onset  of 
claudication pain (claudication distance, CD) and the distance at which the pain caused 
the  subject  to  stop  (maximum  walking  distance,  MWD)  were  recorded.  Prior  to 
assessment,  subjects  were  given  advice  to  avoid  vigorous  activity,  caffeine  and 
excessive alcohol intake for 24 hours. All tests were performed in the morning, and one 
person conducted all the tests in this study. The treadmill speed was set at 3.2 km/hr, 
and the gradient initially set at 0% and increased by 2% every 2 minutes. The subject 
was asked to report the onset of claudication symptoms, and then encouraged to walk as 
far as possible through the pain. Use of the handrails was avoided, as this has been 
shown to potentially reduce the reliability of measurements.
100 Maximum heart rate was 
recorded at the end of the test. Perceived leg pain and perceived exertion scores were 
also recorded using Borg scales (RPE for exertion and CR10 for pain; Appendix 1). 
These  are  reliable  and  reproducible  measures  of  perceived  exertion  and  pain,  and 
enabled the perceived exertion and pain to be assessed between different tests.
24  
 
Calf Muscle Endurance 
Another endpoint measured was calf muscle endurance. Subjects were asked to perform 
repetitive heel raises until forced to stop by calf pain. This technique has been suggested 
as a screening test for peripheral arterial disease, and has been shown to have a similar 
effect on ankle pressures as treadmill walking.
9 Changes in the number of heel raises   94 
also correlate to changes in walking distance, but could have the added benefit over 
treadmill  testing  of  not  having  a  „learning  curve‟  or  be  affected  by  changes  in 
biomechanics  that  occur  after  a  period  of  treadmill  training.
112;178  Subjects  were 
required to perform heel raises at a standardised rate of 20 per minute. At the end of 
each test, perceived pain and exertion were recorded using Borg scales. This test was 
performed about 5-10 minutes after the treadmill test. This non-standardised time delay 
could have affected the results of this test. In addition, the previous test of maximal 
walking  distance  could  have  subsequently  affected  this  test,  due  to  ischaemic 
preconditioning. 
 
Ankle-Brachial Pressure Index 
The ankle-brachial pressure index (ABPI) was used as an outcome measure as a simple 
estimator  of  leg  perfusion.  A  sphygmomanometer  blood  pressure  cuff  and  doppler 
probe  (Huntleigh  Diagnostics  Dopplex  II)  were  used  to  measure  systolic  blood 
pressures in both arms and ankles, from which ABPIs were calculated. 
 
3.1.4  Blood Sample Collection and Processing 
In order to determine genotype and measure changes in gene expression and protein 
levels,  blood  was  collected  from  each  patient  at  the  beginning  of  each  assessment 
session. Peripheral blood mononuclear cells (PBMNs) were isolated from the blood for 
DNA and RNA extraction, and plasma taken for measurement of protein levels. Ideally, 
it would have been preferable to have taken muscle biopsy specimens from each subject 
to examine for local tissue changes in gene expression and protein levels. However, this 
would not have been practical or acceptable for the patients. Thus, PBMNs and plasma 
were used, and should give an indication of changes occurring locally in the tissues.   95 
Approximately 8 ml of blood was taken into Vacutainer
® EDTA Blood tubes (Becton 
Dickinson). These samples were all processed within 20 minutes of collection, using a 
sterile  polysaccharide  (5.7%  w/v)  and  sodium  diatrizoate  (9.1%  w/v)  solution 
(Lymphoprep
TM; Axis Shield) to separate the blood into its constituent components. The 
following protocol was used: 
 
Centrifugation 
Three ml of Lymphoprep
TM was added to two sterile 15 ml centrifuge tubes (Corning). 
Four ml of blood was then carefully layered on top of the Lymphoprep
TM layer (Figure 
3.2),  and  centrifuged  (ALC  PK120  centrifuge)  at  400  g  for  30  minutes  at  room 
temperature.  Lymphoprep
TM  caused  the  erythrocytes  and  granulocytes  to  aggregate, 
increasing their sedimentation rate significantly, while having little effect on PBMN 
sedimentation.
109 Thus, after centrifugation the mixture separated into distinct bands 
(Figure 3.2), with the plasma uppermost, the PBMNs in a thin band or „buffy coat‟ at 
the plasma-medium interface, and the red blood cells and granulocytes in the bottom 
layers. 
 
Plasma Extraction 
The upper plasma layer was aspirated into a 15 ml centrifuge tube, spun at 800 g for 5 
minutes to remove cellular debris, transferred to and frozen in a 1.5 ml Eppendorf tube 
(Starsted) at -20
oC. 
 
Extraction and Lysis of PBMNs 
The  „buffy  coat‟  layer  containing  PBMNs  was  carefully  aspirated  using  a  Pasteur 
pipette, added to a 15 ml centrifuge tube containing 3 ml of Phosphate buffered saline  96 
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Figure 3.2  Schematic Diagram of the Blood/Lymphoprep
TM Layers Before and 
After Centrifugation 
Whole  blood  was  layered  onto  Lymphoprep
TM  in  a  centrifuge  tube.  Following 
centrifugation, the mixture separated out into distinct layers containing different cell 
types.  97 
(PBS; Sigma
®), and made up to 10 ml with more PBS. Following centrifugation at 250 
g  for  10  minutes  the  supernatant  was  discarded,  the  PBMN  pellet  re-suspended  in 
another 10 ml of PBS and spun again at 250 g for 10 minutes. These washes served to 
remove  extraneous  platelets.  After  discarding  the  supernatant,  the  pellet  was  re-
suspended in 200 μl PBS by gentle agitation and 3 ml of TRI reagent
TM (Sigma
®) was 
added.  This  mixture  was  vortexed  for  10  seconds  (Vortex-Genie™;  Scientific 
Industries) to lyse the cells and dissolve the RNA and DNA for future isolation. The 
solution  was  transferred  to  sterile  1.5  ml  Eppendorf  tubes  and  frozen  at  -20 
oC. 
Protocols for the extraction of DNA and RNA from TRI reagent
TM, and the subsequent 
measurement of genotype, gene expression and protein levels are described in Sections 
3.3 and 3.4. 
 
3.1.5  Supervised Training Programme 
Following the baseline assessments, subjects randomised to the treatment group entered 
an 8 week supervised training programme. A supervised programme was chosen as they 
are known to be more effective than unsupervised training, and would therefore produce 
maximal  increases  in  walking  distance.
18;49;243 Patient  compliance  was  also  ensured.  
Each subject was required to train 3 times a week, with each training session lasting 
approximately 30 minutes. The sessions consisted of 10 cycles of 90 seconds walking 
on a treadmill followed by 90 seconds rest. The aim of this training protocol was to 
stimulate a moderate to high level of claudication pain during each walking phase, and 
to allow enough time for the pain to subside between each walk. Training intensity was 
tailored to each patient according to their original walking ability and the following 
equation used as a guide to determine initial training speed: 
Speed (km/hr) = (Claudication Distance (m)/90 s) x 3.6   98 
This equation simply used the subject‟s measured CD (taken at initial assessment) to 
calculate  the  necessary  speed  to  reach  CD  in  90  seconds.  Treadmill  gradient  was 
initially set to 1%. For some individuals with mild symptoms, this equation required a 
speed that was unacceptably high. For these subjects, treadmill speed was set as high as 
the  individual  could  tolerate  (typically  5km/hour)  and  the  gradient  increased 
accordingly to generate claudication within the 90 seconds.  
 
As  a  subject‟s  symptoms  improved  over  the  training  period,  treadmill  speed  was 
increased to continue to stimulate claudication pain. If the subject improved to a degree 
such that claudication pain was not stimulated despite using high treadmill speeds and 
that treadmill speed could not be increased further (to prevent running- typically  at 
5km/hour), treadmill gradient was increased in 0.5% increments. No other advice was 
given  to  the  subjects.  This  training  protocol  is  similar  to  those  that  have  been 
recommended to provide greatest improvements in walking.
71;99 Although some groups 
have recommended 6 month training programmes, shorter programs (6 weeks) have 
also  been  shown  to  work.
99;282  This  exact  programme  has  also  been  shown  to  be 
effective in previous studies in this laboratory.
178 During each session, heart rate was 
continuously monitored (Polar S-series precision toolkit), and the session halted if the 
heart rate exceeded 80% of the maximal predicted heart rate. 
 
3.1.6  Exercise Advice 
Subjects randomised to the control group were given verbal advice on taking exercise 
similar to what they would have been advised in a vascular outpatients clinic. They 
were encouraged to take walks 3 times a week, if possible for 20 minutes or more, and 
to try to walk through the claudication pain as much as possible.    99 
3.2  CELL CULTURE EXPERIMENTS 
In the second part of this thesis, a cell culture model of hypoxia was developed using 
the  nitric  oxide  (NO)  donor  Diethylenetriamine-NO  (DETA-NO)  to  produce  a 
„metabolic hypoxia‟ in an endothelial cell line. The effects of hypoxia on ACE and 
VEGF in these cells, and on cell viability were examined. Subsequently, the manner by 
which presence of the ACE inhibitor ramiprilat modulated these responses was then 
examined. ACE, VEGF121 and VEGF165 mRNA expression was determined by RT-PCR 
of mRNA extracted from cell lysates. ACE and VEGF protein levels were measured by 
ELISA of cell protein obtained from cell lysates. The use of a cell culture model has 
several advantages over a clinical trial using claudicants. One of the major limitations 
affecting most clinical trials in claudicants is the heterogeneity of the subjects used. To 
state a few factors, subjects vary immensely in age, co-morbidities, severity of disease, 
baseline activity levels and lifestyle. To overcome these limitations large sample sizes 
are preferable, but claudicants are difficult to recruit to trials.
69 Cell culture experiments 
have the advantage of using a single population of cells treated identically apart from 
the  specific  treatments,  allowing  a  much  „cleaner‟  experiment  to  be  performed. 
However, a limiting factor is the loss of interaction between different cell types that 
would occur in vivo. 
 
3.2.1  Culture Conditions  
Materials  
A cell line, ECV 304 (Rayne Institute, UCL) was used for these experiments. The ECV 
304 cell line were originally reported to have derived from HUVECs by spontaneous 
transformation, and have been used for over a decade as an endothelial cell model.
249 
However, recent studies have shown that they were in fact derived from the bladder   100 
cancer epithelial cell line T24.
30 Despite these findings, ECV 304 cells still show many 
characteristics of endothelial cells, have been shown to express ACE activity, and are 
still considered an attractive in vitro model for endothelia, given the scarcity of other 
suitable endothelial cell lines.
245 Thus they were chosen to be used in these experiments. 
However,  as  yet  no  evidence  is  available  to  confirm  that  ECV  304  cells  express 
bradykinin,  a  vital  link  in  the  RAS.  In  the  following  experiments,  unless  stated 
otherwise, ECV 304 cells were cultured in medium consisting of Medium 199 with 
Earle‟s Salts and Glutamax
TM (Gibco/Invitrogen) supplemented with 10% sterile foetal 
calf  serum  (FCS;  First  link  (UK)  Ltd),  100  u/ml  penicillin  and  100  μg/ml  of 
streptomycin (Gibco BRL
®/Life Technologies). Culture medium and all reagents were 
warmed to 37
oC prior to use. 
 
Resurrecting Cells from Storage 
A vial of ECV 304 cells frozen at passage 174 was removed from storage and thawed in 
a water bath at 37
oC. Using a sterile pipette, these cells were transferred to a 50 ml 
centrifuge tube (Techno Plastic Products AG; TPP
®) containing 19 ml of warm culture 
medium to wash the cells, and centrifuged at 200 g for 5 minutes to form a pellet. The 
medium was discarded, the cells re-suspended in 5 ml of fresh medium and added to a 
75 cm
2 culture flask (BD Falcon
TM) containing 25 ml of culture medium. The cells were 
incubated in a humidified chamber at 37
oC and 5% CO2. 
 
Passaging Cells 
These cells were sub-cultured at 70 hours at about 80% confluency. The medium was 
carefully aspirated from the flask and the cells rinsed with 15 ml sterile Hanks‟ balanced 
salt  solution  (HBSS;  Sigma)  without  magnesium  or  calcium.  This  rinse  removed   101 
residual FCS which could have inhibited the subsequent trypsin reaction. Magnesium 
and calcium free HBSS was used to facilitate the dissociation process, as these ions 
allow cells to stick together. A cell dissociation solution consisting of 0.25x Trypsin 
with EDTA (Gibco BRL
®/Life Technologies) in Sigma cell dissociation solution with 
PBS was used. After removing the HBSS, 13 ml of the dissociation solution was added 
and the flask incubated for up to 15 minutes at 37
oC. During this time, the cells were 
intermittently monitored for rounding and detachment under a microscope. Once this 
was evident, the cells were released by a sharp tap on the flask, and 35 ml medium 
added to the flask to neutralise the trypsin and prevent further activity that may have 
damaged the cells. This solution was aspirated, added to a 50 ml centrifuge tube and 
centrifuged at 200 g for 5 minutes to pellet the cells. After discarding the medium, the 
pellet was re-suspended in a further 10 ml medium, and 5 ml added to each of two 175 
cm
2 flasks (Nunc filter cap). These flasks were made up to 40 ml total volume with 
medium and incubated humidified at 37
oC and 5% CO2. 
 
Flasks were monitored routinely under the microscope to check for contamination and 
confluency. Subsequently passages were performed every 48-72 hours, when the cells 
reached about 80% confluency. Typically, each 175 cm
2 flask was split into 3 flasks, 
using the same protocol as above. At intervals, some cells were frozen in liquid nitrogen 
for storage.  
 
Freezing Down Cells for Storage 
When passaging the cells, some cells were removed and suspended in medium at a 
density of 2x10
6 cells/ml (see Section 3.2.2 for counting cells). Glycerol (Sigma), a 
cryoprotectant that reduces cell rupture due to ice crystal formation, was added to make   102 
up 10% by volume and mixed well. One ml aliquots were then added to freezer tubes, 
which were placed in a bath of isopropanol overnight in a -80
oC freezer. This bath 
allowed  a  controlled  decrease  in  temperature  of  1
oC/minute,  and  prevented  cell 
disruption  by  ice  crystals.  The  following  day  the  tubes  were  transferred  into  liquid 
nitrogen for storage. 
 
3.2.2  Preparation of Cells for Experiments 
Only clean confluent cultures from 175 cm
2 flasks were used. All experiments in this 
thesis  were  performed  on  cells  between  passages  178  and  190.  Microscopic 
examination  revealed  the  ECV  cells  to  grow  in  monolayers  with  the  typical 
„cobblestone appearance‟ of endothelial cells. 
 
Harvesting Cells 
Cells were harvested using the same dissociation protocol as for passaging the cells. 
However, after the initial removal of the cells and centrifugation to form a pellet, the 
cells were resuspended in 5 ml medium containing either 10% FCS or 1% FCS. Cell 
viability and number was then measured. 
 
Counting the Total Number and the Percentage of Viable Cells 
Cells  were  counted  using  a  haemocytometer  combined  with  a  Trypan  blue  (TB) 
exclusion assay to allow cell density and the percentage of viable cells to be determined. 
A haemocytometer consists of a slide with a grid marked on of known area. There are 9 
large squares on the grid, each with a volume of 0.1 mm
3 once a cover slip is placed on 
top. Thus if the mean number of cells in a square is counted, it is possible to determine 
cell density and hence the total number of cells. TB is taken up by dead cells, turning   103 
them blue and thus allowing the proportion of dead to viable cells to be calculated. Half 
a ml of 0.4% TB (Sigma) was combined with 0.4 ml of PBS, to which was added 0.1 ml 
of the cell suspension to be counted. This solution was mixed well and incubated for 5 
minutes at room temperature, allowing the dead cells to absorb the dye. After placing 
the cover slip onto the haemocytometer, 10 µl of the cell/TB mixture was placed onto 
the area between the cover slip and slide and allowed to be drawn under the cover slip 
by capillary action. The number of unstained and blue stained cells on 5 quadrants (the 
centre and 4 corner squares) of the haemocytometer grid was counted and a mean figure 
recorded. A specific counting pattern was used to avoid bias. For cells overlapping a 
boundary, a cell was counted if it overlapped the top or left grid border, but not if it 
overlapped the bottom or right grid border (Figure 3.3). 
 
The following equation was used to calculate the density of the original cell suspension: 
Cells/ml= Mean number of cells (in 0.1 mm
3) x 10000 x Dilution Factor in TB/PBS 
To calculate the total number of cells present, the number of cells/ml was multiplied by 
the total volume of the original cell suspension. To determine the percentage of viable 
cells, the following equation was used: 
% Viable Cells= (Number of Unstained Cells/Total Number of Cells) x 100 
Only cultures with greater than 90% viability were used for experiments, and from each 
175 cm
2 flask the yield was typically between 8-10 million cells.  
 
Plating Out Cells  
After counting the cells, working solutions of 1x10
6 cells/ml were prepared by adding 
an appropriate volume of culture medium. For cell viability assays, cells were plated out 
onto 96 well plates (Techno Plastic Products AG) with the appropriate drug(s) and the   104 
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Figure 3.3  Counting Cells Using a Haemocytometer  
This diagram shows a schematic representation of a haemocytometer with its grid of 9 
quadrants, and a magnified view of one quadrant. For cells overlapping grid boundaries, 
a cell was counted if it overlapped the top or left grid border, but not if it overlapped the 
bottom or right grid border. Thus in this example, 11 viable cells would be counted and 
1 non-viable cell.   105 
volume in each well made up to 100 µl. Concurrently, some cells were plated out on 6 
well plates (BD Falcon
TM) with the appropriate drug(s) and the volume in each well 
made up to 3 ml. These plates were used to examine for changes in gene expression and 
protein levels. For all experiments cells were incubated in a humidified chamber at 37
oC 
and 5% CO2 until ready for processing. Further details on the preparation of specific 
experiments are described in Section 5.3. 
 
3.2.3  Preparation of Drugs for Experiments 
Diethylenetriamine-nitric oxide (DETA-NO)  
While it would have been preferable to use hypoxic chambers to create the hypoxic 
conditions to be used in this experimental model, they are difficult to obtain and also 
significantly  expensive.  Thus,  given  its  ready  availability  and  in  addition  its 
significantly  lower  cost,  a  decision  was  made  to  use  DETA-NO  (2,2'-
(Hydroxynitrosohydrazono)  bis-ethanimine;  Sigma)  to  create  a  metabolic  model  of 
hypoxia in these experiments. 
 
DETA-NO is a slow releasing NO donor, which has been used widely to study the 
effects of NO on cellular respiration.
55 It allows the controlled release of NO to tissues 
at physiological levels. Evidence has shown that NO affects mitochondrial function, 
specifically by inhibiting the electron transport chain by competing with oxygen for 
binding to cytochrome oxidase at the inner mitochondrial membrane. By binding to 
cytochrome oxidase and preventing the mitochondria from utilising available oxygen, 
NO  inhibits  cellular  respiration  producing  a  „metabolic  hypoxia‟,  driving  cells  into 
anaerobic  metabolism.
6  Pathways  associated  with  hypoxia  are  also  activated,  for 
example the stabilization of HIF-1α is increased.
164   106 
Doses  of  DETA-NO  ranging  from  0.008  mM  to  0.5  mM  were  chosen  for  these 
experiments, and are similar to doses used in other studies.
6;16;164 Half mM of DETA-
NO can generate 1.5 µM of NO locally for up to 18 hours at 37
oC and inhibit respiration 
by up to 80%.
16;55 For these experiments DETA-NO was solubilised using ultra-pure 
water  (Simplicity  185™;  Millipore)  as  the  vehicle.  A  50  mM  master  solution  was 
prepared,  from  which  appropriate  dilutions  for  experiments  were  made.  The  final 
vehicle/water  concentration  in  all  experiments  was  1%,  and  all  experiments  had  a 
control consisting of medium with vehicle, and of medium alone. Further details on the 
preparation of specific experiments are described in Section 5.3. 
 
Ramiprilat 
Ramiprilat (Toronto Research Chemicals Inc.) was chosen as the ACE inhibitor for this 
experiment. Ramiprilat is the active form of the pro-drug ramipril, which in vivo is 
normally converted to its active form in the liver.  
 
Doses of ramiprilat ranging from 1000 nM/l to 1 nM/l were used in these experiments, 
being  similar  doses  to  those  used  in  other  studies  examining  ACE  signalling  in 
endothelial cells.
138;139 For these experiments, ramiprilat was solubilised using dimethyl 
sulphoxide  (DMSO;  Sigma)  as  the  drug  vehicle.  A  20  mM/l  master  solution  of 
ramiprilat  in  DMSO was  prepared, from which appropriate dilutions  for  subsequent 
experiments were made. The final DMSO concentration in all experiments was 0.05%, 
a  level  chosen  to  minimalise  its  potential  effects  on  cellular  metabolism.
210  All 
experiments involving ramiprilat included controls consisting of medium with vehicle, 
and of medium alone. Further details on the preparation of specific experiments are 
described in Section 5.3.   107 
3.2.4  Assessing Cell Viability 
At  the  end  of  each  experiment,  cell  viability  was  assessed  using  the  CellTiter  96
® 
AQueous  One  Solution  Cell  Proliferation  Assay  (Promega).  This  assay  uses  a  novel 
tetrazolium compound: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium  (MTS)  combined  with  an  electron  coupling  reagent 
phenazine ethosulfate. This produces a simple one step assay that can be performed in 
96-well  plates  without  the  need  for  harvesting  the  cells.  The  MTS  is  reduced  by 
NADPH or NADH present in metabolically active cells into formazan, a blue coloured 
product which can then be measured.
22 The following protocol was utilised: 
 
The 96-well plates were assessed under the microscope for confluence and signs of 
infection.  Twenty  µl  of  the  assay  solution  was  added  to  each  well,  and  the  plate 
incubated in a humidified atmosphere at 37
oC and with 5% CO2. In addition to the 
experimental wells, a series of triplicate wells containing culture medium only (no cells) 
were prepared and used as a „blank control‟. After 2 to 4 hours (see Section 5.3 for 
details  of  specific  timings),  the  plates  were  placed  in  a  plate  reader  (Dynex 
Technologies  Ltd)  and  light  absorbance  at  525  nm  recorded.  Two  separate  plate 
readings were taken and a mean of the 2 readings recorded. The mean reading from the 
„blank control‟ wells was then subtracted from the readings of the experimental wells to 
correct for background absorbance. 
 
3.2.5  Processing Cells for RNA and Protein Extraction 
At the end of each experiment, the 6-well plates were processed for RNA and protein 
extraction. Prior to harvesting the plates, they were examined microscopically to assess 
confluence and exclude infection. Rather than preparing individual wells to be harvested   108 
separately for RNA and protein, each experimental well was processed to obtain both 
protein and RNA. This method allowed a direct comparison between RNA expression 
and protein levels in a specific population of cells to be made. To achieve this, the cells 
were lysed with TRI reagent
TM, from which RNA and protein were later extracted. The 
culture medium was aspirated from each well and the cells washed with 3 ml HBSS. 
After discarding the HBSS, 1 ml of TRI reagent
TM was added to each well. Lysis was 
aided by repeat pipetting, and confirmed by microscopy. The products were transferred 
to 1.5 ml eppendorf tubes and frozen for later processing. Protocols for the extraction of 
RNA  and  protein  from  TRI  reagent
TM,  and  the  subsequent  measurement  of  gene 
expression and protein levels are described in Sections 3.3 and 3.6. 
 
3.3  DETERMINATION OF GENE EXPRESSION 
Gene expression, defined as the amount of messenger RNA (mRNA) produced from the 
DNA gene template, was measured semi-quantitatively by RT-PCR. In summary, total 
RNA was extracted from TRI reagent
TM and converted to complimentary DNA (cDNA) 
in a reverse transcriptase (RT) reaction. This cDNA was then amplified by polymerase 
chain reaction (PCR) using specific primers to target the mRNA sequences of interest. 
The quantity of product was measured with a scanning densitometer, and the amount 
expressed  relative  to  the  concurrent  expression  of  Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH-3), which was used as an internal control. 
 
3.3.1  Nucleic Acid Extraction from TRI reagent
TM 
TRI  reagent
TM  is  a  solution  of  guanidine  thiocyanate  and  phenol  in  a  mono-phase 
solution, which enables the simultaneous extraction of DNA, RNA and protein from 
cells as described by Chomczynski.
50 The following protocol was used:   109 
Separation of the Mixture into 3 Phases 
Samples frozen in TRI reagent
TM were thawed by standing at room temperature for 5 
minutes. A fifth of a ml of Chloroform (BDH Laboratory Supplies) for each 1 ml of TRI 
was added to each sample and the tubes vortexed for 15 seconds. After standing at room 
temperature for 10 minutes, the samples were centrifuged at 12,000 g for 15 minutes. 
This separated the solution into 3 phases (Figure 3.4): an upper clear inorganic phase 
(containing RNA), a fine interphase layer (containing DNA) and a lower red organic 
phase (containing protein). 
 
RNA Extraction 
For RNA extraction, the upper aqueous phase was transferred to a fresh Eppendorf tube, 
with care taken not to disturb the interphase. Half a ml of Isopropanol (BDH Laboratory 
Supplies) per original 1 ml of TRI reagent
TM was added to precipitate the RNA, the 
solution  mixed  and  left  to  stand  for  10  minutes  at  room  temperature  and  then 
centrifuged at 12,000 g for 10 minutes to form an RNA pellet. The supernatant was 
removed  and  the  RNA  pellet  washed  in  1  ml  of  75%  ethanol  (BDH  Laboratory 
Supplies) per original ml of TRI reagent
TM.  After centrifuging at 7,500 g for 5 minutes, 
the supernatant was removed and the pellet allowed to partially dry. The pellets from 
individual samples were combined and dissolved in an appropriate volume of ultrapure 
water (usually 60 μl), and stored at -40
oC.  
 
DNA extraction 
The interphase and organic phase were used  for DNA  and protein extraction. After 
carefully removing all of the aqueous phase (to reduce RNA contamination), 0.3 ml of 
100% ethanol per original 1 ml of TRI reagent
TM was added to precipitate the DNA.   110 
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Figure 3.4  Schematic Diagram Showing the 3 Phases after Centrifugation of the 
TRI reagent
TM and Sample Mixture 
Following centrifugation the TRI reagent
TM, chloroform and sample mixture separated 
into  3  distinct  phases:  the  upper  aqueous  phase  containing  dissolved  RNA,  the 
interphase precipitated DNA and the lower organic phase dissolved protein. 
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The solution was gently mixed by inversion, allowed to stand for 3 minutes at room 
temperature, and centrifuged at 2000 g for 5 minutes to pellet the DNA. The protein 
containing supernatant was then removed and stored at -40
oC (see Section 3.6.3 for 
protein extraction). The DNA pellet was washed for 40 minutes in a 0.1 M Sodium 
Citrate/10% Ethanol solution to remove residual phenol.  One ml of wash solution was 
used for each original 1 ml of TRI reagent
TM. The pellet was centrifuged at 4000 g for 5 
minutes and the wash repeated. The supernatant was then discarded, 1.5 ml of 75% 
ethanol wash  added and the pellet left to stand for 20 minutes. After removing the 
ethanol,  the  pellet  was  then  dried  out  and  dissolved  in  an  appropriate  volume  of 
ultrapure water (usually 200 μl). To help dissolution of the pellet, the tubes were placed 
in a water bath at 50
oC for 30 minutes. DNA in solution was stored at -20
oC. 
 
3.3.2  Quantifying the Amount of Available DNA and RNA 
The extraction of nucleic acids from TRI reagent
TM produced differing concentrations 
of DNA and RNA for each sample. It was important to quantify the amount of nucleic 
acid present so that an equal amount of RNA could be added to subsequent reverse 
transcriptase (RT) reactions and DNA in polymerase chain reaction (PCR) experiments. 
Quantification was performed using an ultraviolet (UV) light spectrophotometer (WPA 
UV1101) set to measure light at a wavelength of 260 nm. RNA and DNA both absorb 
UV light maximally at this wavelength, with 50 ng/μl of DNA and 40 ng/μl of RNA in a 
quartz cuvette corresponding to a recorded optical density (OD260) of 1. 
 
Nucleic acid samples were thawed on ice. To „zero‟ the machine, a „blank‟ sample 
containing 150 μl of water in a clean quartz cuvette was used. For test samples, a 50 
fold dilution of the DNA/RNA solution (3 μl of DNA/RNA solution and 147 μl water)   112 
was placed in the cuvette and measured. Between samples, the cuvette was cleaned 
carefully. To calculate the concentration of DNA or RNA in the samples, the following 
equations were used: 
DNA concentration (ng/μl) = (OD260 reading)/(1/50) x dilution factor (50) 
RNA concentration (ng/μl) = (OD260 reading)/(1/40) x dilution factor (50) 
(1/50 and 1/40 correspond to the OD260 of 1ng/μl DNA and RNA respectively.) 
 
3.3.3  Reverse Transcriptase Reaction 
Prior to amplification, it was necessary to convert the relatively unstable single stranded 
RNA into double stranded cDNA by adding a strand of „complimentary‟ bases to the 
RNA template in an RT reaction. A schematic diagram of an RT reaction is shown in 
Figure 3.5. cDNA provides a much more stable platform than RNA, allowing it to be 
used as a template in PCR reactions. 
 
Reagents 
The  complimentary  strand  was  formed  using  an  RNA-dependent  DNA  polymerase 
derived  from  the  Moloney-Murine  Leukaemia  Virus  (M-MLV;  Sigma).  This  was 
supplied with a buffer (10x M-MLV RT buffer; Sigma) containing 500 mM Tris-HCL, 
500 mM KCl, 30 mM MgCl2 and 50 mM DTT to optimise the reaction. To initiate the 
RT reaction, the RNA template needed to be „primed‟ by short strands of nucleotides 
(primers) bound to the RNA template. Random nonamers (Sigma) were chosen and 
came as  a 50 µM solution. These are random  sequences of 9 nucleotides that bind 
randomly to complimentary segments on the RNA template. The use of random primers 
allowed total RNA to be converted to cDNA. They have the advantage over oligo-dTs 
in  that  they  do  not  require  the  presence  of  intact  poly-A  tails  on  messenger  RNA  113 
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Figure 3.5  Schematic Diagram of a Reverse Transcriptase Reaction 
In an RT reaction, unstable single-stranded RNA is converted to stable double-stranded 
cDNA.  Random  nonamers  (primers)  and  dNTPs  are  initially  combined  with  RNA 
template.  After  allowing  the  primers  to  bind,  the  enzyme  M-MLV  is  added,  which 
transcribes a complimentary sequence of bases in a 5‟ to 3‟ direction, forming a cDNA 
strand. Primers and dNTPs are added in excess to ensure the complete conversion of 
RNA into cDNA.  
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(mRNA) to bind. The poly-A tails can often be damaged during processing, resulting in 
a decreased yield of cDNA if oligo-dTs are used and hence a false negative result. 
Finally,  a  deoxynucleotide-triphosphate  mix  (dNTPs;  Sigma),  containing  10  mM  of 
dATP, dCTP, dGTP and dTTP was used. These nucleotides formed the building blocks 
of the reaction by being incorporated into the new complimentary strands. 
 
Protocol 
The  following  protocol  based  on  that  recommended  by  Sigma
®  was  employed.  All 
reactions were set up on ice. For each reaction, 2 µl of dNTPs and 2 µl of random 
nonamers were added to a clean, nuclease-free 0.5 ml eppendorf tube. A volume of 
RNA sample equivalent to 2 μg total RNA was added to each tube, and the volume 
made up to 30 µl with ultrapure water. After gently mixing, the tubes were centrifuged 
briefly to get all components to the bottom of the tube. They were then placed in a 
Progene thermal cycler (Techne Ltd) and heated at 70
oC for 10 minutes to eradicate any 
tertiary  RNA  structures  and  subsequently  allow  efficient  primer  binding.  The  tubes 
were then cooled rapidly on ice to allow the primers to bind, before 10 µl of a „master-
mix‟ containing 2 µl M-MLV (400 units), 4 µl M-MLV buffer and 4 µl water was 
added. The tubes were then incubated in the thermal cycler at 20
oC for 10 minutes, and 
then at 37
oC for 50 minutes to allow the cDNA stand to be synthesised. Finally, the 
tubes  were  heated  to  94
oC  for  10  minutes  to  denature  the  M-MLV  enzyme  and 
terminate the reaction.  
 
In summary, as the amount of RNA (2 μg) used in every reaction was the same, each 
reaction  produced  2  μg  of  cDNA  in  40  μl  total  volume,  resulting  in  a  cDNA 
concentration of 50 ng/μl. The cDNA was stored at -20
oC.   115 
3.3.4  Polymerase Chain Reaction: Overview 
The  processes  described  above  produced  only  a  tiny  quantity  of  the  target  mRNA 
sequences in the form of stable cDNA. In order to quantify gene expression, these target 
sequences needed to be amplified until the relevant cDNA products were present in 
large  enough  quantities  to  be  measured  macroscopically.  The  technique  chosen  to 
amplify  the  cDNA  was  PCR.  This  technique  allows  millions  of  copies  of  a  target 
sequence to be produced in a short length of time. It utilises a cyclical process in which 
the target cDNA sequence is duplicated during each cycle, resulting in an exponential 
increase in the amount of product. Thus, a very small amount of starting product can 
quickly be amplified to a level which can easily be measured. 
 
The PCR Cycle 
Each cycle of a PCR reaction has 3 stages: denaturation, annealing and elongation. 
Denaturation involves heating the cDNA to a high temperature (90-94
oC) to break it 
down  into  its  2  component  strands,  and  thereby  expose  the  nucleotide  bases.  The 
temperature is subsequently reduced during the annealing stage, to provide optimum 
conditions  for  the  binding  of  specifically  designed  oligonucleotide  primers  to  their 
complimentary nucleotide sequences. The temperature is then raised to the optimum 
temperature for the action of DNA polymerase which, using the primers as a starting 
point, adds a strand of nucleotide bases in a 5‟ to 3‟ direction to form a double stranded 
product.  As  each  denatured  strand  is  converted  into  a  new  DNA  strand,  there  is 
effectively a doubling of the target DNA sequence with each cycle. Therefore after 35-
40 cycles, the amount of target DNA present will be substantial. A schematic diagram 
of the first 2 cycles of a PCR reaction is shown in Figure 3.6. A diagram illustrating the 
exponential increase in target DNA sequences is shown in Figure 3.7. At the end of a   116 
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Figure 3.6  Diagram Showing the First 2 Cycles of a PCR Reaction 
Heat denaturation separates the cDNA strand into 2 single stranded templates. Lowering 
the temperature allows oligonucleotide primers specific to the target sequence to anneal. 
DNA  polymerase  (TAQ),  using  the  primers  as  a  starting  point  adds  a  strand  of 
complimentary dNTPs producing 2 new DNA strands. A further doubling occurs in 
cycle 2, resulting in 4 DNA strands.   117 
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Figure 3.7  Diagram Showing the Doubling of cDNA with Each PCR Cycle 
At the end of 6 cycles, there are 64 copies of the original single template. After 35 
cycles, depending on the dynamics of the reaction, there is potential for up to 2
35 copies.    118 
PCR reaction, the amount of target DNA present will be proportionate to the amount of 
starting  template.  In  these  studies,  all  reactions  for  a  specific  target  used  the  same 
amount of starting template, making it possible to form comparisons between the results 
from  different  samples.  However,  it  was  also  necessary  to  control  for  the  general 
activation level of a cell, and also for variation in the efficiency of each reaction. For 
this purpose, a „house-keeping‟ gene or internal control was used.  
 
Internal Control: GAPDH-3 
Even  very  small  variations  in  the  efficiency  of  separate  PCR  reactions  can  have  a 
significant effect on the final yield of product, and need to be controlled for. These 
differences can occur due to disparity in the efficiency of separate RT reactions, loading 
errors, or even due to slight differences between individual PCR machines. In addition, 
it is also necessary to control for the general level of cell activation. For example, in 
proliferative  or  inflammatory  states,  gene  expression  as  a  whole  within  cells  is 
increased. If target gene expression alone is measured, it is not possible to determine 
whether any  changes  in expression are due to  specific changes  in  the  target  gene‟s 
expression or to a more general change in cell activity. To control for both of these 
problems, target gene expression was expressed semi-quantitatively as a ratio relative to 
the expression of the „house-keeping‟ gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH-3). GAPDH-3 is a key enzyme in glycolysis and is constitutively expressed at 
a level reflecting general cell activation.
248 Thus, any change in the ratio of target gene 
expression relative to GAPDH-3 could only have been due to specific gene activation or 
suppression, and not to changes in general cell activity. Likewise, any variation in the 
efficiency of PCR reactions would have affected the final yield of both the target gene 
and GAPDH-3, but not the ratio between them. Therefore, for each sample and each   119 
target gene, 2 reactions were set up to quantify target gene and concurrent GAPDH-3 
expression. To further increase the accuracy of the results, all RT-PCR experiments 
were performed twice and a mean value of recorded. 
 
Reagents 
All reagents were supplied by Sigma
® unless stated otherwise. REDTaq, a heat-stable 
DNA polymerase  which can tolerate temperatures  of up to 100
oC  (and thus  not  be 
denatured in the PCR reaction) was used to synthesize the DNA strands. It was supplied 
in a 1 unit DNA polymerase/µl solution with 20 mM Tris-HCL at pH 8.0, 100 mM KCl, 
0.1 mM EDTA, 1 mM DTT, 0.5% Tween 20, 0.5% Igepal CA-630, inert red dye and 
50% glycerol. For some reactions, Jumpstart
TM REDTaq DNA polymerase was used. It 
was provided as a 1 unit/µl solution and in an identical buffer to REDTaq. Jumpstart
TM 
REDTaq consists of REDTaq blended with an antibody that binds to the enzyme at low 
temperatures, inactivating it. During the initial denaturation stage of the PCR reaction, 
the  antibody  is  displaced,  activating  the  enzyme.  This  system  enables  each  PCR 
reaction to be completely assembled in one step, eliminating the need for the „hot-start‟ 
stage required with REDTaq alone, and thus reduces set up time and the potential for 
contamination.  The  DNA  polymerases  were  provided  with  a  PCR  buffer  (10x 
concentration) containing 100 mM Trizama
®-HCL at pH 8.3 and 500 mM KCl, which 
was diluted 10 fold in the final reaction. A separate 25 mM solution of magnesium 
chloride was also supplied. Magnesium is an essential co-factor for DNA polymerase, 
and adjustment of the final magnesium level (1.5-2.5 mM) allowed the stringency or 
efficacy of each PCR  reaction to be optimised. A dNTP mix containing 10 mM of 
dATP,  dCTP, dGTP  and dTTP  formed the building blocks  of the  reaction. Finally, 
oligonucleotide primers specific for each target were obtained.    120 
Primers 
The sequences for the primer sets used in these experiments were taken from published 
work in the literature or from primers previously used in our own laboratory.
269;273 The 
primer sets all conformed to basic principles of primer design. Each set was designed to 
amplify a small section of the target cDNA sequence between 100-400 base pairs (bp) 
in length, with one primer binding to the sense strand and the other to the anti-sense 
strand  of  the  cDNA  target.  The  primers  were  all  around  20  bp  long,  to  enable  a 
sequence of nucleotides to be designed to allow specific binding to only one location on 
the genome. This was checked using the Basic Alignment Sequence Homology Tool 
(BLAST) on the NCBI website. The target sequences chosen also spanned at least one 
exon-exon boundary on the original mRNA sequence, to prevent the amplification of 
contaminating genomic DNA. The primer annealing temperature (Tm), defined as the 
temperature  at  which  half  of  the  primer  will  anneal  to  the  target  sequence,  was 
approximated for each primer using the “Wallace formula”: 
Tm (
oC) = [4(No. of G/C bases) + 2(No. of A/T bases)] 
The G/C bases contribute more to the Tm as they have stronger hydrogen bonds than 
A/T bases, conferring greater stability. The estimated Tm for each primer set obtained 
using this formula was used as a guide when subsequently optimising the PCR reactions 
(see Section 3.3.5). Details of specific primer sets are shown in Table 3.2. 
 
General PCR Protocols 
The PCR protocols used were based on the protocols recommended by Sigma
® but were 
optimised for each primer set. All experiments were performed in a clean environment 
with sterile technique used throughout, and all plastic wear autoclaved prior to use. 
Reactions using REDTaq were prepared as follows: Aliquots of sample cDNA were   121 
 
 
Table 3.2  Primer Sequences 
Forward  (F)  and  reverse  (R)  primers  for  each  target,  primer  sequences,  calculated 
annealing temperatures (Tm) and product sizes are shown.  
 
Primer  Sequence (5’ to 3’)  Tm 
(
oC) 
Product Size 
(bp) 
ACE 216 (F)  CACCAATGACACGGAAAGTG  64 
216 
ACE 216 (R)  GCATCAAAGTGGGTTTCGTT  64 
VEGF (F)  CATCCTGTGTGCCCCTGATG  64  243 (VEGF121) 
375 (VEGF165)  VEGF (R)  TTCCTCCTGCCCGGCTCAC    64 
VEGFR-1 (F)  TCATGAATGTTTCCCTGCAA  56 
277 
VEGFR-1 (R)  GTGCTGCTTCCTGGTCCTAA  62 
sVEGFR-1 (F)  TCATGAATGTTTCCCTGCAA  56 
119 
sVEGFR-1 (R)  TTTGTTGCAGTGCTCACCTC  60 
VEGFR-2 (F)  AGACTTTGAGCATGGAAG  52 
312 
VEGFR-2 (R)  CCATTCCACCAAAAGATG  52 
GAPDH-3 (F)  GAGTCAACGGATTTGGTCGT  64 
185 
GAPDH-3 (R)  GACAAGCTTCCCGTTCTCAG  64 
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added to 500 µl eppendorf tubes. Positive and negative control tubes, containing proven 
cDNA and ultrapure water respectively, were also set up for each experiment. A pre-
prepared master-mix solution containing 10x PCR buffer, magnesium chloride, dNTPs, 
ultrapure water and primers was then added to each tube to make the volume up to 45 
µl. The tubes were then vortexed for 5 seconds to ensure mixing, and centrifuged briefly 
at 2000 g to collect the tube contents at the base. Each reaction tube was then placed in 
a Progene thermal cycler (Techne Ltd) and heated to 94ºC for 4 minutes to denature the 
DNA  template.  The  temperature  was  reduced  to  65
oC  and  5  µl  of  a  master-mix 
containing 0.5 µl REDTaq, 0.5 µl 10x PCR buffer and 4 µl water added. Adding the 
REDTaq  at  this  stage  in  a  „hot-start‟  protocol  helped  to  decrease  non-specific 
amplification.  Each  tube  then  underwent  35  cycles  of  denaturation,  annealing  and 
elongation, followed by a final 10 minute elongation period at 72ºC to ensure complete 
sequence extension. Final protocols for each primer set are described in Section 3.3.5. 
Jumpstart  REDTaq  was  used  for  all  the  RT-PCR  reactions  in  the  cell  culture 
experiments, and for the VEGF receptor RT-PCR reactions in the claudication trial. The 
experiments were prepared as follows: Aliquots of sample cDNA were carefully added 
to the bottom of the wells on 96-well PCR plates. A pre-prepared master-mix solution 
containing 10x PCR buffer, magnesium chloride, dNTPs, ultrapure water, primers and 
jumpstart REDTaq was then added to each well to make a total reaction volume of 50 
µl. Each plate also had positive control and negative control wells. The plate was then 
covered with a PCR film, placed in a Progene thermal cycler and heated to 94ºC for 4 
minutes  to  denature  the  DNA  template  and  activate  the  REDTaq.  Each  plate  then 
underwent 35 cycles of denaturation, annealing and  elongation,  followed by  a final 
period of 10 minutes of elongation at 72ºC to ensure complete sequence extension. The 
specific optimised protocols for each primer set are described in Section 3.3.5.   123 
3.3.5  PCR: Optimisation and Final Experimental Conditions 
Variations in primer properties, PCR product length and cDNA template availability all 
alter the dynamics of a PCR reaction. Given these variables, it was necessary to adapt 
the basic PCR protocols for each primer set to produce consistent, clean and measurable 
products. This optimisation process was performed by: 
 
Altering Reaction Stringency 
The stringency of a reaction describes its efficacy and specificity, and was altered by 
varying  Tm  and  MgCl2  concentration  (see  Appendix  2).  A  stringent  reaction  will 
produce clean products but will have lower yields than a less stringent reaction, which 
will conversely have a less clean product. Lowering Tm increases primer binding to the 
target site, but it also increases non-specific primer binding, resulting in spurious PCR 
products. Raising Tm has the opposite effect, increasing the stringency of the reaction. 
MgCl2 acts  as  a co-factor for DNA polymerase. High levels  of  MgCl2 increase the 
efficacy of DNA polymerase, but allow sequencing errors to occur (low stringency), 
whilst low magnesium levels have the opposite effect (high stringency). Initially, a Tm 
slightly lower than that predicted by the Wallace formula was chosen, combined with a 
high MgCl2 concentration to produce a low stringency reaction. The stringency was 
then gradually increased (by increasing Tm or lowering MgCl2) until a clean product 
was produced. For these experiments, a final MgCl2 of between 1.0 mM and 2.5 mM 
was used, and annealing temperatures varied between 56
oC and 60
oC. 
 
Varying the Amount of Template 
If raising the stringency of the reaction to obtain a clean product resulted in low product 
yields, the amount of starting template was increased to circumvent this problem (see   124 
Appendix 2). For these experiments, between 50 and 400 ng of cDNA per reaction was 
used. In addition, the concentration of primer could also be altered (0.5 to 1.0 µM used). 
 
Altering PCR Cycle Conditions 
Finally, the PCR reactions could be optimised by varying the PCR cycle conditions (see 
Appendix  2).  Annealing  time  was  varied  between  30-45  seconds,  elongation  time 
between  45-60  seconds,  and  total  number  of  PCR  cycles  between  35-40  cycles. 
Increasing annealing and elongation times allowed greater time for primer binding or 
DNA  synthesis  to  occur  respectively.  Increasing  the  cycle  number  allowed  more 
amplification to occur. 
 
Therefore, following the optimisation process, a specific protocol was developed for 
each primer set. The exact conditions used for ACE 216, VEGF, VEGFR-1, sVEGFR-1 
and VEGFR-2 primers are described in Tables 3.3 to 3.6. For the GAPDH-3 internal 
controls, identical PCR conditions to the study primer set being examined were used. 
The GAPDH-3 controls were prepared concurrently, using the same reagents and run in 
the same thermal cycler or plate as the study experiments. The only difference was that 
the GAPDH-3 experiments required only 50 ng (1 µl) of cDNA template, with the 
volume made up to 50 µl with ultrapure water. 
 
3.3.6  Analysis of PCR Products 
The products of the PCR reactions were analysed by gel electrophoresis to visualise the 
products and separate them by size. A photograph of the gel was scanned, and scanning 
densitometry performed to quantify the amount of product present. 
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Table 3.3  Final ACE 216 PCR Conditions 
For reactions using Jumpstart REDTaq, the initial master-mix was prepared containing 
all the constituents of the reaction (using the same quantities shown below), and the 
PCR cycling conditions were identical except that the hot-start stage was omitted.  
 
Reagent  [Stock]  Volume added (µl)  [Reaction] 
cDNA Template  50 ng/µl  6  - 
       
PCR Master-mix       
PCR Buffer  10x  4.5  1x 
MgCl2  25 mM  3  1.5 mM 
dNTPs  10 mM  1  0.2 mM 
Primers (F+R)  50 µM  0.5  0.5 µM 
Ultrapure water    30  - 
     
TAQ Master-mix     
PCR Buffer  10x  0.5  1x 
REDTaq   1 u/µl  0.5  0.01 u/µl 
Ultrapure water    4  - 
     
Total PCR Reaction Volume  50   
 
  Temperature (ºC)  Time 
Denaturation  94  4 minutes 
Hot-start  65   
     
35 Cycles     
Denaturation  94  30 seconds 
Annealing  60  45 seconds 
Elongation  72  45 seconds 
     
Polyadenylation  72  10 minutes   126 
Table 3.4  Final VEGF PCR Conditions 
For reactions using Jumpstart REDTaq, the initial master-mix was prepared containing 
all the constituents of the reaction (using the same quantities shown below), and the 
PCR cycling conditions were identical except that the hot-start stage was omitted. 
 
Reagent  [Stock]  Volume added (µl)  [Reaction] 
cDNA Template  50 ng/µl  4  - 
       
PCR Master-mix       
PCR Buffer  10x  4.5  1x 
MgCl2  25 mM  3  1.5 mM 
dNTPs  10 mM  1  0.2 mM 
Primers (F+R)  50 µM  1  1 µM 
Ultrapure water    31.5  - 
     
TAQ Master-mix     
PCR Buffer  10x  0.5  1x 
REDTaq   1 u/µl  0.5  0.01 u/µl 
Ultrapure water    4  - 
     
Total PCR Reaction Volume  50   
 
  Temperature (ºC)  Time 
Denaturation  94  4 minutes 
Hot-start  65   
     
35 Cycles     
Denaturation  94  30 seconds 
Annealing  58  45 seconds 
Elongation  72  60 seconds 
     
Polyadenylation  72  10 minutes 
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Table 3.5  Final VEGFR-1 and sVEGFR-1 PCR Conditions 
VEGFR-1 and sVEGFR-1 PCR conditions were identical. The same forward primer 
was used for both primer sets, with the distinct reverse primers targeting the specific 
RNA sequences for each receptor. 
 
Reagent  [Stock]  Volume added (µl)  [Reaction] 
cDNA Template  50 ng/µl  6  - 
       
Jumpstart Master-mix       
PCR Buffer  10x  5  1x 
MgCl2  25 mM  2  1 mM 
dNTPs  10 mM  1  0.2 mM 
Primers (F+R)  50 µM  1  1 µM 
Jumpstart REDTaq   1 u/µl  0.5  0.01 u/µl 
Ultrapure water    34.5  - 
     
Total PCR Reaction Volume  50   
 
  Temperature (ºC)  Time 
Denaturation  94  4 minutes 
     
35 Cycles     
Denaturation  94  45 seconds 
Annealing  58  45 seconds 
Elongation  72  60 seconds 
     
Polyadenylation  72  10 minutes 
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Table 3.6  Final VEGFR-2 PCR Conditions 
 
Reagent  [Stock]  Volume added (µl)  [Reaction] 
cDNA Template  50 ng/µl  8  - 
       
Jumpstart Master-mix       
PCR Buffer  10x  5  1x 
MgCl2  25 mM  4  2 mM 
dNTPs  10 mM  1  0.2 mM 
Primers (F+R)  50 µM  1  1 µM 
Jumpstart REDTaq   1 u/µl  0.5  0.01 u/µl 
Ultrapure water    30.5  - 
     
Total PCR Reaction Volume  50   
 
  Temperature (ºC)  Time 
Denaturation  94  4 minutes 
     
40 Cycles     
Denaturation  94  45 seconds 
Annealing  56  45 seconds 
Elongation  72  60 seconds 
     
Polyadenylation  72  10 minutes 
 
 
   129 
Gel Electrophoresis 
Gel  electrophoresis  was  used  to  separate  the  PCR  products  by  size,  allowing 
confirmation of the presence of correct sized PCR product, and excluding the presence 
of spurious products. Gel electrophoresis involves using an electric field to pull the PCR 
products across a gel matrix, which acts as a sieve separating out the molecules. As 
DNA  is  uniformly  negatively  charged,  the  products  migrate  towards  the  positive 
electrode at a rate according to their size with smaller molecules migrating faster than 
large molecules. All reagents were supplied by Sigma
® unless stated otherwise. A 2% 
agarose gel was prepared by adding 2 g of agarose to 100 ml 1x Tris-Borate-EDTA 
(TBE; 89 mM Tris-borate, 2 mM EDTA, pH 8.3) buffer and heating in a microwave 
until the agarose had completely dissolved. Ten µl of ethidium bromide was then added 
which, by later intercalating with DNA bases allowed PCR products to be visualised 
under ultraviolet (UV) light. The mixture was poured into a gel tray and combs placed 
to create wells for the loading of PCR products. After setting, the gel was placed in a gel 
rig and immersed in TBE buffer. Ten µl of PCR product, combined with 2 µl of loading 
buffer (30% glycerol in water and 0.25% bromophenol blue) was loaded into each well. 
In each lane, a well was loaded with 3 µl of a 100 bp ladder (fragment sizes 100-1000 
bp) to allow product size to be judged. A 120 V, 60 mA current was run across the gel 
for 30 minutes. The gel was then placed on a UV-light illuminator box and a Polaroid 
photo taken using standardised exposure settings (F-stop 8, shutter speed 0.5 seconds). 
A photograph of a typical gel is shown in Figure 3.8. 
 
Scanning Densitometry 
Scanning densitometry was used to quantify band intensity in the gel photographs, and 
hence  measure  the  amount  of  PCR  product  present,  allowing  the  level  of  gene  130 
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Figure 3.8  Photograph of a Typical Agarose Gel  
The products from a VEGF RT-PCR reaction and a concurrently run GAPDH-3 control 
reaction  are  shown.  The  direction  of  migration  (towards  the  positive  electrode)  is 
illustrated, with smaller fragments migrating further through the gel matrix than larger 
products. The size of the products can be assessed using the 100 bp ladder.   131 
transcription to be determined. The photographs were scanned using an Epson GT-9500 
scanner  using  Epson  Twain  software.  Labworks™  Image  Acquisition  and  Analysis 
software (Ultra-Violet Products Ltd) was used to identify the bands on the photograph, 
and the integrated optical density (IOD) of each band recorded. As stated previously, 
gene transcription was expressed semi-quantitatively, as a ratio of the IOD of the target 
gene band to the IOD of the GAPDH-3 band. 
 
3.3.7  Alternatives to RT-PCR for Measuring Gene Expression 
Although RT-PCR was chosen to quantify RNA and gene transcription in this thesis, 
other well recognised methods are available. However, for the following reasons these 
techniques were discounted: Northern blotting analysis and nuclease protection assays 
were  discounted  as  they  are  less  sensitive  than  RT-PCR.  In-situ  hybridization  was 
considered inappropriate as it was not necessary to measure gene expression within the 
tissues, and it is also less sensitive than RT-PCR. Gene arrays were also regarded as 
inappropriate due to extreme cost, decreased sensitivity and as only a few target genes 
were  being  examined.
232  Another  more  recently  developed  technique  for  measuring 
RNA levels is Real-time RT-PCR. This highly sensitive technique is based on the same 
principles as RT-PCR, but has the additional advantage of allowing the quantification of 
PCR products in „real-time‟ as they are manufactured in each cycle. This is usually 
achieved by using a direct fluorescence system. The benefits of this system include the 
elimination  of  the  electrophoresis  and  scanning  densitometry  stages,  increased 
sensitivity  and  increased  accuracy  in  the  quantitation  of  mRNA.
291  However, 
disadvantages include the large number of preliminary experiments required to optimise 
reactions, and the considerable expense of the required equipment. Although RT-PCR 
has some limitations compared to real-time RT-PCR, it still remains a sensitive and   132 
robust  technique  for  RNA  quantification.  Therefore,  due  to  its  availability  and  cost 
advantages, it was chosen to measure gene expression for this thesis. 
 
3.4  ACE GENOTYPE DETERMINATION 
ACE genotype was determined by PCR of patient DNA extracted from whole blood. In 
summary, genomic DNA was extracted from whole blood, as described in Section 3.3.1, 
amplified using primers specific to the polymorphic region on the ACE gene, and the 
products examined by gel electrophoresis to determine genotype. 
 
3.4.1  Overview 
The method used for establishing ACE genotype was first described by Lindpaintner et 
al in 1995.
154 This technique employs two sets of primers: H ACE 3 primers were 
designed to flank the polymorphic region in the ACE gene, amplifying both the deletion 
and insertion alleles, producing two possible products (319 and 597 bp respectively). 
However, in heterozygous (ID) subjects, the D-allele was preferentially amplified by 
these primers, to the extent that the product from the I-allele was difficult to detect after 
gel  electrophoresis. This created  a potential problem of mistyping  ID heterozygotes 
with the DD genotype. To circumvent this problem, a second pair of primers (H ACE 
5),  with  a  binding  site  specific  to  the  287  insertion  sequence  was  designed.  These 
„insertion specific‟ primers produced a 335 bp product only in the presence of the I-
allele, and therefore helped to differentiate between the ID and DD genotypes. 
 
3.4.2  PCR conditions 
PCR was performed on patient DNA samples using REDTaq and a „hot-start‟ protocol 
as described in Section 3.3.4. Details of the primers used and possible PCR products are   133 
illustrated in Figure 3.9. Details of the exact conditions used following an optimisation 
process  are  shown  in  Table  3.7.  The  PCR  products  were  separated  by  gel 
electrophoresis  as  described  in  Section  3.3.6  and  genotype  interpreted  from  the  gel 
photograph. A gel picture illustrating the 3 possible genotypes is shown in Figure 3.10. 
 
3.5  DIFFERENTIAL TRANSCRIPTION OF ACE I/D ALLELES ANALYSIS 
The  mechanism  by  which  the  I/D  polymorphism  at  intron  16  alters  ACE  gene 
expression may relate to increased production or stability of mRNA originating from 
the D-allele, but still remains unclear. However, in healthy I/D heterozygotes, more 
ACE mRNA has been shown to arise from the D-allele compared to the I-allele.
246 In 
this study, the transcription of mRNA from each allele in heterozygotes, and also the 
potential differential  effects  of training on each allele  were  examined.  In summary, 
cDNA was obtained from patient PBMNs as described in Sections 3.1.4 and 3.3.1. The 
cDNA was amplified by RT-PCR using primers targeting a segment of ACE mRNA 
containing a potential restriction enzyme site specific to mRNA originating from the I-
allele.  Following  a  restriction  enzyme  reaction,  the  products  were  examined  by  gel 
electrophoresis and scanning densitometry. All experiments were performed twice on 
separate occasions and the mean result taken. 
 
3.5.1  Overview 
The method used for quantifying mRNA expression from the I/D alleles was based on a 
protocol first described by Suehiro et al in 2004.
246 Since the ACE I/D polymorphism is 
located at intron 16, it is spliced out of the RNA sequence as it is converted to mRNA 
and thus cannot be used to determine the origin of mRNA strands. However, a single 
nucleotide polymorphism (SNP) is known to exist in exon 15, which is directly linked  134 
  
Primer  Sequence (5’ to 3’)  Tm 
(
oC) 
Product Size (bp) 
D-allele  I- allele 
H ACE 3 (F)  GCCCTGCAGGTGTCTGCAGCATGT  64 
319  597 
H ACE 3 (R)  GGATGGCTCTCCCCGCCTTGTCTC  64 
H ACE 5 (F)  TGGGACCACAGCGCCCGCCACTAC  64  No 
Product 
335 
H ACE 5 (R)  TCGCCAGCCCTCCCATGCCCATAA  64 
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Figure 3.9  ACE Genotyping: Primers and Possible Products 
The H ACE 3 primer binding sites flank the insertion site on intron 16, resulting in 2 
possible products depending on the presence of the 287 bp insertion. The „insertion 
specific‟ H ACE 5 primers generate only 1 possible product, indicating the presence of 
the insertion sequence.   135 
Table 3.7  Final ACE Genotype PCR Conditions 
Both H ACE 3 and H ACE 5 primer sets used same PCR conditions. 
 
Reagent  [Stock]  Volume added (µl)  [Reaction] 
cDNA Template  50 ng/µl  2  - 
       
PCR Master-mix       
PCR Buffer  10x  4.5  1x 
MgCl2  25 mM  3  1.5 mM 
dNTPs  10 mM  1  0.2 mM 
Primers (F+R)  50 µM  1  1 µM 
Ultrapure water    33.5  - 
     
TAQ Master-mix     
PCR Buffer  10x  0.5  1x 
REDTaq   1 u/µl  0.5  0.01 u/µl 
Ultrapure water    4  - 
     
Total PCR Reaction Volume  50   
 
  Temperature (ºC)  Time 
Denaturation  94  4 minutes 
Hot-start  65   
     
35 Cycles     
Denaturation  94  45 seconds 
Annealing  64  45 seconds 
Elongation  72  60 seconds 
     
Polyadenylation  72  10 minutes 
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Figure 3.10  Gel Electrophoresis of ACE PCR Products 
PCR using H ACE 3 and H ACE 5 primers allowed ACE genotype to be determined. H 
ACE 3 primers produced 2 possible products depending on the presence or not of the 
287 bp insertion. In heterozygotes (ID) the product representing the I-allele was often 
faint or undetectable. Therefore, H ACE 5 primers specific for the insertion sequence 
were used to confirm or refute presence of the I-allele.   137 
to the I/D polymorphism. This SNP involves a G for A substitution at position 2215 
(G2215A) on the cDNA strand, with the 2215G allele directly linked with the 287bp 
insertion, and the 2215A allele with the deletion.
134 The G2215A SNP is „silent‟ and 
does not change the amino acid sequence, but as it is exonic and thus present in the final 
mRNA strand, can be used to distinguish between mRNA originating from each allele. 
In addition to its direct link to the 287bp insertion, the 2215G allele also creates a 
restriction site in the cDNA which is recognised by the restriction enzyme  HAE II. 
Restriction enzymes were first described in bacteria, where they degrade DNA from 
invading viruses and thereby „restrict‟ viral replication. They act by recognising specific 
nucleotide sequences (restriction sites), and cleaving the DNA at that site. Thus, the 
specific properties of the 2215G allele were exploited to measure mRNA transcription 
from each I/D allele. Flanking primers were used to amplify a 242 bp segment of cDNA 
containing  the  G2215A  polymorphism  by  RT-PCR.  The  PCR  products  were  then 
incubated with HAE II, which cleaved all cDNA strands containing the 2215G allele 
into 2 smaller fragments (153 and 89 bp), whilst strands with the 2215A allele were 
unaffected (Figure 3.11). Thus, for II subjects, all the cDNA products were cleaved 
whilst  in  DD  subjects  no  cleavage  occurred.  In  ID  heterozygotes,  the  products 
originating  from  the  I-allele  were  cleaved  but  the  products  from  the  D-allele  were 
unaffected. Gel electrophoresis was used to separate the products by size, and scanning 
densitometry used to quantify the relative amounts of each product from each allele.  
 
3.5.2  Protocols 
RT-PCR Reaction 
RT-PCR  was  performed  on  patient  cDNA  samples  using  REDTaq  and  a  „hot-start‟ 
protocol  as  described  in  Section  3.3.4.  Details  of  the  ACE  primers  (New  England   138 
Biolabs) and exact details of the conditions used following optimisation are shown in 
Table 3.8. Samples from subjects of all ACE I/D genotypes (II,ID,DD) were studied to 
enable the 100% linkage between the I/D and G2215A polymorphism to be confirmed. 
 
Restriction Enzyme Reaction 
The  HAE  II  restriction  enzyme  protocol  used  was  based  on  the  manufacturer‟s 
recommendations (New England Biolabs). HAE II was supplied as a 20,000 unit/ml 
solution, with 1 unit of enzyme able to digest 1 μg of DNA in 1 hour in a reaction 
volume of 50 µl at 37
oC. It was supplied with a buffer (10x NEBuffer 4) containing 50 
mM  potassium acetate,  20 mM  Tris-acetate, 10 mM  magnesium acetate and 1 mM 
dithiothreiotol when diluted to a 1x solution. Bovine serum albumin (BSA) was also 
provided in a 100x solution. Twenty µl of a master-mix solution containing 10 units 
HAE  II,  1x  NEBuffer  4,  1x  BSA  and  ultrapure  water  was  added  to  each  0.5  ml 
eppendorf tube on ice. Thirty µl of PCR product from each sample was then added to 
make the volume up to 50 µl (Figure 3.11). The tubes were vortexed briefly to mix the 
contents,  and  pulse  centrifuged  at  2000  g  to  collect  the  tube  contents  at  the  base. 
Finally, the tubes were placed in a Progene thermal cycler and incubated at 37ºC for 2 
hours, before the reaction was terminated by denaturing the enzyme at 80ºC for 20 
minutes. This protocol enabled a complete digestion of all the products containing the 
restriction  site,  with  control  experiments  using  12  hours  digestion  time  providing 
identical results. 
 
Gel Electrophoresis and Scanning Densitometry 
The products from the original PCR reaction and the restriction enzyme reaction were 
separated by gel electrophoresis and analysed by scanning densitometry, as described in    139 
Table 3.8  ACE 2215 Primer Details and Final PCR Conditions 
 
Primer  Sequence (5’ to 3’)  Tm 
(
oC) 
Product Size 
(bp) 
ACE 2215 (F)  CACACCCTGAAGTACGGCAC  64 
242 
ACE 2215 (R)  GTGGCCATCACATTCGTCAG  62 
 
Reagent  [Stock]  Volume added (µl)  [Reaction] 
cDNA Template  50 ng/µl  4  - 
       
PCR Master-mix       
PCR Buffer  10x  4.5  1x 
MgCl2  25 mM  4  1.5 mM 
dNTPs  10 mM  1  0.2 mM 
Primers (F+R)  50 µM  1  1 µM 
Ultrapure water    30.5  - 
     
TAQ Master-mix     
PCR Buffer  10x  0.5  1x 
REDTaq   1 u/µl  0.5  0.01 u/µl 
Ultrapure water    4  - 
     
Total PCR Reaction Volume  50   
 
  Temperature (ºC)  Time 
Denaturation  94  4 minutes 
Hot-start  65   
     
35 Cycles     
Denaturation  94  30 seconds 
Annealing  60  30 seconds 
Elongation  72  45 seconds 
     
Polyadenylation  72  10 minutes 
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Reagent  Stock 
Concentration 
Volume/reaction 
(µl)  Final Concentration 
HAE II Master-mix       
HAE II Enzyme  20,000 U/ml  0.5  10 U/reaction 
NEBuffer x4  x10  5  x1 
BSA  x100  0.5  x1  
Ultrapure Water  -  14  - 
       
PCR Product  -  30  - 
       
Total Reaction Volume  50   
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Figure 3.11  ACE mRNA Analysis: HAE II Reaction Conditions and Products 
The recognition site of HAE II on exon 15 of the ACE cDNA and the potential products 
of the restriction reaction with each allele are shown.   141 
Section  3.3.6.  The  analysis  of  the  original  242  bp  PCR  product  in  all  the  samples 
enabled  ACE  gene  expression  to  be  quantified.  In  the  results  section,  ACE  gene 
transcription in the claudicant trial was taken as the mean of the results obtained from 
the ACE 216 and ACE 2215 primers combined. Ten  µl of each restriction enzyme 
reaction was loaded onto the agarose gels. In I/D heterozygotes, the IOD of the single 
band from the uncleaved D-allele (2215A) was compared to the sum of the IOD from 
the 2 fragments representing the I-allele (2215G), to give a ratio of D/I allele mRNA. 
An example of a gel photograph with all the potential products is shown in Figure 3.12. 
 
3.6  MEASUREMENT OF PROTEIN LEVELS 
Measurement  of  changes  in  gene  expression  provides  an  indication  of  cellular 
activation. However, the end-result of any change in cellular activity or processes is an 
alteration in protein expression. The level of protein present reflects the entire pathway 
of  gene  activation,  RNA  transcription,  post-transcriptional  modifications,  translation 
into amino acid  chains and finally post-translational modifications. Thus, measuring 
protein levels is a significant consideration when determining changes resulting from 
any intervention.  
 
Two main techniques are used to quantify soluble proteins. Western blotting allows 
target proteins to be identified according to their molecular weight and by the binding of 
specific antibodies.
270 Enzyme-linked immunosorbant assays (ELISAs) also use highly 
specific antibodies to identify target proteins, but do not discriminate proteins by size 
and cannot discriminate between different isoforms. The main advantages of ELISAs 
are the increased sensitivity and simplicity of the assays.
280 Thus, ELISAs were chosen 
to measure ACE and VEGF levels in this thesis.    142 
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Figure 3.12  Photograph  Demonstrating  the  Products  from  an  ACE  2215 
Reaction 
PCR  products  from  the  original  RT-PCR  reaction  were  used  to  determine  ACE 
expression semi-quantitatively. ACE genotype as established by PCR of genomic DNA 
is  shown.  Samples  from  II  subjects  (2215G  homozygotes)  are  completely  digested 
following  the  HAE  II  reaction.  Samples  from  DD  subjects  (2215A  homozygotes) 
demonstrate  no  digestion,  whilst  ID  heterozygotes  demonstrate  partial  digestion, 
allowing the relative expression of I and D-allele derived mRNA to be analysed.  
   143 
3.6.1  ELISA: Overview 
An ELISA is a simple, sensitive and reliable technique for measuring protein levels. A 
sandwich ELISA was used in these experiments. In a sandwich ELISA, an antibody is 
used to „capture‟ the target protein onto a plate well. A second or „detection‟ antibody, 
which  recognises  a  separate  epitope  on  the  protein,  is  then  added.  The  detection 
antibodies are conjugated to an enzyme assay, which allows the protein to be quantified. 
 
Reagents 
DuoSet ELISA development kits (R&D Systems) for detecting human ACE and VEGF 
were obtained, which use a Streptavidin-HRP colorimetric detection system to quantify 
the amount of target protein. These assays work by exploiting the binding properties of 
biotin and streptavidin. The detection antibodies used are linked to biotin molecules. 
When streptavidin-HRP conjugates are subsequently added, the streptavidin component 
binds tightly to the biotin on the detection antibody, and the active HRP component acts 
on a colour substrate, developing its colour. The intensity of colour produced reflects 
the amount of bound streptavidin-HRP, which is determined by the quantity of detection 
antibodies  bound  to  captured  target  protein,  which  in  turn  is  determined  by  the 
concentration  of  target  protein  in  the  original  sample.  In  addition,  each  detection 
antibody is associated with several biotin molecules, allowing a number of streptavidin-
HRP  conjugates  to  bind  to  each  antibody,  amplifying  the  signal  and  increasing  the 
sensitivity of the assay. 
 
The ACE and VEGF kits both utilised the same protocols, with the only differences 
being the antibodies employed and the diluent used for the samples being measured. 
Goat anti-human ACE antibody at a working concentration of 0.8 μg/ml in PBS (Sigma)   144 
and 1.0 μg/ml mouse anti-human VEGF antibody in PBS were used as the „capture‟ 
antibodies. The VEGF antibodies recognized both VEGF165 and VEGF121 isoforms. One 
percent  BSA  dissolved  in  PBS  (Sigma)  was  used  to  dilute  all  the  other  reagents 
(Reagent diluent), to „block‟ the plates, and also used as the sample diluent for VEGF 
samples. Twenty percent FCS (First Link Ltd) diluted in PBS was used as the sample 
diluent  for  ACE  samples.  Biotinylated  goat  anti-human  ACE  and  VEGF  antibodies 
diluted  in  reagent  diluent  to  working  concentrations  of  200  ng/ml  and  50  ng/ml 
respectively, were used as the „detection‟ antibodies. Streptavidin-HRP (1 in 200 in 
reagent diluent) and a colour substrate (a 1:1 mixture of H2O2 and tetramethylbenzidine) 
comprised the detection system. 2N H2SO4 was used to stop the detection assay. 
 
 Recombinant human ACE and VEGF in reagent diluent were used to produce standard 
curves  to  allow  the  quantification  of  protein.  Seven-point  standard  curves  were 
produced using 2-fold serial dilutions of the recombinant protein, with a high standard 
of  8000  pg/ml  used  for  ACE  and  2000  pg/ml  for  VEGF.  Between  stages,  0.05% 
TWEEN
® 20 (Sigma) in PBS was used as a wash buffer. 
 
Protocols 
The  protocols  used  were  based  on  those  recommended  by  the  manufacturer  (R&D 
Systems) and used for both the claudicant and cell culture studies. All experiments were 
performed  at  room  temperature  on  96-well  microplates  (Nunc™  Products)  with  the 
samples and standards prepared in duplicate wells.  
 
One hundred µl of diluted capture antibody was used to coat the plate wells. The plate 
was sealed and incubated overnight in a fridge to allow the antibodies to attach to the   145 
well surface. The wells were then aspirated, and washed 3 times with wash buffer using 
a squirt bottle to completely fill the wells, with attention taken to completely remove the 
wash buffer after each wash by blotting the plate against clean paper towels.  Three 
hundred µl of 1% BSA in PBS was then added to „block‟ the plate, by coating the 
surfaces  of  the  well  not  already  covered  in  capture  antibody  with  protein.  This 
minimised  subsequent  non-specific  substrate  binding.  After  1  hour  the  wells  were 
aspirated  and  washed  3  times  as  described  above.  One  hundred  µl  of  sample  or 
standards in diluent (see Sections 3.6.2 and 3.6.3 for details) were added to the wells. 
After  incubating  for  1¾  hours,  the  wells  were  again  aspirated,  washed  3  times  to 
remove unbound protein and 100 µl of diluted detection antibody added. The plates 
were incubated for another 1¾ hours. Following 3 washes to remove unbound detection 
antibodies,  the  streptavidin-HRP  conjugate  was  added  and  allowed  to  bind  to  the 
remaining detection antibodies. The plate was left in a dark room for 15 minutes to 
prevent HRP activation, and then washed 3 times to remove unbound streptavidin-HRP. 
One hundred µl of colour substrate (clear) was then added to the wells and left for 15 
minutes. This substrate was catalysed by HRP into a blue solution, with the intensity of 
the solution relating to the amount of bound streptavidin-HRP present. Fifty µl of stop 
solution was added after 15 minutes, which turned the substrate yellow and halted the 
HRP reaction. The colour in each well was immediately assessed using a plate-reader 
(Dynex Technologies Ltd) set to measure optical density at 450 nm (the wavelength of 
the colour produced). A correction wavelength of 540 nm was used to adjust for non-
specific absorbance caused by the plate and reagents. The absorption values obtained 
from  the  samples  were  then  compared  to  the  standard  curves  obtained  from  the 
standards  of  known  concentration  to  calculate  the  amount  of  protein  present.  A 
summary of the protocol can be seen in Figure 3.13.   146 
 
 
 
Base of Well
STEP 2
Blocking Protein
STEP 4
Detection 
Antibody
STEP 5
Streptavidin-HRP
STEP 3
Target Protein
STEP 6
Colourless 
Substrate
Colour Product
STEP 7
Stop Solution
STEP 8
Final Colour Product 
Detected
Biotin
STEP 1
Capture Antibody
 
 
 
Figure 3.13  Schematic Diagram of an ELISA Reaction 
The  steps  involved  in  the  sandwich  ELISA  are  illustrated.  A  thorough  wash  was 
performed after steps 1-5 to remove excess unbound proteins or antibodies. With all 
assay conditions being equal, the final colour intensity was determined by the amount of 
target protein bound by the capture antibody, and hence by the concentration of target 
protein in the samples.    147 
3.6.2  Clinical Trial Subjects 
ACE  and  VEGF  levels  were  measured  in  plasma  obtained  from  whole  blood  as 
described in Section 3.1.4. Although it would have been preferable to have measured 
local  (muscle)  changes  in  protein  levels,  this  would  not  have  been  practical  or 
acceptable for the patients. Thus, plasma was used and should give an indication of 
changes occurring locally in the tissues. 
 
Optimisation and Final Protocols 
The final ELISA protocols were established after the period of optimisation to provide 
an  assay  that  was  sensitive  within  the  range  of  plasma  concentrations  encountered. 
Separate optimisation was required for the ACE and VEGF assays, with each assay 
requiring a different sample diluent and dilution factor for the patient samples. 
 
For the ACE ELISA, the plasma samples were initially diluted 1 in 2 with 1% BSA. 
However, the absorbance readings obtained were all above the upper end of the standard 
curve, and thus unusable. Increasing the dilution factor successively to 1 in 10, 1 in 20, 
and 1 in 40 still resulted in absorbance values above the upper level of the standard 
curve. The sample diluent was therefore changed to FCS in PBS to provide a greater 
degree of block and decrease non-specific substrate binding. Finally, a sample diluent of 
20%  FCS  with  a  1  in  40  dilution  factor  was  utilised.  These  conditions  produced 
absorbance values for the samples consistently within the linear section of the standard 
curve. For the VEGF ELISA, the initial 1 in 2 sample dilution in 1% BSA provided 
absorbance  readings  in  the  lower  part  of  the  standard  curve.  Decreasing  the 
concentration of BSA to 0.1% produced readings consistently within the linear section 
of the standard curve.   148 
3.6.3  Cell Culture Experiments 
In the cell culture experiments, each experimental well was processed to obtain both 
protein  and  RNA  as  described  in  Section  3.2.5.  This  method  allowed  a  direct 
comparison between RNA expression and protein levels in the same population of cells 
to be made. Although the original intention was to measure cellular ACE and VEGF 
levels using Western blotting, the protein yields after extraction from TRI reagent
TM 
were  too  low  to  permit  this.  The  total  protein  yields  obtained  ranged  from 
approximately 10-20 μg. Thus, as there was insufficient protein to perform Western 
blots, the more sensitive ELISA technique was employed. 
 
Protein Extraction from TRI reagent
TM 
During the processing of cells lysed in TRI reagent
TM for the extraction of nucleic acids, 
the protein containing organic phase was separated and frozen as described in Section 
3.3.1. The following protocol based on manufacturer‟s guidelines (Sigma) was used to 
extract  and  solubilise  the  protein  for  later  measurement.  After  thawing,  1.5  ml  of 
isopropanol for each 1 ml of original TRI reagent
TM was added to each tube. The tubes 
were  inverted  several  times,  and  incubated  for  10  minutes  at  room  temperature  to 
precipitate the dissolved proteins. After centrifuging for 4 minutes at 400 g to pellet the 
protein, the supernatant was discarded and the pellet washed in 1.5 ml 0.3 M guanidine 
hydrochloride in 95% ethanol per original 1 ml of TRI reagent
TM for 20 minutes. The 
tubes were then centrifuged for 4 minutes at 400 g, the supernatant discarded and the 
guanidine hydrochloride wash repeated twice for total of 3 washes. Following this, 1.5 
ml 100% ethanol was added to each tube, the pellet vortexed and incubated at room 
temperature for 20 minutes. The pellet was then centrifuged for 4 minutes at 400 g and 
the ethanol supernatant  discarded. Excess  ethanol  was  then removed by  placing the   149 
tubes in an oven at low temperature for 2 hours. The dried pellets were then crushed 
into a powder with a clean spatula, and 100 µl 1% sodium dodecyl sulphate (SDS) 
added to dissolve the pellet. To aid pellet dissolution, the tubes were incubated in a 
water bath at 50
oC for up to an hour, with repeat pipetting and vortexing used every 15 
minutes.  Insoluble  protein  was  then  removed  by  centrifuging  at  10,000  g  for  10 
minutes, the supernatant removed and stored at -20
oC. 
 
Total Protein Measurement  
Although each experimental well originally contained the same number of cells and the 
same extraction protocol used for each sample, the protein yield obtained from each 
well  was  slightly  different.  Measuring  the  total  protein  yield  allowed  the  results  of 
subsequent ELISAs to be corrected for these varying yields. Total protein obtained from 
each sample was thus measured using a Bradford assay.
26 This is a simple, sensitive 
assay which utilises the colour change or absorbance shift in Coomassie Brilliant Blue 
G-250 (CBB) dye when it binds to protein to determine the concentration of protein 
present in a sample. When unbound, the dye absorbs light at a peak of 465 nm, whereas 
the protein bound form has an absorbance maximum at 595 nm. 
 
Bio-Rad protein assay dye reagent (Bio-Rad Laboratories) was obtained. A working 
solution of CBB reagent was prepared immediately prior to use by diluting the dye 1 in 
4 with water. The protein samples stored in 1% SDS were diluted to 0.1% SDS using 
ultrapure water. This step was necessary to prevent the SDS from interfering with the 
assay. Ten µl of each protein sample then was added in duplicate to the wells of a 96-
well plate (Nunc™ Products). A series of protein standards were prepared using BSA 
containing between 0 and 10 mg/ml. Ten µl of each of these standards was each added   150 
to 1 ml of CBB and mixed thoroughly. Two hundred µl from each standard was then 
added in duplicate to the plate. Two hundred μl of CBB reagent was added into each 
sample  well.  The  plate  was  transferred  immediately  to  a  plate  reader  (Dynex 
Technologies Ltd), shaken for 10 seconds and absorbance measured at 595 nm. The 
results from the sample wells were then compared to the standard curve generated by 
the standards, allowing protein concentration to be calculated. From the results of these 
assays, the mean protein yield for each experimental series was calculated, and the yield 
from  each  well  expressed  as  a  ratio  of  the  mean  yield.  This  ratio  was  used  as  a 
corrective  factor  for  subsequent  ELISA  results,  with  the  measured  protein  level 
corrected by dividing the value obtained by the correction factor from the associated 
well. 
 
ELISA Optimisation and Final Protocols 
For the VEGF ELISAs, the protein samples in 0.1% SDS were diluted 1 in 5 with 0.1% 
BSA in PBS as the sample diluent, and 100 µl added to each well. This maintained the 
SDS concentration at 0.02%, a level previously shown not to interfere with ELISAs.
147 
A 2000 pg/ml top standard was used and a 7-point standard curve produced using serial 
2-fold  dilutions.  The  remainder  of  the  ELISA  protocol  was  followed  as  described 
above. The VEGF levels measured were corrected according to the total protein yields 
attained by the Bradford assay, by dividing the measured VEGF level by the ratio of 
protein yield. For ACE ELISAs, the protein samples were again diluted 1 in 5 with 
various  sample  diluents  to  achieve  a  final  SDS  concentration  of  0.02%.  However, 
despite varying the protocols and using different sample diluents including BSA and 
FCS, it was not possible to produce a consistently measurable result with ACE, as the 
levels present were too low to detect.   151 
3.7  STATISTICAL ANALYSIS 
Graphpad Prism 4 was used for statistical analyses and nQuery Advisor 4.0 for power 
and sample size calculations. Non-parametric data are presented as the median with 
range in parentheses, while parametric data is presented as the mean ± standard error of 
the mean (SEM). Two-tailed tests were performed throughout, and p-values of ≤ 0.05 
regarded to indicate statistical significance. 
 
Clinical Trial Data Analysis  
Due to the small numbers involved, the data were analysed using non-parametric tests 
as a normal distribution could not be assumed, and tests of normality were of little use 
with such small sample sizes. All analyses comparing the control and exercise groups 
were performed using the Mann Whitney U-test. Comparisons between pre- and post-
measurements within each group were made using the Wilcoxon matched pairs test. 
Spearman‟s rank correlation test was used for all tests analysing relationships between 
gene expression and protein levels, and between changes in ACE and VEGF. For these 
comparisons,  the  data  from  the  control  and  exercise  groups  were  combined.  Power 
analyses were performed using 1- and 2-sample t-tests. 
 
Cell Culture Data Analysis 
Comparisons between Medium and Vehicle control groups were made using unpaired t-
tests.  Multiple  group  comparisons  were  all  made  by  one-way  analysis  of  variance 
(ANOVA).  Dunnett‟s  multiple  comparison  test  was  performed  to  assess  differences 
within  each  treatment  group  compared  to  the  experimental  control.  Bonferroni's 
Multiple  Comparison  test  was  used  to  identify  differences  between  the  3  treatment 
groups. Power analyses were performed using a 2-sample t-test.   152 
CHAPTER 4 
ACE AND VEGF RESPONSES TO EXERCISE 
TRAINING IN CLAUDICANTS 
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CHAPTER 4 
4.1  BACKGROUND 
Exercise training is well known to improve the symptoms of intermittent claudication, 
although  the  precise  mechanism  by  which  this  occurs  is  relatively  less  well 
recognized.
244;255 Several studies have revealed a role for ACE in exercise performance, 
with low ACE activity related to increased endurance after training in elite athletes and 
army recruits.
170;288 Previous work in this laboratory has demonstrated that the I-allele 
of the ACE I/D polymorphism, which is associated with decreased ACE activity, is 
related to increased improvements in walking ability in claudicants after an exercise 
training programme. Furthermore, in other studies reduction in ACE activity has also 
been  linked  with  increased  VEGF-related  angiogenesis,  with  suppression  of  ACE 
activity resulting in increased VEGF production.
85;233 This relationship between ACE 
and VEGF provides a further potential benefit of reduced ACE activity.  
 
The effects of an exercise training programme in claudicants on VEGF and ACE has not 
yet been reported. A greater understanding of how ACE and VEGF interact and react to 
an  exercise  training  programme,  and  how  these  changes  relate  to  improvements  in 
walking ability will allow potential treatments that modulate ACE and VEGF, such as 
ACE inhibition, to be targeted effectively. 
 
4.2  AIMS 
The aim of this study was to assess the effects of an exercise training programme on 
ACE mRNA and protein expression, VEGF isoform/VEGFR mRNA expression and 
VEGF protein  levels,  and to  examine these changes  in  relation to  improvements  in 
walking  ability.  The  link  between  changes  in  ACE  and  VEGF  expression  was  also   154 
examined, as  well as  differential  allele  expression  and allelic  responses in  ACE  ID 
heterozygotes. 
 
4.3  METHODS 
Patients  were  recruited  to  the  trial  and  managed  as  described  in  Section  3.1. 
Determination  of  ACE,  VEGF121,  VEGF165,  VEGFR-1,  sVEGFR-1  and  VEGFR-2 
mRNA expression was performed as described in detail in Section 3.3. ACE genotype 
was recorded as illustrated in Section 3.4, and differential transcription of ACE I/D 
alleles measured as stated in Section 3.5. ACE and VEGF protein levels were measured 
as described in Section 3.6. All experiments were run twice and a mean value taken 
apart from  experiments  measuring  VEGF  receptor expression, which were  only  run 
once using Jumpstart REDTaq. Overall ACE gene expression was expressed as a mean 
of the results obtained from the ACE 216 and ACE 2215 primers combined. All ELISA 
experiments were run twice in duplicate. 
  
4.4  RESULTS 
Eleven patients consented to take part in the trial, with 6 subjects (5 female, 1 male) 
randomised to the supervised exercise group and 5 subjects (2 female, 3 male) to the 
exercise advice only group. All subjects were Caucasian apart from 1 control of Asian 
origin. Demographic data and medications for each subject are summarised in Appendix 
3. All demographic variables and baseline measurements were independent of treatment 
group at the start of the trial (Table 4.1). In the exercise group, 1 subject was ACE II 
genotype, 3 were ID and 2 were DD genotype. In the control group, 3 subjects were ID 
and 2 were II genotype. All subjects completed all aspects of the trial successfully, with 
no deaths or adverse effects reported from the exercise training programme.   155 
Table 4.1  Baseline Data and Demographics 
All  measurements  were independent  of treatment  group at  initial  assessment  (Mann 
Whitney test). Values shown are medians (range).   
 
   Group    
   Exercise  Control  p-value 
Number  6  5    
       
Age (years)  77 (56-82)  65 (54-80)  0.33 
Height (cm)  165 (162-169)  167 (155-173)  >0.50 
Weight (kg)  61.8 (55.5-84.4)  72.3 (51.2-76.0)  0.43 
BMI (kg/m
2)  22.3 (21.2-30.6)  24.49 (21.3-31.0)  0.25 
Mean Arterial Pressure (mmHg)  107.5 (96.7-108.3)  101.7 (91.7-111.7)  0.33 
Resting Heart Rate (bpm)  76 (60-80)  72 (60-84)  >0.50 
       
ABPI  0.82 (0.68-0.92)  0.72 (0.71-1.30)  >0.50 
CD (m)  300 (175-482)  124 (74-482)  0.25 
MWD (m)  490 (353-718)  366 (134-859)  >0.50 
Heel Raises  55 (25-208)  85 (25-139)  >0.50 
       
ACE Genotype  1 II;3 ID;2 DD  2 II; 3 ID  - 
ACE mRNA Expression  0.56 (0.35-0.93)  0.54 (0.39-0.99)  >0.50 
VEGF121 mRNA Expression  0.36 (0.23-0.68)  0.47 (0.40-0.66)  0.25 
VEGF165 mRNA Expression  0.14 (0.05-0.48)  0.21 (0.11-0.43)  >0.50 
VEGFR-1 mRNA Expression  0.36 (0.19-0.46)  0.35 (0.22-0.45)  >0.50 
sVEGFR-1 mRNA Expression  0.15 (0.09-0.24)  0.15 (0.09-0.23)  >0.50 
VEGFR-2 mRNA Expression  0.11 (0.02-0.25)  0.15 (0.13-0.19)  0.33 
       
ACE Protein Levels  187 (87-229)  186 (107-266)  >0.50 
VEGF Protein Levels  16.9 (7.2-82.3)  25.8 (3.1-49.0)  >0.50 
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4.4.1  Physiological Responses to Exercise Training 
General Responses 
After the 8 week training period, no changes were noted in weight, resting heart rate, 
mean arterial pressure and ABPI in either the exercise or the control groups (Table 4.2). 
 
Walking Ability 
In the control group, there was no improvement in CD (pre 124 (74-482) metres, post 
158 (88-418) metres; p = 0.44) or MWD (pre 366 (134-859) metres, post 361 (135-835) 
metres; p = 0.625). However, in the exercise group CD improved significantly from an 
initial  300 (175-482) metres  to  406  (221-705)  metres  after training  (p <  0.05),  and 
MWD improved from 490 (353-718) metres to 634 (460-864) metres after training (p < 
0.05). When comparing the two groups, the increase in MWD in the exercise group was 
significant (p < 0.01) compared to the control group, but no difference (p = 0.25) was 
found between the groups for the change in CD (Figures 4.1 and 4.2). Maximum heart 
rate  and  perceived  exertion  and  pain  scores  at  MWD  were  also  unchanged  in  both 
groups (Table 4.2). 
 
Heel Raises 
In the control group, there was no change in heel raises (p = 0.06; pre 85 (25-139), post 
54 (18-129)) after 8 weeks. In the exercise group, heel raises increased in 5 of the 6 
subjects, although the increase was not significant (p = 0.06; pre 55 (25-208), post 136 
(42-360); Figure 4.3a). However, the change in heel raises in the exercise group was 
significant compared to the control group (P < 0.005; Figure 4.3b). Perceived exertion 
and pain scores at the end of the heel raise test were also unchanged in both groups 
(Table 4.2).   157 
Table 4.2  Changes in General Measurements after 8 weeks. 
No significant changes were noted in general measurements after 8 weeks (Wilcoxon 
signed rank test). Values shown are medians (range). 
 
   Control Group    
   Pre  Post  p-value 
Weight (kg)  72.3 (51.2-76.0)  72.6 (52.5-75.2)  >0.50 
Resting Heart Rate (bpm)  72 (60-84)  76 (68-92)  0.25 
Mean Arterial Pressure (mmHg)   101.7 (91.7-111.7)  100.0 (85.0-113.3)  >0.50 
ABPI  0.72 (0.71-1.30)  0.79 (0.67-1.33)  >0.50 
       
Heart Rate at MWD (bpm)  100 (76-126)  100 (76-116)  >0.50 
Perceived Pain (RPP) at MWD   4 (3-6)  5 (3-7)  0.50 
Perceived Exertion (RPE) at MWD   15 (13-17)  13 (11-17)  0.50 
RPP at maximum heel raises  5 (4-5)  5 (3-5)  >0.50 
RPE at maximum heel raises  14 (11-17)  15 (11-17)  >0.50 
       
       
       
   Exercise Group    
   Pre  Post  p-value 
Weight (kg)  61.8 (55.5-84.4)  60.0 (54.6-85.2)  0.13 
Resting Heart Rate (bpm)  76 (60-80)  76 (64-84)  0.16 
Mean Arterial Pressure (mmHg)   107.5 (96.7-108.3)  105 (91.7-113.3)  >0.50 
ABPI  0.82 (0.68-0.92)  0.77 (0.64-0.93)  >0.50 
       
Heart Rate at MWD (bpm)  92 (68-114)  90 (80-104)  >0.50 
Perceived Pain at MWD (RPP)  4.5 (3-6)  5 (3-7)  >0.50 
Perceived Exertion at MWD (RPE)  15 (13-15)  15 (13-15)  >0.50 
RPP at maximum heel raises  4.5 (3-7)  5 (3-7)  >0.50 
RPE at maximum heel raises  13 (11-17)  14 (13-15)  >0.50 
            158 
P = 0.44 P < 0.05
P = 0.25
Control Exercise A
B
Control Exercise
-150
-100
-50
0
50
100
150
200
250
C
h
a
n
g
e
 
i
n
 
C
l
a
u
d
i
c
a
t
i
o
n
 
D
i
s
t
a
n
c
e
 
(
M
)
Pre Post
0
200
400
600
800
C
l
a
u
d
i
c
a
t
i
o
n
 
D
i
s
t
a
n
c
e
 
(
M
)
Pre Post
 
Figure 4.1  Changes in CD after Exercise Training 
A  Pre  and  post  CD  in  the  control  and  exercise  groups.  CD  in  the  exercise  group 
increased significantly, but no change was found in the controls (Wilcoxon signed rank 
test). B The exercise group increased CD by 105 (10-223) metres after training, but this 
increase was not significant compared to the controls (Mann Whitney test). 
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Figure 4.2  Changes in MWD after Exercise Training 
A Pre and post MWD in the control and exercise groups. MWD in the exercise group 
increased significantly, but no change was found in the controls (Wilcoxon signed rank 
test). B The  exercise  group increased MWD by 141 (28-426) metres  after training, 
which was a significant increase compared to the control group (Mann Whitney test).   160 
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Figure 4.3  Changes in Heel Raises after Exercise Training 
A No significant changes in heel raises were noted (Wilcoxon signed rank test) although 
in the exercise group 5 of the 6 subjects recorded an increase in heel raises. B Post 
training, repetitive heel raises in the control group decreased by 9 (-44 to -6) while the 
exercise group increased by 36 (0-196). The change in number of repetitive heel raises 
between the 2 groups was significant (Mann Whitney test).   161 
A correlation between the change in number of repetitive heel raises and change in 
MWD was noted (R = 0.81, p < 0.005; Figure 4.4). 
 
4.4.2  Molecular Responses to Exercise Training 
ACE Responses to Exercise Training 
ACE gene expression was unchanged in the control group, but increased 30% (7-57%) 
in the exercise group after 8 weeks training (p < 0.05). The difference between the two 
groups was not significant (Figure 4.5). However, the increases in ACE gene expression 
in the exercise group were not reflected by increases in plasma ACE levels, which were 
unchanged in both groups (Figure 4.6). Interestingly, changes in ACE gene expression 
appeared to be genotype influenced, with DD subjects having a median increase of 
50%, ID subjects 19% and II subjects 16%. In comparing ACE gene expression with 
ACE protein level, there was no correlation between baseline ACE gene expression and 
ACE protein levels (R = -0.536; p < 0.10), and no correlation was found between the 
percentage change in gene expression and protein levels (R = 0.21; p>0.50). 
 
Analysis of the ACE 2215 G/A polymorphism revealed that all patients genotyped (by 
standard PCR of genomic DNA) as DD expressed only the 2215A allele. Likewise, all 
subjects  genotyped as  II  expressed only the 2215G allele, and all  ID  heterozygotes 
expressed  both  the  2215A  and  2215G  alleles.  Thus,  the  direct  linkage  between  the 
2215A and the ACE D-alleles, and between the 2215G and ACE I-alleles, as shown 
previously by Suehiro et al was confirmed.
246 When examining I/D (G/A) heterozygote 
subjects  at  initial  assessment,  in  all  bar  one  subject  expression  of  the  D-allele  was 
greater than the I-allele (Figure 4.7a). Furthermore, in the 3 subjects from the exercise 
group, the D:I allele ratio increased further after the training period, in conjunction with  162 
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Figure 4.4  Correlation Between Changes in Heel Raises and MWD 
The  changes  in  the  number  of  heel  raises  correlated  to  the  changes  in  MWD 
(Spearman‟s correlation test). 
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Figure 4.5  Changes in ACE Expression after Exercise Training 
A Pre and post ACE expression in the control and exercise groups.  In the exercise 
group, ACE expression increased significantly but no change was found in the controls 
(Wilcoxon signed rank test). B In the exercise group, ACE expression increased by 30% 
(7-57%) following the training period, but this increase was not significant compared to 
the controls (Mann Whitney test).   164 
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Figure 4.6  Changes in Plasma ACE Levels after Exercise Training 
A Pre and post ACE levels in the control and exercise groups. No significant change 
was noted in plasma ACE levels for the exercise group or the control group (Wilcoxon 
signed rank test).  B No significant difference was noted between the groups (Mann 
Whitney test). 
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Figure 4.7  ACE D:I Allele Ratio and ACE Expression 
A Among the ID heterozygotes, all bar one subject had a D:I ratio greater than 1 at 
initial assessment. All 3 subjects in the exercise group increased D:I ratio after 8 weeks 
training. B A significant correlation between ACE expression and D:I ratio was noted 
(Spearman‟s correlation test).   166 
an overall increase in ACE gene expression, indicating preferential activation of the D 
allele in these subjects. In the control group, 2 out of 3 subjects decreased the D:I ratio 
after 8 weeks, with 1 subject showing a slight increase (Figure 4.7a). 
 
When examining the link between ACE expression and D:I allele ratio, the results from 
both groups and assessments were combined. Analysis showed a significant correlation 
between ACE expression and the D:I ratio (R = 0.58; p < 0.05, Figure 4.7b). However, 
the correlation between ACE protein level and D:I ratio was not statistically significant 
(R = -0.50; p < 0.10). 
 
VEGF Responses to Exercise Training 
In the exercise group, VEGF121 expression increased by 43% (6-158%, p < 0.05) whilst 
no  change  was  found  in  the  control  group  (Figure  4.8a).  The  increase  in  VEGF121 
expression in the exercise group was significant compared to the controls (Figure 4.8b). 
Similarly, VEGF165 expression also significantly increased by 70% (3-255%; p < 0.05) 
in  the exercise group compared to  the controls,  which did  not  change (Figure 4.9). 
Although VEGF protein levels increased in 5 of the 6 subjects in the exercise group, no 
significant change was found (94% (-7-359%); p < 0.10), and no change detected in the 
control group (Figure 4.10). 
 
No  correlation  was  noted  between  initial  VEGF121  expression  and  baseline  VEGF 
protein levels (R = 0.16; p > 0.50), or between initial VEGF165 expression and VEGF 
levels  (R  =  -0.08;  p  >  0.50).  In  addition,  there  was  no  correlation  between  the 
percentage change in VEGF121 expression (R = 0.16; p > 0.50) or VEGF165 expression 
(R = 0.06; p > 0.50) compared to the percentage change in VEGF protein levels.   167 
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Figure 4.8  Changes in VEGF121 Expression after Exercise Training 
A  Pre  and  post  VEGF121  expression  in  the  control  and  exercise  groups.  VEGF121 
expression increased significantly in the exercise group, with no change in the controls 
(Wilcoxon signed rank test). B VEGF121 expression increased by 43% (6-158%) in the 
exercise group, which was a significant increase compared to the control group (Mann 
Whitney test).   168 
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Figure 4.9  Changes in VEGF165 Expression after Exercise Training 
A  Pre  and  post  VEGF165  expression  in  the  control  and  exercise  groups.  VEGF165 
expression  increased  significantly  in  the  exercise  group,  but  not  in  the  controls 
(Wilcoxon signed rank test). B In the exercise group, VEGF165 expression increased by 
70% (3-255%), which was significant compared to the controls (Mann Whitney test).   169 
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Figure 4.10  Changes in Plasma VEGF Levels after Exercise Training 
A Pre and post VEGF levels in the control and exercise groups. VEGF levels in the 
control group were unchanged, while VEGF increased in 5 of 6 of the exercise group 
although this was not significant (Wilcoxon signed rank test). B An increase of 94% (-
7-359%) in VEGF levels in the exercise group was found, but this was not significant 
when compared to the controls (Mann Whitney test).   170 
VEGF Receptor Responses to Exercise Training 
No  significant  increase  in  VEGFR-1  receptor  expression  was  noted  in  the  exercise 
group,  the  control  group  or  between  the  2  groups  (Figure  4.11).  For  sVEGFR-1 
receptors, expression increased by 63% (2-149%) in the exercise group (P < 0.05), but 
was unchanged in the control group (Figure 4.12a). However, the increase in expression 
in  the  exercise  group  was  not  significant  compared  to  the  controls  (Figure  4.12b). 
Finally, for VEGFR-2 the exercise group again showed a significant (p < 0.05) increase 
in gene expression, with a rise of 72% (22-633%). No change was noted in the controls. 
The increase in VEGFR-2 expression in the exercise group was significant compared to 
the control group (Figure 4.13). 
 
Relationship between ACE and VEGF 
A correlation was found between baseline ACE gene expression and both VEGF121 
expression (R = 0.65, p < 0.05) and VEGF165 expression (R = 0.64, P < 0.05; Figure 
4.14).  However,  no  correlation  was  noted  between  percentage  change  in  ACE  and 
VEGF121 (R = -0.136, p>0.50) or VEGF165 (R = -0.06, p>0.50) expression. For protein 
levels,  there  was  no  correlation  between  initial  ACE  and  VEGF  levels  (R  =  -0.09, 
p>0.50), or in percentage change in ACE and VEGF levels (R = -0.33, p = 0.31). 
 
4.4.3  Correlation between Physiological and Molecular Responses 
No relationship was found between any physiological measurements (CD, MWD, heel 
raises) and initial or changes in ACE, VEGF, or VEGF receptor gene expression and 
protein  levels.  None  of  the  measured  physiological  parameters  appeared  to  be 
influenced by ACE genotype, original ACE concentration or changes in ACE mRNA or 
protein levels.   171 
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Figure 4.11  Changes in VEGFR-1 Expression after Exercise Training 
A Pre and post VEGFR-1 expression in the control and exercise groups. No change in 
VEGFR-1 expression was found in the exercise or control groups (Wilcoxon signed 
rank test). B An increase of 28% (-6-122%) in VEGFR-1 receptor expression was found 
in  the  exercise  group,  but  this  was  not  significant  compared  to  the  controls  (Mann 
Whitney test).   172 
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Figure 4.12  Changes in sVEGFR-1 Expression after Exercise Training 
A Pre and post sVEGFR-1 expression in the control and exercise groups. In the exercise 
group,  sVEGFR-1  expression  increased  significantly  while  the  control  group  was 
unchanged (Wilcoxon signed rank test). B sVEGFR-1 expression increased by 63% (2-
149%)  in  the  exercise  group,  but  this  was  not  significant  compared  to  the  controls 
(Mann Whitney test).   173 
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Figure 4.13  Changes in VEGFR-2 Expression after Exercise Training 
A Pre and post VEGFR-2 expression in the control and exercise groups.  VEGFR-2 
expression increased significantly in the exercise group but not in the control group 
(Wilcoxon signed rank test). B VEGFR-2 expression increased by 72% (22-633%) in 
the  exercise  group,  which  was  significant  when  compared  to  the  controls  (Mann 
Whitney test).   174 
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Figure 4.14  Correlation Between ACE and VEGF Gene Expression  
A correlation was found between ACE gene expression with A VEGF121 expression and 
B VEGF165 expression (Spearman‟s correlation test). 
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4.5  DISCUSSION 
Evidence from gene-association studies and gene-environment interaction studies have 
demonstrated  that  low  ACE  activity  (related  to  the  I-allele  of  the  ACE  I/D 
polymorphism)  is  linked  to  improved  endurance  performance  in  athletes  and  army 
recruits.
123;170;173 Patients with intermittent claudication represent a unique group quite 
different from elite athletes and army recruits. Nevertheless, a pilot study performed in 
this laboratory also suggested that the I-allele was beneficial to training responses in 
claudicants. To date, studies examining the effects of ACE on endurance performance 
have only investigated the link between ACE genotype and endurance. Of potentially 
more relevance is the association between ACE phenotype (gene expression and protein 
activity) and endurance, as a  connection between ACE gene activity and endurance 
would provide stronger evidence of a link. Moreover, ACE phenotype can be readily 
altered using ACE inhibitors.  However, before considering the potential benefits from 
modulating ACE, it is important to assess how exercise training alone affects ACE gene 
activity.  Thus,  in  this  study  the  association  between  changes  in  walking  ability  in 
claudicants after training and responses in ACE gene activity were studied. 
 
A further possible benefit from reduced ACE activity in claudicants is an increase in 
angiogenesis.  Animal  models  of  ischaemia  have  revealed  an  increase  in  VEGF-
mediated angiogenesis with the use of ACE inhibitors.
77;85;233 Indeed, the regulation of 
ACE and VEGF appears to be linked, with variations in ACE affecting VEGF and vice-
versa.
141;219;233 Thus, this study also examined the links between the effects of exercise 
training and changes in VEGF, and the links between changes in VEGF and ACE. To 
appropriately study the effects of the training programme on VEGF, it was necessary to 
examine  changes  in  both  VEGF  isoform  and  receptor  expression,  as  these  all  have   176 
contrasting roles in VEGF biology.
39;46;90 Thus, this study examined the relationship 
between  changes  in  walking  ability  with  changes  in  ACE  and  VEGF.  It  was 
hypothesised that exercise training would lead to increased walking ability, with an 
associated suppression of ACE gene expression and protein levels (already elevated by 
ischaemia), and that there would also be an associated increase in VEGF/VEGFR gene 
expression and protein levels.  
 
Patient Recruitment 
Prior to discussing the results, it is important to consider that the study sample sizes 
were small, with only 6 subjects in the „exercise‟ group and 5 subjects in the „control‟ 
group.  Thus,  statistical  analysis  of  the  results  often  gave  non-significant  results. 
Unfortunately,  poor  recruitment  to  exercise  programmes  and  clinical  trials  among 
claudicants  is  not  uncommon  and  has  been  well  documented  in  the  past.
69;119  Our 
experience in this trial was that many patients had contraindications to entry, such as 
severe heart disease, respiratory disease, and osteoarthritis. Furthermore, a significant 
proportion of potential recruits were already prescribed ACE inhibitors and were thus 
unsuitable  for  the  trial.  Many  were  also  reluctant  to  participate  due  to  having  long 
distances to travel, or were unwilling to commit the necessary time to training sessions. 
As a result, it is questionable as to whether the findings from this trial can be extended 
to cover the claudicant population as a whole. The recruited subjects are likely to reflect 
a select group of well motivated claudicants with limited co-morbidities, a group that 
probably represents a minority of the general claudicant population. 
 
There was also marked heterogeneity between the exercise and control groups (Table 
4.1). Most of the exercise group (5 of 6) were female, whereas the control group was   177 
predominantly male (3 of 5). The exercise group also tended to be older (median ages: 
subjects  77,  controls  65),  and  lighter  (median  BMIs:  subjects  22.3,  controls  24.5). 
Furthermore, CD and MWD were respectively 142% and 33% greater in the exercise 
group at baseline. However, although the subjects were lighter, they performed fewer 
heel raises  (median heel raises: subjects 55, controls 85)  at baseline. VEGF protein 
levels at baseline were also notably different between the groups (median VEGF level: 
subjects 17, controls 26). This heterogeneity between the groups could have affected the 
responses in the trial, making comparisons between the groups potentially unreliable. 
 
Trial Limitations 
When considering the results, other limitations of the study must also be addressed. The 
results from this trial among claudicants cannot be extended to relate to other groups of 
individuals  such  as  athletes.  One  must  also  take  into  consideration  the  varied 
medications  the participants  were prescribed, such as  Aspirin (all participants  bar 1 
control), Beta-blockers (1 control, 1 subject) and Statins (4 controls, 3 subjects). Aspirin 
and statins would have had potential anti-inflammatory effects that could have affected 
the responses to training. Likewise, Beta-blockers would have affected the responses to 
exercise by limiting cardiovascular responses, and also had effects on renin release and 
glucose metabolism. However, to design a trial to control for the potential effects of all 
these medications would not have been feasible. 
 
Another major limitation of this study was that ACE/VEGF mRNA expression were 
determined from PBMNs isolated from peripheral blood and ACE/VEGF protein levels 
measured  from  plasma.  Although  baseline  expression  and  changes  in  expression 
measured in this study may reflect changes occurring locally in the leg muscles, there is   178 
no rationale for this and in this study can only be presumed. It is entirely possible that 
direct measurement of gene activity and protein levels from muscle tissue could have 
produced  different  results,  and  experience  from  previous  studies  has  often  shown  a 
differential effect of a stimulus on ACE depending upon the tissue involved.
77 However, 
in designing this study it was decided that taking muscle biopsies from subjects would 
have been too invasive and thus unacceptable.  
 
Physiological Responses to Exercise Training 
This  study  confirmed  the  already  well  described  finding  that  supervised  exercise 
training improves walking ability among claudicants. In the training group, significant 
increases  in  CD  (105  metres)  and  MWD  (141  metres)  were  recorded  without  any 
significant  change  in  perceived  pain  or  exertion  scores,  demonstrating  decreased 
symptoms  rather  than  an  increased  ability  to  walk  through  pain.  These  results  are 
comparable to other studies of supervised exercise programmes, and add to the weight 
of  evidence  supporting  the  widespread  introduction  of  these  programmes.
18;99;243  In 
addition,  this  trial  also  suggests  that  8  weeks  of  training  is  sufficient  to  produce 
significant increases in walking distance, in contrast to the 6 month period that has been 
previously recommended.
71 Furthermore, no changes were noted in ABPI or maximum 
heart rate, indicating no major changes in gross blood flow or cardiovascular fitness 
underlying these improvements.  
 
Calf muscle endurance, as measured by repetitive heel raises, was also improved in the 
exercise group. Interestingly, as described previously, improvements in heel raises were 
closely  correlated  to  increases  in  MWD.
178  If  confirmed  in  larger-scale  studies, 
assessment of the number of repetitive heel raises could function as a simple and fast   179 
method to objectively gauge a patient‟s claudication symptoms without the need for 
more extensive testing procedures, and so be of use in an outpatient setting. Using a 
heel raise test as an endpoint in studies of claudication may also have benefits compared 
to  treadmill testing. A  heel  raise test is  unaffected by  changes  in  walking  gait that 
contribute to improvements in treadmill walking after training.
142 In addition, a heel 
raise test is independent of the training mode, and gains produced by familiarity with 
the testing apparatus are negated. 
 
Responses of ACE to Exercise Training 
No previous studies have examined the effects of endurance training on ACE mRNA 
expression or ACE levels. In contrary to expectations, this study revealed an increase of 
30%  in  ACE  mRNA  expression  after  exercise  training.  However,  when  examining 
plasma ACE levels, the increase in gene expression was not reflected by a significant 
increase in ACE protein levels. Protein levels are more likely to be reflective of the 
physiological relevance of ACE, as they are directly related to ACE activity.
28 Thus, 
these results suggest that a decrease in ACE activity is not an important mechanism 
underlying improvements in walking ability in claudicants. 
 
The small numbers of subjects also prevented any statistical analysis of ACE genotype 
data. However, when combining the data from both study groups, changes in ACE gene 
expression  appeared  to  be  genotype  influenced,  with  DD  subjects  having  a  median 
increase of 50%, ID subjects 19% and II subjects 16%. It is possible to speculate that 
subjects with different genotypes could have responded in a different way to the training 
programme. For example, those with II genotype could have increased ACE expression 
less than those with DD genotype, still conferring a theoretical advantage. However,   180 
significantly more numbers of subjects would have been needed to perform such an 
analysis. Finally, this study only assessed the impact of training on ACE expression and 
levels. To get a full picture of how exercise training affects the RAS, the whole system 
including Ang-II levels and AT receptor levels would need to be assessed. 
 
Analysis of baseline ACE D- and I-allele expression in ID heterozygotes revealed that 
in 5 out of 6 subjects, more ACE mRNA was produced from the D-allele than the I-
allele. This substantiates the findings of Suehiro et al., who performed their original 
experiment in healthy individuals.
246 In addition, in the 3 ID subjects who underwent 
exercise training, the D:I ratio increased further in conjunction with an overall increase 
in ACE expression, suggesting preferential activation of the D-allele. Furthermore, there 
was a correlation between overall ACE gene expression and D:I ratio, also suggesting a 
link  between  D-allele  activation  and  overall  ACE  gene  activity.  The  mechanism 
underlying the predominance of mRNA originating from the D-allele is not understood. 
However,  it  has  been  speculated  that  it  may  relate  to  selective  enhancement  of 
transcription  of  the  D-allele  or  increased  stability  of  mRNA  produced  from  the  D-
allele.
246 Further studies would be required to elucidate this mechanism. 
 
Responses of VEGF to Exercise Training 
No  previous  studies  have  examined  the  effects  of  training  in  claudicants  on  VEGF 
isoform  mRNA  expression  in  conjunction  with  VEGF  levels  and  VEGF  receptor 
expression.  Analysis  of  transcriptional  data  revealed  a  substantial  increase  in  the 
VEGF121 isoform (43%) and an even greater increase in the more biologically active 
VEGF165 isoform (70%) in the exercise group. This increase was significant compared 
to  the  control  group.  On  examining  VEGF  protein  levels,  baseline  levels  were   181 
comparable  to  those  recorded  in  previous  studies.
190;292  After  exercise  training,  no 
significant increase in VEGF protein was recorded, although 5 of the 6 subjects studied 
had an increase in VEGF protein level after training, giving a median increase of 94%. 
These findings are in line with the only previous study of VEGF responses to exercise 
training  in  claudicants,  which  showed  that  exercise  training  had  no  acute  effect  on 
plasma VEGF levels or on baseline VEGF levels after 6 weeks training.
292 However, the 
sample sizes in both studies were small (n=6 and n=7), and larger scale studies are 
required to fully clarify the situation. 
 
The results obtained from VEGF receptor expression analysis also point towards an 
overall increase in VEGF signalling capacity. Although the expression of sVEGFR-1, 
an  inhibitory  „decoy‟  receptor  was  increased  (63%),  the  expression  of  the  signal 
transducing  VEGFR-1  and  VEGFR-2  receptors  was  also  increased.  Indeed,  the 
transcription of VEGFR-2, which has the strongest signalling properties and is most 
important VEGF receptor in producing the signal for angiogenesis, showed the greatest 
increase  of  all  (72%).
90  The  recorded  increases  in  VEGF  receptors  may  also  have 
masked the true rise in VEGF protein levels, due to increased binding of plasma VEGF 
to endothelial bound VEGF receptors and sVEGFR-1.
129 However, in order to confirm 
the increase in VEGF signalling potential indicated by these mRNA expression studies, 
future  studies  would  also  need  to  assess  tissue  and  plasma  VEGF  receptor  protein 
levels. When considering these results, it is again important to consider the limitations 
of the trial. As discussed above, these results relate to mRNA expression in PBMNs and 
plasma levels of VEGF, and cannot be guaranteed to reflect changes occurring locally 
within the tissues. This issue could help explain the lack of correlation between mRNA 
and protein levels both ACE and VEGF in this study. Overall, the results reveal that   182 
exercise training leads to an overall increase in potential VEGF signalling activity, as 
determined by VEGF121/VEGF165 expression, plasma VEGF levels and VEGF receptor 
expression. Given that these increases in VEGF signalling capacity occur in conjunction 
with increases in walking ability, it is possible to speculate that VEGF and its receptors 
could be a viable target for treatment of intermittent claudication. 
 
Relationship Between ACE and VEGF 
On examining the relationship between VEGF and ACE, a strong positive correlation 
was found between baseline VEGF121/VEGF165 mRNA expression and ACE mRNA 
expression. However, no relationship was noted between changes in ACE and VEGF 
expression after training, or between ACE and VEGF protein levels. The simultaneous 
increase  in  both  ACE  and  VEGF  expression  is  comparable  to  that  described  by 
Saijonmaa et al., who noted that VEGF up-regulated ACE expression in endothelial 
cells, suggesting a synergistic relationship between ACE and VEGF.
219 Conversely, the 
results do not corroborate with evidence from animal models of ischaemia, in which 
reduction of ACE activity increased VEGF expression.
77;233;250 The differences between 
these studies could be related to the use of ACE inhibitors in the animal models. ACE 
inhibitors, as previously described in Section 1.5, can alter gene expression directly via 
their own cell signalling properties, independent from their actions in reducing in ACE 
activity.
93;94 Furthermore, although ACE and VEGF expression both increased in this 
trial, this does not indicate a direct link, and it is possible that the increases occurred 
independently from each other. The lack of a relationship between protein levels also 
counts against a link, although the results for protein could have been affected by issues 
such as the level of receptor binding.
129 Issues relating to the interpretation of mRNA 
and protein data are discussed below.   183 
Relationship Between mRNA Expression and Protein Levels 
In this study, no strong correlation between mRNA expression and protein levels was 
found for VEGF or ACE. In addition, no link was found between changes in mRNA 
expression and protein levels. These findings could be explained by the complexity of 
the  process  in  the  progression  from  genotype  to  phenotype.  The  central  dogma  of 
genetics  states  that  genetic information  progresses  from  DNA to  mRNA to  protein. 
However, in practice this is a hugely complex system and at each stage in this hierarchy 
variation can be introduced, for example by differential transcription of mRNA and 
differential translation of protein.
200 Thus, to an extent the findings in this study are not 
surprising, and many studies have also been published regarding the poor correlation 
between  mRNA  expression  and  protein.
104  The  discrepancies  between  mRNA  and 
protein expression could have been caused by post-transcriptional regulation, as well as 
variation in mRNA/protein stability and turnover.
59;106 However, the measurement of 
both mRNA and protein, as well as the determination of gene polymorphisms, allows a 
more meaningful understanding of complex phenotypes to be established, and is set to 
become a standard method for studying complex human diseases.
200 
 
Relationship Between Physiological Changes and Molecular Changes 
Although  the  results  of  this  study  reveal  increases  in  walking  distance,  ACE  gene 
expression,  and an increase in  VEGF signalling potential, no correlation was  found 
between any of the physiological and molecular changes. There are several reasons to 
explain this. Firstly, the number of subjects was small, and thus statistical tests would 
have  been  unlikely  to  detect  any  correlation.  In  addition,  the  mechanism  for 
improvement with exercise in intermittent claudication is multi-factorial (as described in 
Section 1.2.3), and therefore the effects of a single factor would be difficult to detect   184 
amongst the others.
244;255 The patient group was also quite heterogeneous in terms of co-
morbidities, disease distribution, and baseline gene activity, making it more difficult to 
link the physiological improvements with specific gene targets. 
 
Nevertheless, despite the absence of correlation described above, the findings of this 
study were that exercise training improved measurements of walking ability, and these 
improvements were noted in association with increases in VEGF mRNA expression, 
VEGF receptor expression, VEGF protein levels and ACE expression. Whether these 
molecular changes underlie some of the improvements, and the extent to which they do, 
is uncertain. However, an increase in VEGF signalling and hence angiogenesis is likely 
to be of benefit to subjects with intermittent claudication. 
 
Study Power and Sample Size 
In analysing the data, several results for changes observed in this study were found to be 
statistically insignificant. It is likely that this was at least in part related to the small 
sample sizes attained by this study, which resulted in statistical analyses that were often 
underpowered. In this trial, power for insignificant results typically varied from between 
30-40%. Post-hoc power studies reveal that if sample sizes were increased to 18 in each 
group (control and exercise), then this trial would have had at least an 80% power to 
detect  differences  of the sizes  measured for:  CD (exercise  vs.  control  groups), heel 
raises (exercise and control groups- pre vs. post), ACE mRNA expression (exercise vs. 
control groups), VEGF protein levels (exercise group- pre vs. post), VEGFR-1 (exercise 
group- pre vs. post; exercise vs. control groups) and sVEGFR-1 (exercise vs. control 
groups). Thus, increased sample sizes would have probably produced more statistically 
significant results.   185 
Future studies 
Larger scale studies in claudicants are required to confirm the findings of this study, 
although problems with recruitment will still remain an issue. Furthermore, additional 
studies could, if admissible, use leg muscle biopsies to assess local changes in mRNA 
and  protein  expression.  Muscle  biopsies  would  also  give  the  additional  benefit  of 
allowing assessment of changes in capillary density with exercise training. An increase 
in capillary density after training in relation to increased VEGF would provide stronger 
evidence for the role of VEGF in walking improvements. Future studies could also 
examine the effects of exercise training on the products downstream of ACE (Ang-II 
and BK) and on Ang-II receptors. 
 
4.6  SUMMARY 
The  results  of  this  study  relate  to  a  small  number  of  subjects,  and  so  few  firm 
conclusions  can  be  drawn.  However,  the  exercise  training  programme  produced 
significant increases in treadmill walking ability and calf muscle endurance. Exercise 
training was associated with an increase in ACE, VEGF121, VEGF165, sVEGFR-1 and 
VEGFR-2  mRNA  expression.  In  ACE  I/D  heterozygotes,  more  mRNA  appeared  to 
originate from the D-allele than from the I-allele. These results suggest that increased 
VEGF  signalling  may  play  a  role  in  exercise  associated  improvements  in  walking 
ability  and  VEGF  may  thus  be  a  viable  target  for  modulation  in  the  treatment  of 
claudicants. 
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CHAPTER 5 
EFFECTS OF ACE INHIBITION ON ACE AND 
VEGF RESPONSES TO HYPOXIA 
 
   187 
CHAPTER 5 
5.1  BACKGROUND 
Several studies have revealed the potential role of ACE in exercise performance. Low 
ACE activity allied to the I-allele of the ACE I/D polymorphism is associated with 
improved  endurance  performance.
170;288  Furthermore,  pharmacological  reduction  of 
ACE  activity  using  ACE  inhibitors  has  also  been  linked  with  increased  muscular 
efficiency  and  endurance,  reduced  inflammation,  ischaemic  preconditioning  and 
enhanced  endothelial  function.
74;166;256;288;300  Thus,  the  use  of  ACE  inhibitors  in 
claudicants could be of therapeutic benefit by improving endurance performance and 
hence walking ability. Another potential gain from ACE inhibition is an increase in 
angiogenesis. Several animal models of ischaemia have confirmed that ACE inhibitors 
augment angiogenesis by up-regulating VEGF expression.
77;233 Thus, ACE inhibitors 
may  have  dual  benefits  in  ischaemia,  by  increasing  VEGF  activity  while  also 
maintaining low ACE activity. However, the results of clinical trials of ACE inhibitors 
in claudicants have shown conflicting results, and the possible benefit from using ACE 
inhibitors  to  treat  intermittent  claudication  remains  unclear.
3;155  One  way  to  better 
understand the potential role of ACE inhibition in claudicants would be to assess how 
ACE  inhibition  in  a  human  model  of  hypoxia  affects  ACE  and  VEGF  biology,  as 
determined by mRNA expression and protein levels. 
 
5.2  AIMS 
The first aim of this study was to develop a human endothelial cell culture model of 
hypoxia in which the cells were stable and viable, and in which ACE and VEGF were 
reliably expressed. This subsequently allowed the effects of ACE inhibition on ACE 
and VEGF in a human model of hypoxia to be assessed.   188 
5.3  METHODS 
Genomic DNA was harvested from ECV 304 cells and ACE genotype determined as 
described  in  Section  3.4.  ECV  304  cells  possessed  the  DD  genotype  (linked  to 
intrinsically high ACE activity). This high ACE activity was considered an advantage 
when studying the effects of ACE inhibition. However, the differential expression of I- 
and  D-alleles  was  not  able  to  be  assessed.  ACE,  VEGF121  and  VEGF165  mRNA 
expression was determined by RT-PCR as described in Section 3.3. ACE and VEGF 
protein levels were measured by ELISA as stated in Section 3.6. 
 
5.3.1  Work up Experiments 
A series of work-up experiments were initially performed in order to determine the 
optimal cell culture conditions and drug doses for use in the final experiments. Control 
experiments were performed using medium supplemented with 1% or 10% FCS. This 
allowed the viability and stability of cells in low nutrient conditions (1% FCS), and also 
the potential stimulatory and proliferative effects of a growth factor rich medium (10% 
FCS) to be assessed. 
 
Cell Viability Control Experiment 
The first control experiment examined ECV 304 cell viability over time for different 
nutrient  concentrations  and  cell  densities.  The  aim  was  to  find  a  cell  number  and 
medium concentration where cell viability was stable over time, with the cells quiescent 
but viable and not proliferating. 
 
ECV cells at passage number 178 were prepared as described in Section 3.2.2. On 96-
well plates 1500, 3000, 15,000 and 30,000 cells were seeded in triplicate for both FCS   189 
concentrations. Four identical plates were set up, with viability assessed immediately in 
one plate (as described in Section 3.2.4) and subsequently at 24, 48 and 72 hours. The 
medium was refreshed every day for unprocessed plates. When assessing cell viability, 
the plates were read 4 hours after incubation with the assay solution. From the results of 
this experiment (Appendix 5) a density of 15,000 cells per well was chosen for future 
experiments. However, to help with time restrictions all experiments were subsequently 
processed at 18 hours and viability assessed 3 hours after adding the assay solution.  
 
Effects of DETA-NO or Ramiprilat alone 
These  experiments  examined  the  individual  effects  of  DETA-NO  and  ramiprilat  on 
ECV 304 cell viability and gene expression. Again, the effect of low nutrient (1% FCS) 
and growth factor rich conditions (10% FCS) was examined. The aim was to examine 
the dose-response curves for both drugs and thus choose the drug doses and medium 
concentration for the final experiment. 
 
Cells at passage 183 were prepared as described in Section 3.2.2 in both 1% and 10% 
FCS. Fifteen thousand cells were seeded per well for the cell viability experiments and 
5x10
5 cells seeded per well on 6-well plates for examination of gene expression. The 
cell numbers were chosen so that the cell density was the same in both the 6- and 96-
well plates. Doubling doses of DETA-NO from 0.008 to 0.5 mM and ten-fold increases 
of ramiprilat from 1 to 1000 nM/l were used in these experiments. „Medium control‟ 
experiments  (containing  cells  and  medium),  and  „vehicle  control‟  experiments 
(containing  cells,  medium  and  drug  vehicle)  were  also  set  up.  All  cell  viability 
experiments were run in quadruplicate, while gene expression experiments were run in 
single wells, with one RT-PCR run used to assess gene expression. The plates were   190 
processed after 18 hours for cell viability and ACE/VEGF gene expression as described 
in Sections 3.2.4, 3.2.5 and 3.3. The results are shown in Appendix 5. 
 
5.3.2  Final Experiment 
The conditions for the final experiment were decided from the results of the work up 
experiments  (Appendix 5).  In  all  the  work-up  experiments,  no  major  differences  in 
viability or gene expression were noted between the 1% and 10% FCS experiments. 
However, as medium with 1% FCS contains less growth factors and has less stimulatory 
properties  that  could  interfere  with  the  results,  1%  FCS  was  chosen  for  the  final 
experiments.  Doubling  doses  of  DETA-NO  from  0.008  to  0.250  mM  were  used  to 
create a „metabolic hypoxia‟, and the effects of 2 doses of ramiprilat (100 and 1000 
nM/l) on these responses to hypoxia studied. 
 
The final experiment was run twice on 2 separate occasions using identical conditions. 
For the first run, ECV cells at passage 188 were used, and for the second ECV cells at 
passage 190. For each run, the effects of DETA-NO alone, DETA-NO with 100 nM/l 
ramiprilat, and DETA-NO with 1000 nM/l ramiprilat were examined.  
 
ECV 304 cells were harvested and the experiments were set up as described in Sections 
3.2.2  and  3.2.3.  Specifically,  the  wells  used  as  the  overall  experimental  controls 
contained  ECV  cells,  medium  and  both  drug  vehicles.  In  the  DETA-NO  only 
experiment, all wells also contained 0.05% DMSO, the drug vehicle used for ramiprilat. 
In the DETA-NO with ramiprilat experiments, all wells contained either 100 or 1000 
nM/l ramiprilat. The „medium control‟ wells in these experiments contained ECV cells 
in medium and ramiprilat, while the „vehicle control‟ wells  contained ECV cells in   191 
medium, ramiprilat and the drug vehicle for DETA-NO (water). These control wells 
allowed the effects of ramiprilat alone to be studied. The experiments were all run for 
18 hours. A summary of experimental well contents is described in Appendix 6.  
 
Cell viability was assessed as described in Section 3.2.4. Cells from 6 well plates were 
harvested for RNA and protein as described in Section 3.2.5. ACE and VEGF gene 
expression  was  determined  as  described  in  Section  3.3,  and  VEGF  protein  levels 
measured as described in Section 3.6. The viability studies for both experimental runs 
were run in quadruplicate. Due to a lack of time and resources only a single RT-PCR 
run was used to assess gene expression from each experiment, and thus no statistical 
tests were able to be performed on the gene expression results. RT-PCR results for ACE 
expression were obtained using the ACE 216 primer set. For ELISA measurements, 
each  experimental  run  was  measured  once  in  triplicate.  The  raw  data  obtained  is 
illustrated in Appendix 7. 
 
5.4  RESULTS 
All  experimental  wells  were  examined  microscopically  to  assess  confluence  and 
infection at the end of the 18 hour experiment period. In all experiments, the wells were 
found to be free of infection and the cells confluent. Wells containing ECV cells in 
medium and both drug vehicles were used as the experimental controls throughout. 
 
5.4.1  Effects of DETA-NO Alone 
Cell Viability 
In  the  cell  viability  experiments,  there  was  no  difference  in  viability  between  the 
medium and the vehicle controls (Medium 1.99 ± 0.07, Vehicle 2.04 ± 0.06; unpaired t-  192 
test: p>0.50). On examining the effects of DETA-NO, doses ranging from 0.008 to 0.25 
mM did not have significant effects on ECV 304 cell viability (Figure 5.1). 
 
ACE and VEGF Gene Expression 
As only 2 experimental runs were performed statistical testing was not possible on the 
gene  expression  data,  and  thus  broad  observations  only  could  be  made.  DETA-NO 
generally produced an increase in ACE expression, with a 42% increase in expression 
observed at 0.06 mM (Figure 5.2). DETA-NO did not appear to elicit any clear effect on 
VEGF121 and VEGF165 expression (Figure 5.3). 
 
VEGF Protein Levels 
Unfortunately, due to low protein yields ACE levels were not consistently detectable 
using  our  ELISA  kit.  However,  VEGF  levels  increased  significantly  at  the  highest 
DETA-NO dose, with a 53 ± 11% increase in VEGF protein noted at 0.25 mM DETA-
NO (Figure 5.4). There was no difference in VEGF levels between the medium and 
vehicle controls (Medium 132.2 ± 10.6, Vehicle 118.2 ± 12.9; unpaired t-test: p = 0.42). 
 
5.4.2  Effects of Ramiprilat Alone 
To assess the effects of ramiprilat alone the gene expression results from the two final 
experiment runs were combined with the results from the ramiprilat control experiment, 
which used identical conditions. 
 
Cell Viability 
There was no difference in viability between the medium and the vehicle controls in 
either the 100 nM/l ramiprilat (Medium 2.0 ± 0.1, Vehicle 2.1 ± 0.1; unpaired t-test: p =  193 
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Figure 5.1  Effects of DETA-NO on Cell Viability 
Increasing doses of DETA-NO from 0.008 to  0.250 mM did not have a significant 
effect on ECV 304 cell viability (1-way ANOVA, p>0.50). The bars represent the mean 
values, and error bars SEM, of 2 repeat experiments each run in quadruplicate wells.   194 
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Figure 5.2  Effects of DETA-NO on ACE Expression 
With increasing DETA-NO, ACE gene expression also generally appeared to increase, 
with a maximal increase of 42% noted at 0.063 mM DETA-NO. The points represent 
individual values and the horizontal bars the mean from 2 repeat experiments. 
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Figure 5.3  Effects of DETA-NO on VEGF Gene Expression 
The effects of DETA-NO on A VEGF121 and B VEGF165 expression are shown. DETA-
NO did not appear to have any noticeable effects on VEGF121 and VEGF165 expression. 
The points represent individual values and the horizontal bars the mean from 2 repeat 
experiments.   196 
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Figure 5.4  Effects of DETA-NO on VEGF Protein Levels 
There was a 53 ± 11% increase in VEGF protein level recorded at 0.250 mM DETA-
NO (1-way ANOVA with Dunnett‟s multiple comparison test; * p < 0.05 vs Control). 
The bars represent the mean values, and error bars SEM, of 2 repeat experiments each 
run in triplicate wells.   197 
0.37)  or  1000  nM/l  ramiprilat  (Medium  1.9  ±  0.0,  Vehicle  2.0  ±  0.1;  p  =  0.43) 
experiments. In addition, neither dose of ramiprilat had any significant effect on cell 
viability (Figure 5.5). 
 
ACE and VEGF Gene Expression 
Ramiprilat augmented ACE gene expression, with a 40 ± 10% increase recorded with 
1000 nM/l ramiprilat (Figure 5.6). In contrast, ramiprilat lowered VEGF expression. 
VEGF165 expression was reduced 16 ± 0.4% and 22 ± 2% by 100 nM/l and 1000 nM/l 
ramiprilat  respectively  (Figure  5.7).  Ramiprilat  did  not  significantly  decrease  the 
expression of VEGF121 (Figure 5.7). 
 
VEGF Protein Levels 
There was no difference in VEGF levels between the medium and the vehicle controls 
in either the 100 nM/l ramiprilat (Medium 180 ± 16, Vehicle 186 ± 3; unpaired t-test: 
p>0.50)  or  1000  nM/l  ramiprilat  (Medium  199  ±  5,  Vehicle  211  ±  23;  p>0.50) 
experiments.  While  ramiprilat  decreased  VEGF165  gene  expression  at  18  hours,  the 
amount  of  VEGF  protein  increased.  Increasing  doses  of  ramiprilat  progressively 
augmented VEGF levels, with a 58 ± 3% increase with 100 nM/l ramiprilat and a 79 ± 
19% increase with 1000 nM/l ramiprilat (Figure 5.8). 
 
5.4.3  Effects of Ramiprilat on Responses to Metabolic Hypoxia  
Cell Viability 
Ramiprilat combined with increasing doses of DETA-NO did not have any significant 
effect on cell viability compared to the experimental control (1-way ANOVA: 100 nM/l 
ramiprilat/DETA p = 0.82, 1000 nM/l ramiprilat/DETA p = 0.98). In addition, at each  198 
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Figure 5.5  Effects of Ramiprilat on Cell Viability 
Ramiprilat  at  100  and  1000  nM/l  did  not  have  an  effect  on  cell  viability  (1-way 
ANOVA, p = 0.69). The bars represent the mean values, and error bars SEM, of 2 
repeat experiments each run in quadruplicate wells.   199 
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Figure 5.6  Effects of Ramiprilat on ACE Gene Expression 
Ramiprilat  stimulated  ACE  gene  expression  at  the  highest  dose,  with  a  40  ±  10% 
increase in expression noted with 1000 nM/l ramiprilat (1-way ANOVA with Dunnett‟s 
multiple comparison test; ** p < 0.01 vs Control). The bars represent the mean values, 
and error bars SEM, of 3 repeat experiments. 
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Figure 5.7  Effects of Ramiprilat on VEGF Gene Expression 
The  effects  of  ramiprilat  on  A  VEGF121  and  B  VEGF165  expression  are  shown. 
Ramiprilat  did  not  reduce  VEGF121  expression.  However,  a  significant  decrease  in 
VEGF165  expression  was  recorded  with  1000  nM/l  ramiprilat  causing  a  22  ±  2% 
reduction  (1-way  ANOVA  with  Dunnett‟s  multiple  comparison  test;  *  p  <  0.05  vs 
Control, ** p < 0.01 vs Control). The bars represent the mean values, and error bars 
SEM, of 3 repeat experiments.   201 
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Figure 5.8  Effects of Ramiprilat on VEGF Protein Levels 
Increasing doses of ramiprilat significantly augmented VEGF levels, with a 58 ± 3% 
increase  noted  with  100  nM/l  ramiprilat  and  a  79  ±  19%  increase  with  1000  nM/l 
ramiprilat  (1-way  ANOVA with  Dunnett‟s multiple comparison  test;  *  p <  0.05 vs 
Control, ** p < 0.01 vs Control). The bars represent the mean values, and error bars 
SEM, of 2 repeat experiments each run in triplicate wells. 
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DETA-NO dose there was no significant change in cell viability with either 100 or 1000 
nM/l ramiprilat compared to DETA-NO alone (Figure 5.9). 
 
ACE and VEGF Gene Expression 
To compare the medium (M) and vehicle (V) controls for ACE and VEGF121/VEGF165 
expression, gene expression results for the DETA only, DETA/100 nM/l ramiprilat and 
DETA/1000  nM/l  ramiprilat  control  groups  were  combined.  The  results  showed  no 
difference between the control experiments for ACE expression (M 0.28 ± 0.02, V 2.53 
± 0.02; unpaired t-test p = 0.32), VEGF121 expression (M 0.56 ± 0.02, V 0.55 ± 0.03; p 
> 0.50) or VEGF165 expression (M 0.44 ± 0.02, V 0.44 ± 0.02; p > 0.50). 
 
As stated previously, only 2 experimental runs were performed, not allowing statistical 
tests to be performed. Thus, only broad observations can be made. On examining ACE 
gene expression, there was an apparent increase in ACE expression with the ramiprilat 
groups compared to DETA-NO alone. At every DETA-NO dose, ACE gene expression 
was greater (by 12-71%) with both 100 and 1000 nM/l ramiprilat than for DETA-NO 
alone  (Figure  5.10).  On  studying  VEGF121  gene  expression,  there  was  an  apparent 
decrease in VEGF121 expression with both 100 nM/l and 1000 nM/l ramiprilat compared 
to DETA-NO alone. At every DETA-NO dose, VEGF121 gene expression was reduced 
by  both ramiprilat  doses  (by 8-27%) than with DETA-NO alone (Figure 5.11).  For 
VEGF165 gene expression, the tendency again appeared to be for ramiprilat to decrease 
VEGF165 expression in hypoxia (Figure 5.12). VEGF165 gene expression was lower with 
both ramiprilat doses (by 6-21%) at all DETA-NO doses compared to DETA-NO alone. 
There was no obvious difference between the 2 ramiprilat groups for ACE, VEGF121 or 
VEGF165.  203 
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Figure 5.9  Effects of Ramiprilat and Metabolic Hypoxia on Cell Viability 
At  each  dose  of  DETA-NO  there  was  no  significant  change  in  cell  viability  with 
ramiprilat (1-way ANOVA). Each bar represents the mean, and the error bars SEM, of 2 
repeat experiments each run in quadruplicate wells. 
   204 
 
50
100
150
200
DETA-NO (mM)
A
C
E
/
G
A
P
D
H
-
3
 
(
%
 
C
o
n
t
r
o
l
)
0
0.008 0.016 0.031 0.063 0.125 0.250
DETA Only
DETA and 100 nM/l Ramiprilat
DETA and 1000 nM/l Ramiprilat
 
 
Figure 5.10  Effects of Ramiprilat on ACE Expression in Response to Hypoxia 
100 nM/l and 1000 nM/l ramiprilat appear to increase ACE gene expression compared 
to  DETA-NO alone.  At every  DETA-NO dose, both  100 and 1000  nM/l ramiprilat 
produced an increase in ACE expression. Each point represents the value obtained from 
2 repeat experiments, and the horizontal bars the mean. 
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Figure 5.11  Effects  of  Ramiprilat  on  VEGF121  Expression  in  Response  to 
Hypoxia 
An  apparent  decrease  in  VEGF121  expression  with  both  100  nM/l  and  1000  nM/l 
ramiprilat compared to DETA-NO alone is noted. At every dose of DETA-NO, 100 and 
1000 nM/l ramiprilat decreased VEGF121 mRNA expression compared to DETA-NO 
alone. Each point represents the mean, and the error bars SEM, of 2 repeat experiments. 
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Figure 5.12  Effects  of  Ramiprilat  on  VEGF165  Expression  in  Response  to 
Hypoxia 
VEGF165 expression appears to be suppressed with 100 nM/l and 1000 nM/l ramiprilat 
compared to DETA-NO alone. Both doses of ramiprilat consistently decreased VEGF165 
expression compared to DETA-NO alone, although these differences are small. Each 
point represents the mean, and the error bars SEM, of 2 repeat experiments.   207 
VEGF Protein Levels 
Ramiprilat augmented increases in VEGF levels in response to hypoxia (Figure 5.13). 
100 nM/l ramiprilat significantly increased VEGF levels over the experimental control 
at all DETA-NO doses (1-way ANOVA with Dunnett‟s test: 0.008 to 0.125 mM p < 
0.05, 0.250 mM p < 0.01). 1000 nM/l ramiprilat also significantly increased VEGF 
levels compared to the experimental control at all DETA-NO doses (1-way ANOVA 
with Dunnett‟s test: 0.008 to 0.250 mM p < 0.01). There was no significant change in 
VEGF levels with either dose of ramiprilat compared to DETA alone, apart from at 
0.016  mM  DETA-NO,  where  100  nM/l  and  1000  nM/l  ramiprilat  increased  VEGF 
levels by 54 ± 26% (p < 0.05) and  60 ± 7% (p < 0.01) respectively (1-way ANOVA 
with Bonferroni‟s multiple comparison test). However, at each DETA-NO dose VEGF 
levels were higher (but not significantly) in the 2 ramiprilat groups than for DETA-NO 
alone.  There  was  no  significant  difference  between  the  2  ramiprilat  groups  (Figure 
5.13). 
 
5.5  DISCUSSION 
Studies  of  ACE  inhibition  in  patients  with  heart  failure  and  in  animal  models  of 
ischaemia suggest that ACE inhibitors could produce several benefits in patients with 
intermittent claudication. Heart failure, like peripheral arterial disease, is characterised 
by poor tissue perfusion.
53 The use of ACE inhibitors in patients with heart failure has 
been  linked  with  benefits  including  increased  oxygen  extraction  and  exercise 
performance.
73;74 Interestingly, these effects are appear to be separate from the effects of 
ACE inhibitors on cardiac output and blood pressure, and have been suggested to result 
from increased metabolic efficiency.
167 Low ACE activity related to the I-allele of the 
ACE I/D polymorphism has also been related to enhanced metabolic efficiency and   208 
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Figure 5.13  Effects  of  Ramiprilat  on  VEGF  Protein  Levels  in  Response  to 
Hypoxia 
There  was  no  significant  change  in  VEGF  levels  with  either  dose  of  ramiprilat 
compared to DETA alone, apart from at 0.016 mM DETA-NO where both ramiprilat 
doses  increased  levels  significantly  (1-way  ANOVA  with  Bonferroni‟s  multiple 
comparison test: * p < 0.05 ** p < 0.01). Each bar represents the mean, and the error 
bars SEM, of 2 separate repeat experiments with each ELISA run twice in triplicate 
wells. 
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endurance performance.
170;288 In addition, animal models of ischaemia have revealed 
that ACE inhibitors increase VEGF expression and subsequently increase angiogenesis, 
an effect related to the accumulation of BK.
85;233 Moreover, ACE inhibitors also possess 
cell-signalling  properties,  directly  increasing  ACE,  COX-2  and  potentially  VEGF 
expression,  while  maintaining  low  ACE  activity.
10;23;93  Thus,  ACE  inhibitors  have 
potential  dual  benefits  for  improving  walking  ability  in  claudicants,  by  increasing 
metabolic efficiency and by potentiating angiogenesis. Small scale clinical trials have to 
date  produced  conflicting  results  regarding  the  benefits  of  ACE  inhibitors  in 
claudication, although the largest study to date showed a marked improvement.
3 This 
study was designed to assess the effects of ACE inhibition on VEGF and ACE in a 
human model of hypoxia. A cell model of hypoxia was developed, and the effects of the 
ACE inhibitor ramiprilat on ACE and VEGF expression examined. The hypothesis was 
that ramiprilat would increase both ACE and VEGF expression in hypoxia. 
 
Effects of Hypoxia on ACE and VEGF 
DETA-NO, a nitric oxide donor, was used in ECV 304 cells to produce a „metabolic 
hypoxia‟, as described previously by Moncada et al.
164 No significant effect of DETA-
NO on cell viability was noted. Increasing doses of DETA-NO mediated an apparent 
increase in ACE mRNA levels, although more experimental runs would be required to 
confirm this statistically. However, previous studies that have shown hypoxia to up-
regulate ACE.
136;171;306 The mechanism for this increase has been demonstrated to occur 
via HIF-1, with Ang-II and HIF-1 acting in a positive feedback loop.
141 DETA-NO did 
not appear to have any noticeable effect on VEGF121 and VEGF165 mRNA expression. 
However, in contrast DETA-NO produced an increase in VEGF protein levels of 53% 
at 0.250 mM. Of note, the changes ACE and VEGF recorded in this cell culture model   210 
of  hypoxia  are  comparable  to  those  found  after  exercise  training  in  claudicants,  as 
described  in  Chapter  4.  In  these  subjects,  repetitive  ischaemia  caused  by  regular 
exercise training resulted in increased ACE gene expression, and raised VEGF levels, 
suggesting  a  similar  response  to  hypoxia  in  both  models.  The  increases  in  VEGF 
expression with hypoxia in this study conform with previous reports of raised VEGF 
levels  with  hypoxia.
29;174  A  HIF-1  mediated  mechanism  is  likely  to  underlie  these 
increases in VEGF transcription.
95;226 Hypoxia also stabilises VEGF mRNA, which is 
normally intrinsically unstable due to destabilising elements in its 3‟ and 5‟ UTR/coding 
regions, and thereby increases the half-life of VEGF mRNA.
70;242 
 
In this study, hypoxia did not appear to affect VEGF121 or VEGF165 mRNA expression 
but did increase VEGF protein levels. This disparity has been noted previously, with 
VEGF mRNA and protein not always adapting in parallel. Indeed, low VEGF mRNA 
levels with conversely high VEGF protein levels has been linked with angiogenesis.
161 
Increased VEGF protein in a time of low mRNA expression could partly be explained 
by  post-transcriptional  events  such  as  translation  via  an  alternative  ribosome  entry 
site.
241 Finally, it is possible that the high VEGF protein levels could downregulate 
transcription  in a negative feedback loop,  although thus  far there is  no evidence to 
support this. In summary, the evidence in this study supports the notion that hypoxia 
stimulates VEGF production, creating a favourable environment for angiogenesis. 
 
Effects of Ramiprilat on ACE and VEGF 
The doses of ramiprilat used did not have a significant effect on cell viability. However, 
ACE  inhibition  in  normoxic  conditions  did  influence  ACE  and  VEGF  expression. 
Ramiprilat produced an increase in ACE mRNA expression, with 1000 nM/l ramiprilat   211 
inducing a 40% rise in ACE mRNA levels. This stimulation of ACE transcription as a 
result of ACE inhibition is in keeping with previous studies.
58;138 Increases in ACE 
expression during ACE inhibition have been attributed to a lack of negative feedback by 
Ang-II.
223  In  addition,  the  cell  signalling  properties  of  ACE  mediated  by  ACE 
inhibitors, as described by Kohlstedt et al. could also contribute to the increases in gene 
expression.
138;139  However,  even  with  these  increases  in  ACE  levels,  overall  ACE 
activity would still be likely to be suppressed due to the continued presence of the ACE 
inhibitor.
23 
 
Ramiprilat had an inhibitory effect on VEGF mRNA levels, reducing levels by up to 
22% in the case of the more biologically active VEGF165. However, in contrast to these 
decreases in VEGF gene transcription, significant increases in VEGF protein levels of 
up  to  79%  were  noted.  This  paradox  is  similar  to  that  seen  with  DETA-NO,  and 
possible  explanations  for  this  have  been  discussed  above.  The  increases  in  VEGF 
protein levels with ACE inhibition are  also similar to those previously described in 
animal  studies  on  the  effects  of  ACE  inhibitors  in  angiogenesis.
77;233  Given  the 
measured  increases  in  VEGF  protein,  these  results  suggest  that  ACE  inhibition 
amplifies  VEGF  production  in  an  endothelial  cell  model,  thereby  increasing  the 
potential for angiogenesis.  
 
Effects of Ramiprilat on Responses to Hypoxia 
Lastly, the effect of ramiprilat on ACE and VEGF expression in the cell culture model 
of  hypoxia  was  studied.  No  effect  on  cell  viability  was  recorded.  Given  that  cell 
viability remained stable and confluent cultures were used in all experiments, changes 
were likely to reflect changes in gene expression rather than cell proliferation or death.   212 
Ramiprilat appeared to potentiated ACE gene expression compared with hypoxia alone, 
although  more  experimental  runs  are  needed  to  confirm  this  statistically.  However, 
ramiprilat  significantly  increased  VEGF  protein  levels  in  hypoxic  conditions.  The 
increases in VEGF promoted by ACE inhibition in hypoxia indicate a potential role for 
the use of ACE inhibitors to augment angiogenesis in claudicants. This effect is similar 
to that previously described in animal models of ischaemia.
77;85;233;234 The mechanism 
for  this  increase  has  been  suggested  to  involve  the  induction  of  VEGF  expression 
secondary  to  the  accumulation  of  BK  during  ACE  inhibition.
85;233  Another  possible 
mechanism could relate to the „outside-in‟ signalling pathway triggered by the binding 
of  an  ACE  inhibitor  to  membrane-bound  ACE.
93;138  This  pathway  has  been 
demonstrated  to  up-regulate  COX-2  expression,  which  itself  can  increase  VEGF 
expression.
10;139  This  same  pathway  could  also  partially  account  for  the  potential 
increases in ACE gene expression observed in this study. Although an increase in ACE 
expression would not appear to be beneficial in hypoxia, the continued presence of an 
ACE inhibitor would negate these increases, maintaining low overall ACE activity.
23 
Thus, in this model of hypoxia, ACE inhibition produced 2 effects that could be of 
benefit if repeated in claudicants: an increase VEGF expression (thereby enhancing the 
potential  for  angiogenesis),  and  secondly  an  inhibition  of  ACE  activity  (thereby 
providing metabolic advantages and improved endothelial function). 
 
Limitations of the Experimental Protocol 
It is important to discuss several limitations associated with the experimental protocol. 
Unfortunately, ACE levels were not reliably detected in our experimental protocol. One 
possible reason for this was the processing of the same experimental wells to harvest 
both RNA and protein, resulting in low yields. The use of separate wells for protein and   213 
RNA could have increased yields and allowed better protein analysis, using techniques 
such as Western blotting. Furthermore an assumption, based on previous studies, was 
also  made  in  the  discussion  that  ACE  activity  remained  decreased  during  ACE 
inhibition despite increases in ACE expression.
23 However, to confirm this it would be 
preferable to measure ACE activity in addition to ACE expression and levels. 
 
The cell culture model used in this study also had several limitations. It consisted of a 
simple experiment created in an endothelial cell model using DETA-NO to create a 
„metabolic  hypoxia‟.  This  model  could  not  expect  to  replicate  the  very  complex 
environment  and  processes  occurring  in  a  claudicant,  with  the  repeated  episodes  of 
ischaemia and reperfusion, or the complex interactions between different cell types. For 
example, peri-endothelial cells, VSMCs and the extracellular matrix play a large role in 
angiogenesis by interacting with the endothelium, which could not be replicated in our 
model.
57 Moreover, ECV 304 cells are not proven to express bradykinin, a vital link in 
both  the  RAS  and  angiogenesis.  However,  our  model  did  give  an  insight  into  how 
endothelial cells react to a hypoxic environment, and the effects of an ACE inhibitor on 
these responses. Another limitation of the experimental protocol was the use of DETA-
NO to produce the hypoxic conditions in our model. DETA-NO acts as a slow releasing 
NO-donor,  and  has  been  shown  to  inhibit  mitochondrial  function  by  binding 
cytochrome oxidase, interrupting the electron transport chain and preventing aerobic 
metabolism.
7 However, although the effects of NO in this study could be attributed to 
„metabolic hypoxia‟, other effects of NO cannot be excluded as a cause. The majority of 
the physiological actions of NO have been attributed to its ability to bind to soluble 
guanylate cyclase (sGC), an enzyme that acts to produce the second messenger cyclic 
GMP (cGMP) from GTP. cGMP acts on cGMP-dependent protein kinases or cGMP-  214 
gated ion channels to mediate many physiological actions.
5;165 To exclude this pathway 
as a possible mechanism for the changes noted in this study, further experiments using a 
sGC inhibitor such as oxadiazolo-quinoxalin are required to differentiate the cGMP-
mediated effects from the cytochrome oxidase effects of NO. Alternatively, hypoxic 
chambers  could  be  used  to  generate  hypoxia,  although  these  too  have  their  own 
limitations. 
 
Study Power and Sample Size 
A  major  consideration  in  this  study  is  the  restricted  number  of  experimental  runs 
performed due to the limited time and resources available. For the final experiment, 
only 2 runs were conducted (each associated with a single RT-PCR or multiple-well 
ELISA run). As a result, only a few statistically significant results were obtained when 
comparing the three treatment groups. As only 2 RT-PCR experiments were performed 
in total, no statistical testing was allowable for mRNA expression, and only general 
impressions  from  the  data  could  be  made.  The  small  sample  sizes  also  resulted  in 
statistical analyses that were often underpowered, with power typically between 15-
40%. Post-hoc power studies reveal that if the number of experimental runs (sample 
size) was increased to 4, the power of the analyses in the study would have increased 
substantially. With this sample size, at least an 80% power would have been attained to 
detect differences of the sizes measured for the effects of 100nM ramiprilat alone on 
ACE expression and 1000 nM/l ramiprilat on VEGF protein levels. 
 
Future Studies 
As described above, a simple experimental protocol of hypoxia was used in this study, 
which provided a only a limited amount of information. Further experiments using the   215 
same  experimental  model  could  use  intermittent  episodes  of  hypoxia  (ischaemia) 
followed  by  re-oxygenation  (reperfusion)  to  create  a  more  representative  model  of 
claudication. In addition, other experiments could examine the time course for changes 
in gene expression and protein levels. It would also be important to study the effects of 
ACE inhibition on VEGF receptor expression, as changes in the various VEGF receptor 
types could potentiate or diminish the effects of the increases in VEGF protein levels. 
Another  study  could  examine  changes  in  AT1  and  AT2  receptors,  as  these  have 
opposing effects in angiogenesis. 
 
To further elucidate the mechanism underlying the increases in VEGF expression with 
ACE inhibition, other studies could be performed to assess the role of each potential 
pathway. The role of BK could be assessed by using a BK-antagonist such as HOE-
140.
120 The contribution of the ACE „outside-in‟ signalling pathway could be studied 
using  an  endothelial  cell  line  expressing  a  non-phosphorylatable  ACE  mutant 
(Ser1270), which would interrupt this pathway.
138;139 Finally, the involvement of COX-
2  on  ACE  inhibitor  mediated  increases  in  VEGF  could  be  assessed  using  COX-2 
inhibitors.   
 
Although  in-vitro  studies  can  provide  information  about  how  ACE  inhibitors  effect 
cellular responses to ischaemia, the only way to ascertain the potential benefits of ACE 
inhibition in claudicants would be to perform a large scale clinical trial. This would 
need  to  be  a  randomised  double  blind trial  of an  ACE  inhibitor  against  placebo  in 
humans enrolled on an exercise training programme, measuring changes  in  walking 
ability as the key endpoint. However, given the difficulty in recruiting suitable patients, 
this study would be difficult to achieve. The other possible beneficial effects of ACE   216 
inhibition,  namely  decreased  inflammation,  improved  endothelial  function,  and 
enhanced metabolic efficiency, could also be studied in these patients. 
 
5.6  SUMMARY 
This study suggests that in ECV 304 cells, hypoxia stimulates VEGF expression. ACE 
inhibition with ramiprilat appears to potentiate this increase. These results concur with 
previous reports showing that ACE inhibitors are pro-angiogenic in animal models of 
ischaemia. Thus, ACE inhibitors could be of benefit in the treatment of intermittent 
claudication, by reducing ACE activity and enhancing angiogenesis.   217 
CHAPTER 6 
DISCUSSION AND CONCLUSIONS 
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CHAPTER 6 
Although  exercise  training  has  long  been  associated  with  improvements  in  walking 
ability  in  claudicants,  the  precise  mechanism  by  which  exercise  results  in  these 
improvements is not completely appreciated. The process is likely to involve several 
facets,  which  include  improvements  in  blood  flow  or  distribution,  and  peripheral 
changes in the muscle physiology.
244 The RAS, and low ACE activity in particular, has 
been  linked  with  improved  endurance  performance,  enhanced  metabolic  efficiency, 
improved endothelial function, and reduced inflammation; all associations that could 
improve  walking  ability  in  claudicants.
166;288  Similarly,  VEGF  is  known  to  play  a 
crucial  role  in  angiogenesis,  another  phenomenon  that  could  aid  claudicants.
253 
Moreover, interactions are known to exist between the RAS and VEGF, with low ACE 
activity linked to increased VEGF levels. Studies of ACE inhibitors in animal models of 
ischaemia  have  demonstrated  both  increased  VEGF  and  enhanced  angiogenesis  in 
animal models of ischaemia.
233 The aim of this thesis was to investigate the role of ACE 
and  VEGF  in  exercise  associated  improvements  in  walking  ability.  The  potential 
benefits of ACE inhibition with regards ACE and VEGF were also studied. The main 
findings of the thesis are as follows:  
 
6.1  EFFECTS OF EXERCISE TRAINING ON WALKING ABILITY, ACE AND 
VEGF 
The first part of this thesis examined the effect of repetitive supervised exercise training 
in  claudicants  on  ACE  and  VEGF  mRNA  and  protein  levels,  and  related  these  to 
changes  in  walking  ability.  In  accordance  with  the  accepted  literature,  supervised 
exercise training produced significant increases measures of walking ability and calf 
muscle endurance.
178;198;244 However, contrary to predictions, exercise training did not   219 
lead  to  a  suppression  of  ACE,  with  increases  in  ACE  mRNA  expression  recorded, 
although there was no increase in measured ACE protein levels. Given the concurrent 
improvements in walking ability noted in this study, it is unlikely that suppression of 
ACE is a mechanism that contributes to improvements in walking ability after exercise 
training in claudicants. Nevertheless, these findings do not exclude suppression of ACE 
as a potential means to improve claudication, but only exclude the likelihood of ACE 
being important in exercise induced improvements. On examining differential I/D allele 
expression in ACE ID heterozygotes, more mRNA was shown to be produced from the 
D-allele than the I-allele, in corroboration with previous reports.
246 Exercise training 
also appeared to preferentially activate the D-allele, further increasing the D:I ratio. The 
mechanism underlying this predominance of mRNA from the D-allele is not understood 
and will need further studies to elucidate.  
 
Although an increase in ACE expression could be associated with potentially negative 
effects  in  claudicants  (such  as  decreased  metabolic  efficiency),  the  clear  gains 
associated with exercise training suggest other beneficial mechanisms outweigh these 
potential disadvantages. In this study, substantial increases in VEGF mRNA expression, 
greatest in the most biologically active isoform VEGF165, and protein levels were found. 
In  addition,  expression  of  VEGF  receptors  was  also  increased,  with  the  greatest 
increases noted in the transcription of VEGFR-2, which has the strongest signalling 
properties. Thus, exercise training had an overall effect of increasing the potential for 
VEGF signalling. Likewise, in the cell culture model of hypoxia, VEGF protein levels 
were  also  increased,  as  shown  previously.
95;174  Given  that  ACE  expression  had 
increased, it can be concluded that following exercise training in claudicants, VEGF 
expression is not stimulated by a mechanism related to decreased ACE activity. The   220 
lack of correlation between changes in ACE and VEGF expression in our subjects also 
supports this notion. Hence, increases in VEGF are more likely to be related primarily 
to stimulation by the well described HIF-1 pathway.
226  
 
No  correlation  was  found  between  physiological  improvements  and  molecular 
adaptations, primarily because of small numbers of subjects involved. Although a link 
between  improvements  in  walking  ability  and  increases  in  VEGF  cannot  be 
demonstrated  by  this  study,  the  increases  in  VEGF  were  associated  with  improved 
walking  ability  in  our  subjects.  An  increase  in  VEGF  mediated  angiogenesis  is  a 
reasonable explanation as part of the mechanism underlying these improvements.   
 
6.2  EFFECTS OF ACE INHIBITION ON ACE AND VEGF RESPONSES TO 
HYPOXIA 
Although  the  results  from  the  claudicant  study  do  not  associate  increased  walking 
ability  with  ACE  suppression,  ACE  inhibitors  could  still  play  a  role  in  increasing 
walking ability, by further potentiating VEGF increases and secondarily by reducing 
ACE activity. The second part of this thesis examined how ACE inhibitors modulate 
ACE  and  VEGF  in  hypoxia.  In  accordance  with  previous  reports,  ramiprilat  in 
normoxic conditions increased ACE expression.
58;138 Under hypoxic conditions, ACE 
expression appeared to further increase beyond that observed in response to hypoxia 
alone. Although this may seem to be a unfavourable response, in the continued presence 
of an ACE inhibitor, ACE activity would be likely to remain suppressed.
23 Ramiprilat 
also stimulated VEGF production, increasing VEGF levels in normoxic conditions and 
potentiating VEGF increases in response to hypoxia. In other words, ACE inhibition 
and  hypoxia  would  seem  to  act  synergistically  to  enhance  VEGF  production.  The   221 
mechanism underlying this increase could be related to the accumulation of BK during 
ACE inhibition, or to a signalling pathway triggered by the binding of the ACE inhibitor 
to  membrane-bound  ACE.
10;139;233  The  comparative  contribution  of  these  pathways 
could be determined by future experiments in which each pathway could be separately 
antagonised.    
 
The  findings  of  this  study  are  comparable  to  previous  reports  in  animal  models  of 
ischaemia which demonstrate upregulation of VEGF in response to ACE inhibition. In 
these studies, increases in VEGF were also related to improved angiogenesis and blood 
flow.
85;233;250 Thus, there could be a role for the use of ACE inhibitors in claudicants to 
stimulate angiogenesis in ischaemic leg muscles, and thereby improve walking ability. 
An additional benefit may also come from a reduction in ACE activity. Indeed, one 
small scale study has already demonstrated a beneficial effect of ramipril on pain-free 
and maximum walking time in claudicants.
3 However, in contrast a previous pilot study 
performed in this laboratory showed no benefit from ramipril and a large randomised 
double blind placebo controlled trial is required to definitively address this issue. 
 
6.3  CONCLUSIONS 
Exercise training in claudicants improves walking ability, and is associated with notable 
increases in VEGF protein and receptor mRNA expression. In a cell culture model of 
hypoxia,  ACE  inhibitors  also  increase  VEGF  expression.  Thus,  the  use  of  ACE 
inhibitors could be advantageous to claudicants, by potentiating VEGF and facilitating 
angiogenesis, and secondarily by reducing ACE activity, producing metabolic benefits 
and increasing endurance performance.   222 
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APPENDIX 2: RT-PCR OPTIMISATION 
EXAMPLES 
   255 
The optimisation process  of the PCR conditions  for ACE 216 primers is  illustrated 
below. The following parameters were adjusted until consistent clean PCR products 
were  obtained.  Representative  gel  pictures  showing  the  results  of  the  optimisation 
process are shown: 
 
Annealing Temperature 
The  annealing  temperature  was  increased  in  2
oC  increments  from  58
oC  to  62
oC, 
gradually increasing the stringency of the PCR reaction. A final annealing temperature 
of 60
oC was chosen. 
 
60 62 58
Annealing Temperature (
oC) 
 
 
Magnesium Concentration 
The reaction magnesium concentrations were increased from 1.0 and 2.0 mM, gradually 
decreasing the stringency of the PCR reaction. A final concentration of 1.5 mM was 
chosen. 
 
Magnesium (mM)
2.0 1.5 1.0
 
   256 
cDNA Template Levels 
The initial cDNA template level put into each reaction was varied between 100 and 
300ng. A final template level of 300ng was chosen. 
 
cDNA Template (ng)
100 200 300
 
 
PCR Cycle Conditions 
The number of PCR cycles was increased from 30 to 40 cycles, increasing the final 
product  yield.  At  40  cycles,  the  PCR  products  became  saturated,  so  35  cycles  was 
chosen for the final reactions. 
 
Number of PCR Cycles
30 35 40
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APPENDIX 5: CELL CULTURE WORK-UP 
EXPERIMENT RESULTS   268 
Cell Viability Control Experiments 
For both medium concentrations, the wells seeded with 1,500 and 3,000 cells showed 
evidence of changes in cell viability over time. This was especially obvious in the wells 
seeded with 3,000 cells in 10% FCS, which proliferated markedly over the experimental 
period. More stability in cell viability was shown in the wells seeded with 15,000 and 
30,000 cells, which were confluent throughout the experiment, although in wells seeded 
with 30,000 cells in 10% FCS there was a significant rise in absorbance (Figure A). 
From  these  experiments,  a  decision  was  made  to  use  15,000  cells/well  in  future 
experiments, as at this density the cells were always confluent and stably viable over 72 
hours. In this quiescent state, the cells were more likely to have steady gene and protein 
expression. 
 
DETA-NO Only Experiment 
In  the  cell  viability  experiments,  there  was  no  difference  in  viability  between  the 
medium and the vehicle controls in both the 1% FCS experiment (Medium only 1.53 ± 
0.08, Vehicle 1.77 ± 0.20; p = 0.32) and the 10% FCS experiment (Medium only 1.80 ± 
0.07, Vehicle 1.93 ± 0.09; p = 0.28). The vehicle control was used as the experimental 
control.  With  increasing  doses  of  DETA-NO,  there  was  no  significant  change  in 
viability from the controls (Figure B) although the viability appeared to drop slightly at 
higher DETA-NO doses. Changes in ACE and VEGF gene expression are shown in 
Figures C and D respectively. From the results of these experiments, DETA-NO doses 
between 0.008 to 0.25 mM were used in the final experiments.   269 
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Figure A  Graphs of Cell Viability for Varying Cell Numbers in 1% and 10% FCS 
over Time 
Higher absorbance readings indicate increased cell viability or proliferation. The bars 
represent means (of triplicate readings) and the error bars SEM. T0 represents the start 
of the experiment, with further readings taken every 24 hours. The differences between 
time points were analysed by 1-way ANOVA with Bonferroni‟s multiple comparison 
test. * p < 0.05 vs T0, **  p < 0.01 vs T0.   270 
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Figure B  Cell Viability with Increasing Doses of DETA-NO with 1% and 10% 
FCS 
The  bars  represent  means  (of  quadruplicate  readings)  and  the  error  bars  SEM.  The 
control  experiments  consisted  of  cells,  medium  and  drug  vehicle.  No  significant 
difference in viability from the controls was found (1-way ANOVA: 1% FCS p = 0.89; 
10% FCS p = 0.98).   271 
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Figure C  Changes in ACE Expression with Increasing Doses of DETA-NO with 
1% and 10% FCS 
With both serum concentrations, increasing doses of DETA-NO resulted in an increase 
in ACE expression over the controls. However, at higher DETA-NO doses with 1% 
FCS this increase was attenuated. The bars represent the results of a single RT-PCR run. 
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Figure D  Changes in VEGF121 and VEGF165 Expression with Increasing doses of 
DETA-NO with 1% and 10% FCS 
With both serum concentrations, increasing doses of DETA-NO resulted in an increase 
in VEGF121 and VEGF165 expression over the controls. However, at the highest DETA-
NO dose, VEGF expression was reduced. The bars represent the results of a single RT-
PCR run.   273 
Ramiprilat Only Experiment 
In  the  cell  viability  experiments,  there  was  no  difference  in  viability  between  the 
medium and vehicle controls in both the 1% FCS experiment (Medium only 1.67 ± 
0.15, Vehicle 1.96 ± 0.15; p = 0.22) and the 10% FCS experiment (Medium only 2.13 ± 
0.11, Vehicle 2.17 ± 0.11; p = 0.77). The vehicle control was used as the experimental 
control. With increasing doses of ramiprilat, there was no significant change in viability 
from the controls (Figure E). Changes in ACE and VEGF gene expression are shown in 
Figures E and F respectively. From the results of these experiments, the ramiprilat doses 
100 and 1000 nM/l were used in the final experiments. 
 
   274 
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Figure E  Cell Viability and ACE Expression with Increasing doses of Ramiprilat 
with 1% and 10% FCS 
In the viability graphs, the bars represent means (of quadruplicate readings) and the 
error bars SEM. No significant difference in viability from the controls was found (1-
way ANOVA: 1% FCS p = 0.84; 10% FCS p = 0.28). Increasing doses of ramiprilat 
augmented ACE gene expression at both FCS concentrations.    275 
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Figure F  Changes in VEGF121 and VEGF165 Expression with Increasing doses of 
Ramiprilat with 1% and 10% FCS 
In  both  1%  and  10%  FCS,  increasing  doses  of  ramiprilat  progressively  suppressed 
VEGF121 and VEGF165 expression compared to the controls, with a more marked effect 
seen with 1% FCS.   276 
APPENDIX 6: FINAL CELL CULTURE 
EXPERIMENTS- WELL CONTENTS 
   277 
DETA-NO Only Experiments 
All wells contained 15,000 ECV 304 cells in 1% FCS and 0.05% DMSO with: 
Well   Additional Contents 
DO-M „Medium Control‟  - 
DO-V „Vehicle Control‟  1% water 
DO-0.008  0.008 mM DETA-NO in water (1% of total volume) 
DO-0.016  0.016 mM DETA-NO in water (1% of total volume) 
DO-0.031  0.031 mM DETA-NO in water (1% of total volume) 
DO-0.063  0.063 mM DETA-NO in water (1% of total volume) 
DO-0.125  0.125 mM DETA-NO in water (1% of total volume) 
DO-0.250  0.250 mM DETA-NO in water (1% of total volume) 
The „DO-V‟ experimental wells  (containing cells,  medium,  and both  drug vehicles) 
were used as the overall experimental controls. 
 
Ramiprilat 100 nM/l Experiments 
All wells contained 15,000 ECV 304 cells in 1% FCS, 100 nM/l ramiprilat and 0.05% 
DMSO with: 
Well   Additional Contents 
R100-M „Medium Control‟  - 
R100-V „Vehicle Control‟  1% water 
R100-0.008  0.008 mM DETA-NO in water (1% of total volume) 
R100-0.016  0.016 mM DETA-NO in water (1% of total volume) 
R100-0.031  0.031 mM DETA-NO in water (1% of total volume) 
R100-0.063  0.063 mM DETA-NO in water (1% of total volume) 
R100-0.125  0.125 mM DETA-NO in water (1% of total volume) 
R100-0.250  0.250 mM DETA-NO in water (1% of total volume)   278 
Ramiprilat 1000 nM/l Experiments 
All wells contained 15,000 ECV 304 cells in 1% FCS, 1000 nM/l ramiprilat and 0.05% 
DMSO with: 
Well   Additional Contents 
R1000-M „Medium Control‟  - 
R1000-V „Vehicle Control‟  1% water 
R1000-0.008  0.008 mM DETA-NO in water (1% of total volume) 
R1000-0.016  0.016 mM DETA-NO in water (1% of total volume) 
R1000-0.031  0.031 mM DETA-NO in water (1% of total volume) 
R1000-0.063  0.063 mM DETA-NO in water (1% of total volume) 
R1000-0.125  0.125 mM DETA-NO in water (1% of total volume) 
R1000-0.250  0.250 mM DETA-NO in water (1% of total volume) 
 
The DO-M, R100-M and R1000-M wells, combined with the previous ramiprilat only 
work-up experiment results, were used to assess the effects of ramiprilat alone.    279 
APPENDIX 7: CELL CULTURE EXPERIMENT 
DATA   280 
 
  ECV 304 Cell Viability  Viability 
  Experiment 1  Experiment 2    (% Control) 
    1  2  3  4  1  2  3  4  Mean  SEM  Mean  SEM 
                         
DO-M  2.137  2.288  2.181  1.838  1.949  1.886  1.941  1.717  1.992  0.068  -  - 
DO-V  2.098  2.328  1.842  1.869  2.038  1.999  1.948  2.194  2.039  0.058  100.0  2.848 
DO-0.008  2.329  2.037  1.936  2.073  1.994  2.061  1.815  1.779  2.003  0.061  98.2  2.971 
DO-0.016  2.254  2.012  2.047  2.026  1.954  2.059  2.122  1.823  2.037  0.044  99.9  2.156 
DO-0.031  1.841  2.074  2.167  2.079  2.143  1.857  2.233  1.941  2.042  0.052  100.1  2.533 
DO-0.063  2.028  2.159  2.261  2.214  2.172  2.187  2.286  1.759  2.133  0.060  104.6  2.946 
DO-0.125  1.914  2.166  2.194  1.937  2.183  2.205  2.075  2.035  2.089  0.041  102.4  2.032 
DO-0.250  2.308  2.062  2.204  1.993  1.807  1.995  2.094  1.974  2.055  0.054  100.7  2.647 
                         
R100-M  2.016  2.129  1.996  1.882  2.365  2.202  1.790  1.840  2.027  0.069  -  - 
R100-V  2.175  2.047  2.450  1.730  2.006  2.269  2.120  2.172  2.121  0.074  104.0  3.633 
R100-0.008  2.404  2.223  2.092  1.774  2.227  2.186  2.184  1.773  2.108  0.079  103.3  3.880 
R100-0.016  2.192  2.472  2.102  2.146  2.309  2.290  2.194  1.867  2.196  0.062  107.7  3.053 
R100-0.031  2.254  2.319  2.013  1.753  2.347  2.298  2.407  1.993  2.173  0.080  106.5  3.946 
R100-0.063  2.411  2.581  2.028  1.845  2.146  2.266  2.322  1.946  2.193  0.088  107.5  4.306 
R100-0.125  2.204  2.391  2.062  1.896  2.378  2.351  2.259  1.941  2.185  0.070  107.1  3.413 
R100-0.250  2.430  2.422  2.042  2.074  2.255  2.161  2.158  1.687  2.153  0.084  105.6  4.121 
                         
R1000-M  2.005  2.005  1.987  1.813  1.856  1.903  1.899  1.901  1.921  0.025  -  - 
R1000-V  2.249  2.441  2.530  1.674  1.789  1.768  1.812  1.887  2.019  0.119  99.0  5.818 
R1000-0.008  2.244  2.603  2.454  1.629  1.819  1.693  1.854  1.937  2.029  0.128  99.5  6.264 
R1000-0.016  2.280  2.285  2.048  1.707  1.831  1.748  1.896  1.993  1.973  0.079  96.8  3.851 
R1000-0.031  2.263  2.173  2.173  1.581  1.893  2.011  1.993  1.863  1.994  0.077  97.8  3.792 
R1000-0.063  2.304  2.262  2.443  1.583  1.909  2.027  2.123  1.969  2.077  0.095  101.8  4.672 
R1000-0.125  2.270  2.362  2.219  1.528  2.055  1.856  2.160  2.010  2.057  0.094  100.9  4.624 
R1000-0.250  2.337  2.400  2.148  1.480  1.770  1.728  1.834  1.843  1.942  0.113  95.2  5.556 
       
   
             
 
DO:  DETA-NO  alone,  R100:  DETA-NO  with  100  nM/l  Ramiprilat,  R1000:  DETA-NO  with  1000  nM/l 
Ramiprilat, M: Medium Control, V: Vehicle Control, 0.008-0.250: represent doses of DETA-NO. 
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  ACE Expression 
  Ratio ACE/GAPDH-3  ACE (% Control) 
  Exp 1  Exp 2  Mean  SEM  Mean  SEM 
             
DO-M  0.180  0.273  0.226  0.047  -  - 
DO-V  0.198  0.217  0.207  0.009  100.0  4.51 
DO-0.008  0.249  0.242  0.246  0.003  118.5  1.62 
DO-0.016  0.213  0.258  0.236  0.023  113.7  10.90 
DO-0.031  0.254  0.279  0.266  0.012  128.5  5.97 
DO-0.063  0.288  0.302  0.295  0.007  142.1  3.39 
DO-0.125  0.291  0.273  0.282  0.009  136.0  4.25 
DO-0.250  0.246  0.197  0.222  0.025  106.9  11.99 
             
R100-M  0.300  0.306  0.303  0.003  -  - 
R100-V  0.269  0.256  0.262  0.007  126.5  3.20 
R100-0.008  0.300  0.312  0.306  0.006  147.6  2.93 
R100-0.016  0.319  0.279  0.299  0.020  144.3  9.64 
R100-0.031  0.280  0.302  0.291  0.011  140.5  5.32 
R100-0.063  0.341  0.314  0.328  0.013  158.0  6.32 
R100-0.125  0.393  0.322  0.358  0.035  172.5  16.98 
R100-0.250  0.374  0.364  0.369  0.005  178.0  2.35 
             
R1000-M  0.288  0.359  0.323  0.036  -  - 
R1000-V  0.254  0.324  0.289  0.035  139.2  16.85 
R1000-0.008  0.254  0.341  0.298  0.043  143.5  20.97 
R1000-0.016  0.303  0.337  0.320  0.017  154.3  8.09 
R1000-0.031  0.313  0.321  0.317  0.004  152.9  2.00 
R1000-0.063  0.305  0.359  0.332  0.027  160.0  12.96 
R1000-0.125  0.317  0.324  0.321  0.003  154.6  1.55 
R1000-0.250  0.311  0.332  0.321  0.010  155.0  4.98 
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  VEGF121 Expression 
  Ratio VEGF121/GAPDH-3  VEGF121 (% Control) 
  Exp 1  Exp 2  Mean  SEM  Mean  SEM 
             
DO-M  0.614  0.618  0.616  0.002  -  - 
DO-V  0.621  0.666  0.643  0.023  100.0  3.54 
DO-0.008  0.621  0.711  0.666  0.045  103.5  6.98 
DO-0.016  0.644  0.719  0.681  0.038  105.9  5.84 
DO-0.031  0.632  0.713  0.672  0.040  104.5  6.29 
DO-0.063  0.638  0.730  0.684  0.046  106.3  7.13 
DO-0.125  0.593  0.687  0.640  0.047  99.5  7.33 
DO-0.250  0.601  0.601  0.601  0.000  93.4  0.04 
             
R100-M  0.540  0.510  0.525  0.015  -  - 
R100-V  0.518  0.502  0.510  0.008  79.3  1.21 
R100-0.008  0.546  0.512  0.529  0.017  82.2  2.63 
R100-0.016  0.566  0.557  0.562  0.005  87.3  0.74 
R100-0.031  0.576  0.582  0.579  0.003  90.0  0.47 
R100-0.063  0.583  0.545  0.564  0.019  87.7  2.96 
R100-0.125  0.550  0.490  0.520  0.030  80.9  4.68 
R100-0.250  0.575  0.497  0.536  0.039  83.3  6.11 
             
R1000-M  0.521  0.539  0.530  0.009  -  - 
R1000-V  0.473  0.524  0.499  0.025  77.5  3.95 
R1000-0.008  0.471  0.540  0.505  0.035  78.5  5.38 
R1000-0.016  0.491  0.522  0.507  0.016  78.8  2.45 
R1000-0.031  0.538  0.534  0.536  0.002  83.3  0.36 
R1000-0.063  0.561  0.567  0.564  0.003  87.6  0.43 
R1000-0.125  0.554  0.542  0.548  0.006  85.1  0.93 
R1000-0.250  0.585  0.512  0.548  0.037  85.2  5.68 
             
 
   283 
 
  VEGF165 Expression 
  Ratio VEGF165/GAPDH-3  VEGF165 (% Control) 
  Exp 1  Exp 2  Mean  SEM  Mean  SEM 
             
DO-M  0.458  0.482  0.470  0.012  -  - 
DO-V  0.486  0.488  0.487  0.001  100.0  0.29 
DO-0.008  0.479  0.517  0.498  0.019  102.3  3.84 
DO-0.016  0.515  0.530  0.523  0.008  107.3  1.54 
DO-0.031  0.503  0.546  0.525  0.022  107.8  4.42 
DO-0.063  0.503  0.540  0.521  0.019  107.0  3.84 
DO-0.125  0.494  0.478  0.486  0.008  99.8  1.74 
DO-0.250  0.502  0.443  0.472  0.030  96.9  6.06 
             
R100-M  0.412  0.422  0.417  0.005  -  - 
R100-V  0.427  0.428  0.428  0.001  87.9  0.11 
R100-0.008  0.434  0.427  0.430  0.004  88.3  0.73 
R100-0.016  0.447  0.464  0.456  0.008  93.6  1.70 
R100-0.031  0.498  0.472  0.485  0.013  99.5  2.65 
R100-0.063  0.492  0.456  0.474  0.018  97.4  3.62 
R100-0.125  0.456  0.388  0.422  0.034  86.6  6.91 
R100-0.250  0.478  0.373  0.426  0.053  87.4  10.82 
             
R1000-M  0.383  0.458  0.421  0.037  -  - 
R1000-V  0.409  0.379  0.394  0.015  80.9  3.11 
R1000-0.008  0.384  0.451  0.417  0.034  85.7  6.93 
R1000-0.016  0.379  0.458  0.418  0.039  85.9  8.11 
R1000-0.031  0.478  0.463  0.470  0.007  96.6  1.51 
R1000-0.063  0.448  0.500  0.474  0.026  97.3  5.35 
R1000-0.125  0.477  0.439  0.458  0.019  94.1  3.90 
R1000-0.250  0.447  0.426  0.436  0.011  89.6  2.21 
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  VEGF Level (pg/ml)  VEGF Level 
  Experiment 1  Experiment 2     (% Control) 
    VEGF 
Level 
Corr. 
Factor 
Corr. 
VEGF 
VEGF 
Level 
Corr. 
Factor 
Corr. 
VEGF  Mean  SEM  Mean  SEM 
                     
DO-M  126.7  0.89  142.8  109.6  0.90  121.6  132.2  10.59  -  - 
DO-V  143.6  1.10  131.0  98.9  0.94  105.3  118.2  12.86  100.0  10.9 
DO-0.008  158.4  1.02  154.6  126.3  0.97  130.0  142.3  12.32  120.4  10.4 
DO-0.016  151.7  0.99  153.2  118.3  0.97  121.7  137.5  15.74  116.4  13.3 
DO-0.031  174.9  0.96  183.0  152.3  1.08  141.3  162.2  20.87  137.2  17.7 
DO-0.063  192.7  1.11  173.7  135.0  0.85  159.2  166.4  7.25  140.9  6.1 
DO-0.125  195.4  1.06  184.6  160.0  1.10  146.0  165.3  19.31  139.9  16.3 
DO-0.250  181.8  0.94  193.6  181.7  1.08  168.5  181.1  12.58  153.2  10.6 
                     
R100-M  196.0  1.20  164.0  214.4  1.10  195.7  179.8  15.83  -  - 
R100-V  155.4  0.85  183.3  177.7  0.94  189.3  186.3  3.00  157.6  2.5 
R100-0.008  167.7  0.92  181.9  203.8  0.90  226.1  204.0  22.09  172.7  18.7 
R100-0.016  178.8  0.96  187.0  206.3  0.95  216.1  201.6  14.55  170.6  12.3 
R100-0.031  186.6  1.06  176.3  220.4  1.01  218.8  197.5  21.27  167.2  18.0 
R100-0.063  165.4  0.90  182.9  242.9  1.08  225.3  204.1  21.20  172.7  17.9 
R100-0.125  189.9  0.99  191.8  205.4  0.90  227.9  209.9  18.07  177.6  15.3 
R100-0.250  197.7  1.02  193.0  221.3  0.92  240.8  216.9  23.90  183.6  20.2 
                     
R1000-M  201.5  0.99  203.5  233.8  1.20  194.4  199.0  4.52  -  - 
R1000-V  215.5  0.92  233.9  202.6  1.08  187.9  210.9  22.99  178.5  19.5 
R1000-0.008  207.3  0.97  213.0  192.1  1.03  187.4  200.2  12.83  169.4  10.9 
R1000-0.016  221.5  1.02  216.3  230.4  1.15  200.5  208.4  7.88  176.4  6.7 
R1000-0.031  234.5  1.09  214.6  192.9  1.03  188.2  201.4  13.21  170.5  11.2 
R1000-0.063  239.7  1.16  206.4  247.9  1.01  246.1  226.3  19.83  191.5  16.8 
R1000-0.125  225.1  0.97  231.3  197.9  0.95  207.4  219.4  11.96  185.6  10.1 
R1000-0.250  213.2  0.94  227.1  222.3  0.87  256.7  241.9  14.80  204.7  12.5 
       
 
           
 
Corr. Factor: Corrective factor based on protein yields as measured by Bradford assay. 
 